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The systemic adverse effects of inhaled corticosteroids were investigated in
dose-response studies. By measuring Cortisol suppression, it was shown that a more
potent inhaled corticosteroid (fluticasone propionate (FP)) exhibits greater systemic
bioactivity (2-fold at highest licensed doses) than a weaker steroid (triamcinolone
acetonide (TAA)). No differences were detected between inhaled corticosteroids of
similar potency (TAA and flunisolide), even when using sensitive and novel measures
e.g. low dose ACTH stimulation and early morning urine Cortisol excretion. The latter
test may prove to have clinical implications for monitoring patients, as it was shown to
be more sensitive than dynamic or basal serum Cortisol measures. However, the lung
delivery of a corticosteroid has a greater effect on systemic bioactivity than its dose or
potency, as the systemic activity of FP via two different inhaler devices was shown to
vary more than 5-fold. Studies comparing oral prednisolone with inhaled FP, showed FP
to exhibit dose-related suppression of serum Cortisol in a 1:8.5mg ratio compared to
prednisolone. Interestingly, the effects of FP on markers of bone metabolism were less
marked than adrenal suppression, compared to the effects of prednisolone. Intra-nasal FP
also produced significant urinary Cortisol suppression, whereas other intra-nasal
corticosteroids (TAA, budesonide (BUD), beclomethasone, and mometasone) had no
significant effects on 24 hour Cortisol, bone or blood markers. Furthermore, the addition
of intranasal to inhaled FP resulted in more patients with sub-normal Cortisol values.
When assessing therapeutic effects of inhaled corticosteroids, it was shown
that a lower dose ofBUD was required to optimise symptoms, lung function and exhaled
nitric oxide (NO), compared to other surrogate markers of inflammation such as serum
eosinophilic cationic protein (ECP), and bronchial hyperreactivity to adenosine
monophosphate (AMP) and methacholine. Thus airway inflammation may be
inadequately controlled by titrating steroid dose according to lung function alone.
However, higher doses of BUD resulted in greater adverse effects and a lower
therapeutic index.
The anti-inflammatory effects of steroid sparing agents were, therefore,
investigated. A leukotriene receptor antagonist, montelukast (MON), was less effective
than inhaled plus intra-nasal BUD as monotherapy in patients with allergic rhinitis and
asthma, in terms of airway hyperreactivity to AMP challenge, nasal and exhaled NO,
and there was a trend towards lesser effects with symptoms, peak expiratory and nasal
inspiratory flow rates. MON, however, did demonstrate anti-inflammatory activity in
terms of exhaled NO and AMP challenge. In a similar comparison of BUD and the long
acting (32-agonist, formoterol (FM), there were no anti-inflammatory effects seen in
terms of AMP challenge, eNO or ECP with FM. However lung function improved
equally with both therapies and indeed patients preferred FM therapy. The combination
of BUD and FM conferred additive effects. Finally, the effects of a long-acting P2
agonist (salmeterol) and MON were compared as second-line therapy in asthmatic
patients not controlled on inhaled corticosteroids. This demonstrated similar
improvements in lung function and symptom control with both drugs but MON seemed
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Allergic diseases result from an exaggerated immune response, on exposure of harmless
environmental antigens, in previously sensitised individuals. Examples of such antigens
include house dust mite, pollens and animal dander. The term allergy means "altered
working" and was first used in 1906 by Von Pirquet to describe the fatal reaction that
dogs, immunised with venom proteins from another animal, had after another injection
of that protein(1). The 'alteration' in response was that the dogs had an adverse effect
(anaphylaxis) rather than the normal prophylactic response to immmunisation. More
recently is has been realised that the allergic response is an immunoglobulin E (IgE)
mediated or type 1 hypersensitivity reaction.
Individuals who have a tendency to develop such a response are described as being
atopic. It is well recognised that atopy runs in families although the precise inheritance
has currently not been fully evaluated. Bodner et al(2) have shown in a case control study
that the onset ofwheezing is related to atopic status and family history of atopic disease,
with relative risk of 3.28 and 5.49 respectively. Atopy is usually diagnosed by the
presence of a positive reaction on skin prick testing with common allergens(3), and in this
respect, positive skin prick tests and specific IgE levels are associated with underlying
asthma'4'5-1. The association is more striking when assessing skin prick or
radioallergosorbent testing (RAST) to house dust mite(6'7).
Although allergic diseases encompass conditions such as eczema, urticaria, food and
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venom allergies, it is the involvement of the upper and lower airways (allergic rhinitis
and asthma) which are the most common, and will be the focus of the work in this thesis.
Asthma is defined as a condition of widespread narrowing of the bronchial airways
changing in severity over short periods of time, either spontaneously or with treatment'81.
Allergic rhinitis, however, is characterised by sneezing, rhinorrhoea, nasal congestion
and pruritis of nose and eyes with a temporal correlation to exposure of allergen'91. Often
included in the description of both conditions is a reference to inflammation and
mucosal hyperresponsiveness.
The prevalence of asthma and allergic rhinitis is increasing'10'111 and worldwide, up to
20% of young adults have asthma'121. The United Kingdom has one of the highest
prevalence rates'13', where there are more than 100,000 admissions to hospital per
year'101. The prevalence of rhinitis is more difficult to calculate as many patients are self-
treating, however, in adults it may be as high as 20%'12'141. Although few patients with
rhinitis require hospitalisation, it results in impairment in the quality of life of sufferers.
As mentioned above, patients with allergic airways disease produce specific IgE to
inhaled allergens. After exposure to an allergen, antigen presenting cells (e.g.
macrophages and dendritic cells) present immunogenic information to T-lymphocytes in
association with major histocompatibility complex class II molecules, which in turn
communicate with B-lymphocytes'1'151. Macrophages normally have an
immunosuppressive action and are weak antigen presenting cells, in contrast to dendritic
cells, although this seems to be altered in asthma'161. It is now accepted that there are two
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subsets ofT helper lymphocytes (Thl and Th2)(15'17). Both Thl and Th2 develop from an
initial common state (ThO). Thl cells produce interferon gamma and promote cell
mediated immune responses, whereas Th2 produce interleukin (IL)-4, IL-5 and IL-13,
and promote humoral immune responses. IL-12 and IL-18 promote Thl cells, whereas
IL-4 induces Th2 cells. It is thought that the balance between these two cell types is in
favour of Th2 responses in allergic individuals'1*'.
High affinity receptors for IgE are found on mast cells and basophils whereas
lymphocytes, monocytes and eosinophils possess low affinity receptors. The importance
ofmast cells in allergic rhinitis and asthma is evident by the increased numbers of these
cells in nasal and lower airway mucosa after exposure to aeroallergen'19,20'. When
antigen binds to two specific IgE molecules, which themselves are attached to mast cells
receptors, cross-linking of the receptors occurs, producing degranulation of the mast
cell. This results in a release of inflammatory mediators which are either pre-formed and
stored in granules, or newly synthesised in the mast cell'2'I These inflammatory
mediators induce a variety ofprocesses including increased vascular permeability, which
results in oedema, and swelling of tissues, airway smooth muscle contraction which
results in bronchoconstriction, as well as infdtration of further inflammatory cells.
Stimulation of nocioceptors in neural fibers may give rise to sneezing and coughing in
rhinitis and asthma respectively. Mast cells can also be triggered independently of IgE,
by changes in oncotic pressure as seen during exercise or pharmacologically by
adenosine monophosphate (see sections 1.2.2 and 2.12.2). More recently mast cells have
been shown have role in modulating the inflammatory response by secreting IL-4(22).
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After challenge with antigen, patients with allergic rhinitis or asthma experience airway
narrowing which occurs within a few minutes and lasts for about an hour. This is called
the early phase reaction or type 1 immediate hypersensitivity reaction, and occurs as a
result of the process outlined above. However, after a few hours there is a further (late-
phase) response, which is considered to be due to an influx of inflammatory cells to the
submucosa, and is associated with an increase in non-specific bronchial/nasal
hyperreactivity. The submucosa becomes infiltrated with chronic inflammatory cells
which release a plethora of cytokines (e.g. IL-1 to 5, IL-13), chemokines (e.g. IL-8,
RANTES, MCP-3 and 4) and other mediators (e.g. platelet activating factor) acting to
cause further increased production, migration, adhesion, priming and survival of
inflammatory cells(23). This late phase reaction can be attenuated by cromoglycate,
which stabilises mast cells suggesting a mechanistic link between early and late phase
reactions.
The eosinophil has been recognised to be associated with atopic airways disease for
many years, with blood levels being higher in atopic individuals(24). Increased numbers
of eosinophils have been found in the pathology specimens of patients dying of acute
asthma, and more recently, in the sputum and bronchoalveolar lavage of patients with
asthma(25"27). Furthermore, the increase in peripheral blood eosinophil count occurring
24 hours after allergen challenge is related to non-specific airway
hyperresponsiveness(28). Eosinophilic granule proteins, for example major basic protein,
eosinophil peroxidase and eosinophilic cationic protein (ECP), have been shown to have
cytotoxic effects on airway epithelium(29), and to activate other pro-inflammatory cells.
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Eosinophils also contribute to the inflammatory process by releasing other mediators
such as platelet activating factor, leukotriene C4 (both of which can cause
bronchoconstriction and mucous secretion), and pro-inflammatory cytokines including
IL-1, IL-3, IL-5 and granulocyte/macrophage colony stimulating factor (GM-CSF)(30).
Basophils, also possess IgE receptors, synthesise histamine, and are involved in the late
phase of the allergic response. Neutrophils are present in the airways of patients with
severe asthma and contribute to the inflammatory process although their presence is
short-lived(31). Indeed in patients with sudden fatal asthma neutrophilia may be greater
than eosinophilia. The epithelium is also involved by expressing inflammatory
cytokines, chemotactic factors and adhesion molecules(32).
The inflammatory process detailed above leads to damage and denudation of the airway
epithelium. This, in turn, may result in exposure of sensory nerves, and give rise to
sneezing and coughing. Epithelial cell damage will reduce the production of epithelial-
derived relaxant factor and may exacerbate bronchoconstriction13 ]). A characteristic
result of mucosal inflammation and epithelial damage is hyperresponsiveness, or the
tendency for airways to react to specific or non-specific stimuli at doses less than in the
normal population. This can be seen in both asthma and allergic rhinitis (see section
1.2.2).
As well as inflammatory cell infiltration and inflammation, the pathogenesis of asthma
also includes smooth muscle hypertrophy(33), thickening of airway wall due to
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subepithelial fibrosis(34), increased vascularity and oedema formation(35). All of these
factors lead to airway narrowing, which is compounded by mucus secretion and plug
formation as a result of goblet hypertrophy. Other non-inflammatory mechanisms such
as lung hyperinflation also contribute to symptomatology in asthma.
It is evident that there is a similar pathophysiology between asthma and allergic
rhinitis(36). Indeed, the two conditions frequently co-exist(37"39). Patients with allergic
rhinitis have higher indices of lower airways inflammation compared to healthy
controls(40"45). Mechanisms of this phenomenon include a neural reflex between upper
and lower airways(46~48), increased incidence of mouth breathing due to nasal
obstruction(49), and post nasal drip of secretions from the nose into the trachea. As there
is significant overlap in the pathophysiologies of allergic rhinitis and asthma, it is
important to optimise the control of nasal inflammation when treating patients, in order
to optimise control of lower airway inflammation<50). Studies have shown that in patients
with allergic rhinitis and concomitant mild asthma, intra-nasal corticosteroids as
monotherapy prevent the increase in airway hyperreactivity during the pollen
season(51'52), and improve asthmatic symptoms(53). Also in patients with allergic rhinitis,
orally inhaled budesonide, without nasal exposure, decreases nasal lavage ECP
concentration(54). There are obvious anatomical differences between the nose and lungs
for example the nasal mucosa has greater capacitance blood vessels and no smooth
muscle. Also the allergen may be different as pollen sensitisation is more common in
rhinitis whereas allergy to house dust mite is more common in asthma(55).
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1.2 MEASURES OF INFLAMMATION AND DISEASE CONTROL
1.2.1 Symptoms and lung function
The simplest method of assessing disease control is to determine the severity of patients'
symptoms. This is main outcome measure in clinical practice. Clinical trials also assess
treatment response by quantifying the symptoms using methods ranging from simple
scoring to complex questionnaires. The commonest method is to ask patients to score
their overall asthma or rhinitis symptoms on a scale e.g. between 0 and 3. More in depth
assessment will quantify individual components of asthma or rhinitis symptomatology.
For example, patients can be asked about their cough, wheezing, breathlessness or nasal
blockage, sneezing, rhinorrhoea or itching eyes'56'57*. It is particularly important to assess
nocturnal symptoms in asthma as well as nocturnal wakening. Validated general or
disease specific quality of life questionnaires are also available'58"60*. Rescue usage with
reliever medication can also be employed'01* as can exacerbation rates in large sample
studies'62*.
The most commonly used objective measure of asthma disease control is that of
pulmonary function testing. Peak expiratory flow rate (PEFR) is the simplest method
and can be measured at home by the patient using a non-expensive device. This has the
advantage of assessing daily changes in measurements as well as diumal variation,
which is a sensitive marker of disease control'63*. However, Cote et al'64*, reported that
patients record only one third of readings after 1 year despite regular reinforcement.
Furthermore, more than one quarter of patients fabricated their results most of the time.
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Nasal function can also be measured simply by a peak nasal inspiratory flow rate but
until recently this is not routinely performed in the domiciliary setting(65).
Laboratory measures of lower airways function include spirometry and airways
resistance(66). The most common measures being forced expiratory volume in the first
second of expiration (FEVi) and mid expiratory flow rate (FEF25.75). These have the
advantage of reflecting changes in smaller airway caliber, which is more relevant in
asthma. Airways resistance is determined by the ratio of the pressure difference between
the mouth and alveolus to the air flow. Nasal obstruction, an important feature of
seasonal allergic rhinitis'14\ can be measured in the laboratory by acoustic rhinometry
and rhinomanometry. The former measure assesses geometric changes by quantifying
nasal volume and cross sectional area, whereas the latter measures function in terms of
nasal resistance. Both of these parameters have been validated as sensitive measures of
assessing rhinitis(67'68). Elowever, as the equipment required for these laboratory
measurements is often bulky and expensive, they are rarely performed in the domiciliary
setting and therefore day to day variation cannot be determined.
1.2.2 Challenge testing
Hyperresponsiveness is a characteristic feature of both allergic rhinitis and asthma. It is
related to the degree of underlying mucosal inflammation(<59'70) and correlates well with
disease severity, requirement for therapy(71'72), and other markers of inflammation.
Studies have shown that after allergen inhalation there is eosinophilic airway
inflammation and associated increase in bronchial hyperresponsiveness(26'73). Also, after
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viral infection there is an inflammatory infiltrate and hyperresponsiveness'74'.
In order to quantify the degree of hyperresponsiveness, an airways (either bronchial or
nasal) challenge test is performed'75'. Increasing amounts of a chemical or physical
stimulus is applied to the mucosa until a predetermined response is detected. This is
normally in terms of airway narrowing such as nasal resistance, spirometry (e.g. FEVi)
or airway resistance. The stimuli produce their response either by directly acting on the
airway, or indirectly by inducing the release of inflammatory mediators which, in turn,
result in airway narrowing. Examples of stimuli acting directly are histamine and
methacholine, whereas allergen, adenosine monophosphate, cold air, and exercise all act
indirectly. When using pharmacological stimuli, the concentration or dose of drug
required to cause a fall in FEV] of 20% is usually calculated (PC20, or PD20
respectively).
In terms of bronchial challenge testing, direct stimuli are regarded as the gold
standard'8'. Methacholine bronchial challenge has recently been shown to correlate
significantly with eosinophil numbers from induced sputum, airway biopsies and
bronchoalveolar lavage in asthmatic patients treated with inhaled corticosteroids'76'. In a
study of children, responders to methacholine amounted to 98% of asthmatic children
and 37% of healthy children'77'. Elowever, adenosine monophosphate bronchial
challenge, which causes bronchoconstriction indirectly by inducing the release of
inflammatory mediators from primed mast cells'78'79', has been shown to be more
sensitive in detecting anti-inflammatory effects and is probably more clinically
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relevant'80'81 \
Airway hyperresponsiveness may not only reflect the degree of airway inflammation(69).
Although studies have shown correlations with hyperresponsiveness and inflammation,
there are other studies showing no association with bronchial hyperresponsiveness and
inflammatory changes in sputum, bronchoalveolar lavage or biopsy'82'. Also, in the
studies showing significant correlation, the correlation coefficient tends to be in the
region of 0.6 indicating that other factors are involved. These include airway
remodeling, bronchial smooth muscle contractility, airway compliance and lung elastic
recoil'83'84'.
There is a unimodal distribution of airways hyperreactivity in the population with
asthmatic patients representing one end of the spectrum'85'86'. Therefore an arbitrary cut
off value for the diagnosis of asthma is used. Most commonly a histamine PC20 of
8mg/ml is taken as the limit of normality. However, this will include up to 30% of
healthy individuals'87'. Furthermore, as asthma is a condition which varies in severity,
the degree of bronchial hyperresponsiveness will vary on a day to day, and month to
month basis(88). The variability of the test is such that the dose required to cause the
required effect can vary up to 2-fold (or one doubling dose) in a given stable
individual189'. Bronchial challenge testing, therefore, is currently not often used to




Nitric oxide concentration is increased during airways inflammation by "up-regulation"
of its generating enzyme, inducible nitric oxide synthase, by cytokines, including
nuclear factor kappa B (NF-kB), IL-1 (3, and TNF-a which are generated in the
inflammatory cascade(90>. Nitric oxide may be involved in the inflammatory process by
increasing mucosal blood flow and plasma exudation'9". Measuring the concentration of
nitric oxide in exhaled or nasal air is a simple, non-invasive and reliable measure of the
activity of this enzyme which in turn may reflect the degree of inflammation'92 981. It has
been found to be particularly useful in investigating the effects of steroids, as the
activated glucocorticoid receptor complex inhibits the induction of this enzyme by
inhibiting NF-kB(99). Exhaled nitric oxide levels have been shown to be higher in
untreated asthmatic patients'96'100) and to be reduced when treated with
corticosteroids'10" but not with bronchodilators'102). The level of exhaled nitric oxide has
been shown to increase after bronchial challenge'1031 and during acute exacerbations of
asthma'1041. It also correlates well with sputum eosinophil counts in patients with
asthma'1051. Nitric oxide has also been shown to be elevated in the nasal passages of
patients with allergic rhinitis and to be suppressed with intra-nasal corticosteroid
therapy'971.
Although nitric oxide production has been shown to be suppressed by anti-inflammatory
therapy other than corticosteroids, for example with pranlukast'1061 and montelukast"071,
it seems to be particularly sensitive to corticosteroid therapy. This is probably because
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the activated glucocorticoid receptor avidly inhibits the induction of nitric oxide
synthase by inactivating NF-kB which is an important inducing cytokine of nitric oxide
synthase(99). Using nitric oxide alone to compare different forms of anti-inflammatory
therapy may therefore lead to problems with interpretation as, for example, inhaled
corticosteroids may have a greater effect than leukotriene receptor antagonists on
exhaled nitric oxide for a given anti-inflammatory effect on the airways.
The technique of measuring nitric oxide may also lead to problems. As the normal
concentration of nitric oxide from the upper airways is 100 times higher than from the
lower airways, contamination of lung nitric oxide may occur unless the soft palate is
able to closed off the upper airway (see section 2.13.2). Furthermore it may not be
possible to accurately measure nasal nitric oxide in patients with severe nasal blockage
as the technique involves the analyser drawing air from one nostril at a constant rate.
1.2.4 Blood Markers
Investigators have used measurements of peripheral blood markers to infer the state of
asthmatic and rhinitic inflammation(108). Blood eosinophil counts are known to be higher
in patients with inflammatory conditions as the process releases cytokines which
increase the production of these cells from the bone marrow(109). Both peripheral blood
eosinophil count and their state of activity, as measured by serum ECP, are considered to
be sensitive surrogate markers of asthmatic inflammation1'08'11<0. Serum ECP correlates
well with bronchoalveolar lavage ECP, eosinophil cell concentration in bronchial
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biopsies and asthma exacerbations"11'112'. Serum ECP levels have also been shown to be
elevated in patients who are pollen sensitive during the pollen season"13'. However, in a
study by Hoshino et al"14', serum ECP correlated with mucosal eosinophil numbers, but
not with airway hypersensitivity, pulmonary function or symptoms. Furthermore, Kips
and Pauwels"15' felt that ECP should not be used as a diagnostic aid, but could be used
to follow up patients with asthma. More recently, Gruber et al"16' showed that patients
with bronchial hyperresponsiveness to cold air or histamine had higher levels of serum
ECP, although this was not statistically significant and there was no correlation with
serum ECP and histamine PC20.
1.2.5 Other measures
Other, more invasive techniques can be employed but have not been utilised in any of
the studies in this thesis. They include nasal biopsy or bronchoalveolar lavage and
bronchial biopsy obtained during fibreoptic bronchoscopy. An alternative to
bronchoscopy studies is to induce a patient to produce sputum by inhaling hypertonic
saline"17' which, although better tolerated, is unpleasant, can be contaminated by saliva
and is representative of the more proximal airways only"18). These techniques have been
validated"17'119', although cannot be repeated in quick succession as this causes an
increase in neutrophil counts"20'121', probably due to the inflammatory nature of the
procedure"22'. As the smaller airways are important in asthma some investigators have
performed endobronchial airway challenge tests, by instilling histamine down a
bronchoscope and measuring airway resistance in the bronchi"23'. In general all
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measures of airway inflammation or disease control are related although the correlations
are moderate. It is likely that all the currently available methods assess slightly different
aspects of asthma or rhinitis inflammation and therefore their results should be taken
together to gain a fuller picture of allergic airways disease control.
1.3 CORTICOSTEROIDS
1.3.1 Molecular mechanisms of Corticosteroids
When corticosteroids bind to the glucocorticoid receptor complex in the cytoplasm they
cause dissociation of proteins (e.g. heat shock protein) enabling the glucocorticoid
receptor to enter the nucleus and bind the DNA at sites called glucocorticoid response
elements. This results in "up" or "down" regulation ofmany genes which are involved in
the inflammatory process and subsequently favorable synthesis of inflammatory proteins
and cytokines(99'124l
The activated glucocorticoid receptor also alters the inflammatory process by binding to
transcription factors which are activated by cytokines. For example, RANTES is
regulated by activator protein 1 and NF-kB, both of which are blocked by
corticosteroids^25). As discussed above, this is also the mechanism whereby
corticosteroids attenuate the production of nitric oxide in the airways, as NF-kB causes
activation of inducible nitric oxide synthase (section 1.2.3).
Corticosteroids have been shown to reduce the numbers of inflammatory cells in the
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airways by inhibiting their survival and recruitment. For example, cytokines required to
prolong the existence of eosinophils and vascular adhesion molecules, which aid their
infiltration into the mucosa, are both inhibited by corticosteroids. Corticosteroids also
reduce the inflammatory action of these cells(126), reduce epithelial shedding,
microvascular permeability1127), goblet cell hyperplasia, basement membrane
thickness(128'129) and reduce airway hyperresponsiveness11301.
Asthma and allergic rhinitis are considered to be chronic inflammatory conditions and
all patients have persistent underlying airways inflammation1131 '132). For this reason, an
important aim ofmedical therapy should be to control the disease activity by treating the
inflammatory process. In this respect, topical corticosteroids have been shown to be the
most effective anti-inflammatory therapy in the treatment of both asthma and
rhinitis19'1331 which is in keeping with the current asthma management guidelines1134"1361.
For example, clinical studies have shown intra-nasal corticosteroids to be more clinically
effective than either placebo or antihistamines151'137"1401. Likewise inhaled corticosteroids
have greater effect on asthma symptoms than theophylline11411, cromoglycate(142) or
antihistamines1143). However there are few data regarding the natural history of asthma
and the long-term effects of corticosteroid therapy1144).
1.3.2 Pharmacokinetics
The topical potency of the basic corticosteroid nucleus is increased by substitution of an
ester group (triamcinolone acetonide, beclomethasone dipropionate) or a halomethyl
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carbothioates group (fluticasone propionate, mometasone furoate). Relative potency can
be measured in vivo by the McKenzie Vasoconstrictor Test(l45'146), which assesses the
degree of skin blanching after topical application. It can also be determined by in vitro
measurement of glucocorticoid receptor affinity and glucocorticoid receptor complex
residency time using radio-labeled competition assays with homogenised lung tissue1147
More recently Stellato et al(148) compared the in vitro potency of inhaled corticosteroids
by assessing basophil histamine release, eosinophil viability, and expression of a
vascular cell adhesion molecule in the human bronchial epithelial cells. The results of
these methods all give results with the following rank order of potency: fluticasone
propionate = mometasone furoate > budesonide > beclomethasone dipropionate =
triamcinolone acetonide > flunisolide<148"154). As it is not possible to directly extrapolate
the effects of corticosteroids between different tissues, the McKenzie Vasoconstrictor
assay may have limitations. However, in vitro methods also have limitations as, for
example, it is known that inflammatory cytokines can modulate glucocorticoid receptor
affinity(155). Although potency is an important factor in determining anti-asthmatic
efficacy, it also has a critical effect on systemic adverse responses.
Lipophilicity, as measured by reverse phase high performance liquid chromatography,
also differs between available corticosteroids(156), with fluticasone propionate being
more lipophilic that other corticosteroids. Highly lipophilic drugs have been shown to
have greater tissue retention within the mucosa(l57), and greater glucocorticoid receptor
affinity(150'156), however, they also have a greater volume of distribution and systemic
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tissue accumulation158).
As a large proportion of inhaled medication is swallowed, the degree of first-pass
hepatic metabolism greatly influences systemic bioactivity. In this respect, fluticasone
propionate and mometasone furoate have virtually complete metabolism, whereas
budesonide, triamcinolone acetonide and flunisolide have first pass-metabolism of 11%,
23% and 20% respectively*159"163'. However, thorough mouth rinsing after inhalation,
which is a recommended technique as it reduces the adverse topical effects of oral
candidasis and dysphonia, can also reduce the swallowed fraction. In theory, inhaled
corticosteroids can be absorbed systemically via the buccal mucosa thus by-passing first-
pass hepatic metabolism, although this is thought to have a negligible effect on the
systemic bioactivity(164).
As well as potency, receptor affinity and residency time, lipophilicy, volume of
distribution, and extent of first pass metabolism, the plasma elimination half life also
influences the systemic adverse effects of inhaled corticosteroids. In this respect
fluticasone propionate (14.4 hours) has a considerably greater plasma elimination half
life than the other corticosteroids (beclomethasone monpropionate: 6.5 hours,
triamcinolone acetonide: 3.6 hours, budesonide: 2.3 hours, flunisolide: 1.6 hours/158"
161,165,166) jonger elimination half-life of fluticasone propionate will result in greater
accumulation at steady state(158).
28
1.3.3 Lung and Nasal Delivery
It is important to consider the lung and nasal delivery of inhaled corticosteroids, as well
as the above pharmacokinetic properties1167As modern inhaled corticosteroids have a
high degree of first pass hepatic metabolism of the swallowed fraction, but no first-pass
metabolism of the inhaled or intra-nasal fraction of the drug, lung or nasal delivery will
influence the systemic bioactivity as well as the clinical efficacy'168'169). Therefore, the
effect of each patient-drug-device combination must be assessed when considering the
relative therapeutic ratio of inhaled or intra-nasal corticosteroids"701. In a dose-ranging
study of 35 severe asthmatic patients, some of whom were prednisolone dependant,
Toogood et al(i71) showed that the same dose of inhaled budesonide (either 400pg or
1600jag per day) doubled the asthmatic efficacy in terms of change in FEV] when given
with a spacer compared to a metered dose inhaler alone. Furthermore there was not the
same effect on systemic measures and therefore this resulted in a greater therapeutic
ratio.
The importance of the inhaler device is also illustrated by in vitro data. In a study using
the Andersen impactor chamber, respirable fractions (percentage of particles less than
5 pm in diameter) of fluticasone propionate and budesonide were compared when
delivered by their respective metered dose inhalers or dry powder devices"721. With the
metered dose inhalers the respirable fraction was 35% with fluticasone propionate and
21% with budesonide, however, fluticasone propionate Diskhaler produced only 12%
respirable particles compared to 40% with budesonide Turbuhaler. Thus fluticasone
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propionate metered dose inhaler had greater lung delivery than budesonide but this
situation was reversed when comparing the dry powder inhalers. It is therefore not
possible compare these two drugs without taking account of the inhaler device.
1.3.4 Measures of the Adverse Effects of Inhaled Corticosteroids
1.3.4.1 Hypothalamic-Pituitary-Adrenal Axis
Although corticosteroids have potent anti-inflammatory properties, they are also
associated with adverse effects. These include osteoporosis and altered bone
metabolism, thinning of the skin and bruising, cataracts, diabetes and psychological
abnonnalities. There are also concerns regarding growth retardation in children. Due to
the similarities between the glucocorticoid receptor in all bodily tissues(173), it has not yet
been possible to separate these beneficial and adverse effects.
The hypothalamic-pituitary-adrenal (HPA) axis is a fundamental hormonal cascade
regulating glucocorticoid production from the adrenal cortex. Corticotropin releasing
factor (CRF) is produced in the median eminence of the hypothalamus in response to
physical or emotional stress, secreted into the hypophysial portal system and then carried
to the anterior pituitary gland where it induces adrenocorticotrophic hormone (ACTH)
secretion. ACTH acting through a membrane bound receptor induces cyclic adenosine
monophosphate production, which in turn induces the enzymatic cascade resulting in
Cortisol production from cholesterol. Exogenous corticosteroids, produce negative
feedback by stimulating glucocorticoid receptors on the anterior pituitary and
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hypothalamus with a resultant fall in Cortisol production and, in the longer term,
adrenocortical atrophy. The degree of HPA-axis suppression can therefore be used to
measure the systemic bioactivity of inhaled and intra-nasal corticosteroids0 74). It can be
assessed by either basal or dynamic measures of adrenal function0 75).
Measurement of Cortisol, the endpoint of the HPA-axis, can be used to assess the whole
cascade and can be determined in blood, urine or saliva samples. Production of Cortisol
is in a pulsatile manner and also varies throughout the day according to a circadian
rhythm0 76). For this reason a single sample ofplasma Cortisol is less able to reflect HPA-
axis activity than repeated samples integrated with respect to time(177). However, studies
have used 8am or 9am serum/plasma Cortisol samples as this coincides with the time of
greatest secretion078'. Preferably, samples should be precisely at 0800hrs in patients who
have been lying supine in a relaxed environment, as the lack of Cortisol suppression of
inhaled corticosteroids compared to placebo in some studies may be attributable to non-
controlled conditions0 79080). Twenty-four hour integrated plasma Cortisol measurements
are time consuming and cannot be used in clinical practice although they are frequently
employed in clinical trials049'181"183'.
Measurement of urinary Cortisol excretion has the advantage of smoothing out the
fluctuations of serum Cortisol. Indeed 24 hour urinary Cortisol excretion has been shown
to be more sensitive than 8am serum Cortisol at detecting the systemic bioactivity of
inhaled corticosteroids084'. However, a 24 hour sample of urine is difficult to obtain in
an out-patient setting and, for reasons of compliance, fractionated samples have been
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used. Mclntyre et al(185) showed an overnight urinary Cortisol collection (from 2200hrs to
0800hrs) was as sensitive as the full 24 hour collection when corrected for creatinine,
and more sensitive than morning serum Cortisol measurements. This is understandable
when considering the diurnal circadian rhythm of Cortisol secretion, with highest levels
during the night and early morning. It may also be possible to use an 8am spot sample of
urinary Cortisol, however, at present there are little data on the reliability of this measure.
The actual measurement of urinary Cortisol may be performed in different ways and
therefore different values can be obtained from different laboratories. It is important to
measure free Cortisol and therefore an extraction process should be performed*186).
Measurements can then be made by radioimmunoassay or high performance liquid
chromatography. The advantage of radioimmunoassay is that it is a relatively cheap,
quick process, although some of the commercially available kits have cross-reactivity
with prednisolone.
Dynamic adrenal function testing may be more clinically relevant than basal measures as
these tests mimic the body's response to physiological stress. The most commonly used
is the 250pg ACTH stimulation test given as a bolus or 6 hour infusion. However, this
dose is considered to be supraphysiological and although it is routinely used in clinical
practice in the diagnosis of Addison's disease, it may not be sensitive enough to
determine subtle abnormalities in the HPA-axis induced by inhaled corticosteroids*175).
In this respect, a low dose (0.5pg) ACTH test has been shown to more sensitive that the
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250pg ACTH test, and correlates well with the insulin stress test(l87). In a study by
Broide et al(188), comparing the high dose and low dose ACTH test, a quarter of adults
and children who were taking long-term maintenance inhaled corticosteroids had a sub-
optimal response to low dose but a normal high dose ACTH response. Kannisto et al(189)
assessed the effects of fluticasone propionate and budesonide in asthmatic children, after
6 months using the low dose (0.5pg) ACTH test. The test was abnormal in 9 out of 30
children receiving budesonide, but only 5 out of 30 in the fluticasone propionate group,
which is in keeping with the finding of more growth suppression in the budesonide
group. Unfortunately, the ACTH stimulation test is now contra-indicated in the UK data
sheet (Synacthen, Ciba Laboratories, Horsham, UK) in patients with allergy and asthma
because of occasional reports of hypersensitivity and fatal anaphylactic reactions. Hence
for ethical reasons, at least in the United Kingdom, studies using ACTH stimulation are
limited to healthy volunteers.
The insulin stress test is regarded as the gold standard pituitary function test.
Hypoglycaemia stimulates the hypothalamus to secrete CRF which then activates the
HPA-axis. Unfortunately the hypoglycaemia necessary for the test results in unpleasant
side effects and it cannot be routinely used for screening purposes. The human
corticotropin releasing factor (hCRF) stimulation test also examines the integrity of the
whole HPA-axis and has been shown to be as sensitive as the insulin tolerance test(190).
However, unlike the insulin tolerance test it is not associated with unpleasant reactions
and there have been no reported cases of anaphylaxis. Also, the lOOpg hCRF test
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produces more of a physiological response than the high dose ACTH stimulation test.
On a negative side the hCRF test is very expensive when compared to other tests, and
has not been used in many clinical studies.
Studies by Brown et al(184), Broide et al(l88) and Grebe et al(191) have also shown that
patients who have impaired basal tests of adrenal function also have subnormal
stimulation tests. For example in the study by Broide et al(188) there was a positive
correlation between the peak Cortisol response to ACTH and the 24 hour urinary
cortisone excretion. Furthermore those patients who had an abnormal ACTH test had
significantly lower 24 hour urinary Cortisol than those with a normal response.
1.3.4.2 Bone
Although there have been reported cases of Addisonian crisis in patients who have been
exposed to stress at the same time as stopping their inhaled corticosteroid therapy(192,1 3),
and it is recommended that patients on long-term high dose therapy may require
supplementary oral corticosteroids during stress challenges, this is extremely rare(194).
However, an important long term adverse effect of inhaled corticosteroid therapy is
steroid induced osteoporosis and the associated risk of fracture0 95). At present, as there
is no way of directly correlating between the effects on one tissue and another0%),
clinical studies need to be performed to assess the effects on bone metabolism.
Corticosteroids alter bone metabolism by a number of different mechanisms. The
dominant effect is through suppression of the osteoblasts and alteration in the bone
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multicellular unit*197'198*. There is also increased bone resorption under the influence of
increased parathyroid hormone, as a result of steroid induced reduction in the absorption
of calcium from the gastrointestinal tract and renal tubules(199) amd disruption of
collagen metabolism, bone matrix formation and sex hormone balance*l97). The main
sites of decreased bone density and osteoporosis are the vertebrae, ribs and pelvis as
these areas contain mainly trabecular bone which is ten times more metabolically active
than cortical bone(200). However, inhaled corticosteroids may also increase bone density
by increasing mobility and weight bearing activity.
Although dual energy bone densitometry is the standard method of diagnosing
osteoporosis and risk of fracture*20'~203), this measurement is time consuming, expensive
and, as the changes take many years, long term studies are required to compare
treatments. For these reasons only a few studies have utilised bone density to compare
inhaled corticosteroids, and biochemical blood bone markers have been used as a
surrogate*175,204'205). However, Herrala et al*206) performed dual-energy X-ray
absorptiometry (DEXA) at the lumbar spine and at the left proximal femur in non¬
smoking women with asthma treated with beclomethasone dipropionate lmg per day,
and found no difference after 1 year compared to healthy control subjects. Osteocalcin is
a hormone produced only by osteoblasts and is a specific surrogate marker of their
activity*207-1. It is therefore is more specific than other measures such as urinary calcium
excretion and plasma alkaline phosphatase, and more sensitive than urinary
hydroxyproline*208*.
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Studies have shown greater suppression of osteocalcin with oral prednisolone than
budesonide at therapeutically equivalent doses'208'209'. In a study by Bootsma et al'210',
inhaled fluticasone propionate was also reported to have less effect on osteocalcin
production than beclomethasone dipropionate for a given change in spirometry.
Interestingly both drugs had no effect on urinary Cortisol excretion. The fact that
different inhaled corticosteroids were found to have different tissue sensitivity has
important consequences as it may be possible to have a greater effect on the lung
compared to the adrenal gland. However only one dose of each drug was investigated
and the results may therefore reflect different sensitivities of the tests rather than the
tissues themselves. More useful information would have been obtained from a dose-
ranging study (see section 1.4.1).
There is evidence that the dose-response curve for osteocalcin is not linear with a
plateau above 800pg of beclomethasone dipropionate'211', analogous to the effects of
Cortisol. There are no dose-response studies comparing the effects of two different
inhaled corticosteroids in terms of osteocalcin suppression. Also there are no data
regarding intra-nasal corticosteroids and osteocalcin.
Furthermore, there is not sufficient information as yet to determine whether changes in
osteocalcin level directly correlates with results of long term bone densitometry studies.
It may only reflect recent treatment with inhaled corticosteroids'212'. Sorva et al(213)
showed 8% suppression of osteocalcin in asthmatic children with inhaled budesonide
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after 1 month of therapy and a similar level after 5 months. However, Hanania et al(2l4)
found the product of dose and duration of inhaled corticosteroids, when corrected for
body mass index, correlated to bone density measurements and adrenal suppression but
not to osteocalcin levels. Osteoclacin did not correlate with the bone density. Urinary
and serum break-down and formation proteins from collagen metabolism are also
used(2l5), although these have not been investigated in this thesis.
1.3.4.3 Other measures of adverse effects of inhaled corticosteroids
As hypercortisolism results in oesinopenia, suppression of peripheral blood eosinophil
count can been used to compare corticosteroids(175'196'216). However, Wood et al(10<),
showed that after allergen challenge there was an increase trafficking of eosinophils
from the bone marrow to the lung in dogs suggesting that suppression of blood
eosinophil counts may reflect a reduction in the inflammatory response rather than a
systemic adverse effect. There are other methods of assessing the systemic adverse
effects of inhaled corticosteroids which have not been utilised in this thesis including
determining eye changes in tenns of cataract formation and ocular pressure, bruising and
skin thinning, and growth in children measured by knemometry(175'195'217). Ferguson et
al(218) compared fluticasone propionate 400pg per day and budesonide 800pg per day in
moderately severe asthmatic children. They showed that growth was reduced with
budesonide, however, there was no suppression of adrenal function.
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1.4 COMPARISION BETWEEN DIFFERENT CORTICOSTEROIDS
1.4.1 Requirement for dose-response studies
It is widely accepted that, for a given level of clinical efficacy, inhaled corticosteroids do
not exhibit the same degree of adverse effects as oral corticosteroids. Comparisons have
also been made between different inhaled corticosteroids, however, there is still doubt
about their relative degree of systemic activity.
In a review article, Barnes et al(124) discuss the various study designs used to compare
inhaled corticosteroids. The most valuable designs were felt to be dose-response
comparisons, where at least two doses of each drug is compared on the steep part of the
dose response-curve, or dose down-titration comparisons, where the doses of two drugs
are reduced to the lowest clinically effective dose. These are the only methods by which
potency ratios can be calculated. Of the two published dose-response studies comparing
two different corticosteroids in terms of clinical efficacy, one compared budesonide and
beclomethasone dipropionate(219) and the other compared beclomethasone dipropionate
and fluticasone propionate(220). However, in neither study was there a dose response
effect of either drug and neither looked at systemic adverse effects.
There is one study which has compared the clinical efficacy of two inhaled
corticosteroids using a back titration design(221). The minimal dose of fluticasone
propionate and budesonide, when given by their dry powder devices, required to control
symptoms in asthmatic children was shown no different between the two corticosteroids.
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This result may have been confounded by the fact that the minimum dose of each drug
was lOOpg per day, as it was not possible to administer a dose lower than this. In theory
titration should have been continued down to zero, as there may have been differences
between the drugs at lower doses. However the majority of patients (75%) had an
exacerbation of asthma and the same findings were apparent when the analysis was
performed only on those patients.
A less satisfactory alternative is to perform a dose-ranging study of one drug and
compare that to one dose of another drug. This was the method employed by Dahl et
aj(222) conciucie(i that 400pg per day of beclomethasone was equivalent to 200pg
per day of fluticasone propionate. However, there was no dose response effect of
fluticasone propionate and no significant difference between beclomethasone
dipropionate and fluticasone propionate at 1600pg per day.
For efficacy studies the steroid sparing potential of inhaled corticosteroids can be
investigated. Nelson et al(223) showed oral prednisolone to be eliminated in 75%, 89%
and 9% of patients receiving fluticasone propionate lmg, 2mg and placebo respectively;
and Noonan et al(224) showed 69%, 88% and 3% elimination with 0.75mg, lmg and
placebo.
Barnes et al(124) felt that comparing one dose of two drugs had little or no value in
establishing the potency of drugs. However, Pauwels et al(225) compared fluticasone
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propionate 250pg per day and beclomethasone dipropionate 500pg per day and showed
no difference in clinical efficacy, however fluticasone propionate had better adverse
effects in terms of bone density and osteocalcin. Lorentzen et al(226) compared
fluticasone propionate lmg per day versus beclomethasone dipropionate 2mg per day
and showed fluticasone propionate to have better effect on spirometry than
beclomethasone dipropionate. Ayres et al(179) showed that after 6 weeks of treatment,
fluticasone propionate at doses of lmg per day and 2mg per day had a change in peak
expiratory flow rate of 21 and 24 1/min respectively, and budesonide at 1.6mg per day
had a 13 1/min improvement. However, there was a difference of only 3 1/min between
the two doses of fluticasone and no dose-response effect. Barnes et al(180) showed
fluticasone propionate lmg had similar effects to beclomethasone dipropionate 2mg in
terms of Cortisol and peak expiratory flow rate. Leblanc et al(227) compared fluticasone
propionate at 200pg per day with beclomethasone dipropionate 400pg per day. Both
drugs had a similar improvement in peak expiratory flow rate, but fluticasone propionate
had less effect on Cortisol suppression.
However, Boe et al(228) compared fluticasone propionate 2mg per day with budesonide
1.6 mg per day and showed similar clinical efficacy, although fluticasone propionate had
greater Cortisol suppression. The data from this last study could be used to conclude that
budesonide has a greater therapeutic ratio. However, this interpretation would be in
contrast to the results of a meta-analysis performed by Barnes et al(229). For this reason,
single dose comparisons of inhaled corticosteroids at unknown points on the dose
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response curve afford little information regarding the relative effects of inhaled
corticosteroids. It is necessary therefore to compare inhaled corticosteroids using
sensitive markers in appropriate patients at doses on the steep part of the dose-response
curve.
1.4.2 Dose-response comparisons for systemic effects
1.4.2.1 Adrenal suppression
Of all the dose-response studies for adrenal suppression comparing two inhaled
corticosteroids, fluticasone propionate and budesonide have been investigated the most.
Donnelly et al(l81), Grahnen et al(182) and Boorsma et al(183) have all shown dose related
suppression for both drugs with greater suppression with fluticasone propionate in terms
of 24 hour area under the curve (AUC) plasma Cortisol, when compared on a microgram
equivalent basis in healthy adult volunteers. Granhen et al<182) compared the drugs
delivered by their respective dry powder devices while the other authors assessed these
steroids delivered by a pressurised metered dose inhalers. More recently Derom et al(230)
compared the effects of 400pg and 2mg of fluticasone propionate versus 400pg and
1.6mg of budesonide via their dry powder inhalers in moderately severe asthmatic
patients. Compared to placebo there was no suppression of serum AUC0-20 Cortisol at
low doses but 34% and 16% suppression with high dose fluticasone propionate and
budesonide respectively. There was a significant improvement in FEVi with all active
treatments compared to placebo. Clark et al(231), in two separate dose-response studies
comparing fluticasone propionate and budesonide given by metered dose inhalers,
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showed greater suppression with fluticasone propionate in asthmatic adults, using
overnight urinary Cortisol, after single(232) and steady-state'231' dosing. With regard to
children, Clark et al(233) performed in a dose-response study comparing 400pg, 800pg
and 1250pg of inhaled budesonide and fluticasone propionate. Suppression with
fluticasone, but not budesonide occurred at all doses. Lipworth et al(234), however,
showed no suppression in a chronic dosing study with 400pg per day of either drug. The
reason for the apparent discrepancy is that in the former study the total dose of the
inhaled corticosteroids were given at night, whereas in the later the dose was given twice
daily. The influence of a single dose on the HPA-axis is greater when given at night is
greater than when given as divided doses, especially on measurements made the
following day(235). The only dose-ranging study to compare budesonide and
beclomethasone dipropionate using 24 hour AUC plasma Cortisol also showed
budesonide to produce less suppression1149).
It is surprising that there is only limited published data regarding the HPA-axis effects of
inhaled triamcinolone acetonide and flunisolide considering that, until recently, they
were the most commonly used inhaled corticosteroids in the USA. Altman et al(236)
performed a dose ranging study of triamcinolone acetonide at 800pg, 1200pg and
1600pg per day in asthmatic patients. Adrenal function was measured in terms of the
250pg ACTH test and 24 hour urinary Cortisol after 2 weeks and 1, 3 and 6 months.
There was no impairment of the dynamic stimulation test and the suppression of urinary
Cortisol was not out with the normal reference range. In a parallel group study of steroid
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naive mild asthmatics, sequential cumulative doubling doses of triamcinolone acetonide
(800-3200 p.g per day) and flunisolide (1000-4000pg per day) were administered with
dose increments at weekly intervals1161In terms of 24 hour uncorrected urinary Cortisol
excretion, triamcinolone acetonide had no detectable effect at 800pg per day, but
produced 7% suppression at 1600pg per day, as compared to 13% and 15% suppression
with lOOOpg per day and 2000pg per day respectively of flunisolide. In another study of
healthy volunteers, 3.5 days treatment with triamcinolone acetonide 2000|ug per day and
flunisolide 2000pg per day produced no significant effect on 24 hour urinary Cortisol
excretion11471.
There have been two dose-ranging studies comparing the relative effects of oral
prednisolone and inhaled budesonide in terms of HPA-axis suppression. Toogood et
al<1%1, in adult asthmatic patients, and Jennings et al(209), in healthy volunteers, showed
dose related suppression with both drugs although there was greater suppression with
prednisolone. There have been no dose-response studies comparing prednisolone with
other inhaled corticosteroids.
While there have been some reports of systemic adverse effects with intra-nasal
corticosteroids12371, other studies have shown no adverse effects1238"2411 and these drugs
are generally regarded as being completely safe. There have been no studies comparing




Pauwels et al(225) showed that fluticasone propionate improved bone mineral density
after 1 year, compared to beclomethasone dipropionate, and this was associated with
higher serum osteocalcin levels. When comparing budesonide (1.6mg per day) and
fluticasone propionate (lmg per day), Hughes et al(242) also showed an increase in bone
density which was significantly related to change in osteocalcin levels after 1 year. In
another study, no change in bone density, osteocalcin or morning Cortisol with
fluticasone propionate via a Diskhaler at 500pg twice daily after 2 years was found(243).
However, there was significant suppression of the 8hour 250pg ACTH test(243). Gregson
et al(244) compared beclomethasone dipropionate 200pg twice daily and fluticasone
propionate lOOpg twice daily for 20 months, and found no effect on bone density in
children.
1.4.3 Dose-Response Relationships for Measures of Clinical Efficacy
There are only a few dose-response studies, which address clinical efficacy of intra-nasal
corticosteroids, and it is unusual for clinicians to titrate the dose of corticosteroids for
individual patients. The licensed dose is different for adults and children and there is
usually an initial dose and a lower maintenance dose, but otherwise no dose alteration
occurs. Dolovich et al(245) compared fluticasone propionate 200pg once daily with
200pg twice daily in patients with seasonal allergic rhinitis and found no difference for
nasal blockage or rhinorrhoea although the patients taking the higher dose had
significantly less nasal itching. A dose-response study with mometasone furoate 50pg,
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lOOpg 200pg and 800pg per day for 1 month in seasonal allergic rhinitis showed clinical
efficacy with all doses(246). There was no advantage of 800pg per day over 200pg per
day. However, the lower doses showed less activity after 1 week.
There is clinical and experimental evidence to suggest that the dose of inhaled
corticosteroids required to adequately control asthmatic patients symptoms may not
result in normal values for other methods of assessing clinical efficacy. In other words
the dose-response curves for different measures of disease control will have different
shapes. In a study by Pedersen and Hansen(247) moderately severe asthmatic children
were given inhaled budesonide at lOOpg, 200pg and 400pg per day. There was a dose-
response relationship for exercise induced bronchoconstriction but a plateau in response
after lOOpg per day for symptoms and peak expiratory flow rate. In another study with
fluticasone propionate there was a significant improvement between lOOpg per day and
200|ixg per day in terms of methacholine bronchial challenge but not in terms of lung
function (FEVi, PEF) or asthma symptoms(248). Toogood et al(249) showed that the shape
of the dose-response curve depended on which measure of efficacy that was used.
Patient severity will also influence the dose-response curve, by shifting it to the left or
right, and each patient will have their own dose-response curve for a given marker of
efficacy. For example, in a study with beclomethasone dipropionate there was no
improvement in terms of FEVi when increasing the dose from 400pg to 1600pg per day
in patients who were controlled on inhaled corticosteroids'250'. Whereas in another study
in more severe patients, requiring oral corticosteroids, a significant dose response effect
45
was seen when increasing the dose of inhaled beclomethasone dipropionate from 200pg
to 1600pg(249). This probably reflects the flat dose response curve in milder patients after
400pg per day but in more severe patients a plateau is not reached until at least 1600pg
per day.
The duration of treatment also influences the dose response curve, as the time taken for
each measurement to reach maximal response varies according to the endpoint chosen.
For example, a clear response in terms of symptoms will occur before changes in lung
function and airways hyperreactivity^51}. In general the longer the period of treatment
the greater the chance of achieving the maximum effect. However, longer term studies
are less likely to achieve good patient compliance. Furthermore, alterations in asthma
control, due to the normal variability of disease severity, are more likely to effect long
term studies. The majority of the effects of inhaled corticosteroids are achieved with
most markers of efficacy in about 3 weeks(251'252).
Most dose-ranging studies have shown a statistically significant improvement between
placebo and active treatment, regardless which inhaled corticosteroid was evaluated.
Studies have shown dose-response effects for beclomethasone dipropionate(249,253) and
budesonide(254 256) up to 1600pg per day; and fluticasone propionate up to lOOOpg per
day(257'258). It is not possible to be certain about the shapes of the dose-response curves
for different measures of efficacy, as there have been no dose-response studies
comparing symptoms, lung function, serum markers and bronchial challenge tests in the
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one group of patients.
1.5 SECOND-LINE THERAPY
Given the fact that all topical corticosteroids have adverse systemic effects at high doses
it is important to ensure the dose is kept to a minimum. In patients not adequately
controlled on low dose inhaled corticosteroids, second-line therapy may be
introduced(134'259). The purpose of introducing second-line therapy is to achieve adequate
disease control without increasing the corticosteroid dose. As discussed above (see
section 1.2) there are many ways of assessing optimal disease management, which
include symptom control, normalisation of lung function and quality of life and absence
of exacerbations of asthma. However, as asthma and rhinitis are inflammatory
conditions, it is also important to consider the anti-inflammatory properties of second-
line therapy as there is evidence that long-term untreated inflammation may lead to
airway remodeling and irreversible airflow obstruction(260 262). The aim of this thesis is to
investigate the anti-inflammatory therapy in allergic airways disease and therefore this
will be the main focus when considering the properties of second-line agents.
1.5.1 P2-adrenoceptor agonists
P2-adrenoceptor agonists, the most effective known bronchodilators, are divided into
two classes according to their duration of action. Short-acting P2-agonists exhibit their
effects for 3-6 hours, whereas long-acting p2-agonists (formoterol and salmeterol) last
for more than 12 hours. As well as causing bronchodilation, p2-agonists demonstrate
47
protection against bronchoconstricting stimuli such as exercise(263) and allergen'264'. This
functional antagonism and long duration of action make long-acting (32-agonists ideal
candidates for second-line therapy in patients who were not adequately controlled on
inhaled corticosteroids'134,135'265'. Furthermore, there is considerable evidence to suggest
that long-acting p2-agonists improve symptoms, exacerbation rates and lung
function'62,266'.
When prescribed in conjunction with inhaled corticosteroids, they have also been shown
to be as effective as giving double the dose of inhaled corticosteroid alone. For example,
Greening et al'267' performed a parallel study comparing 426 asthmatic patients who
were randomised to either beclomethasone dipropionate 200pg twice daily plus
salmeterol 50pg twice daily or beclomethasone dipropionate 500pg twice daily. After 6
months there was significantly greater improvements in morning and evening peak flow
rate with the salmeterol plus beclomethasone dipropionate limb than the higher dose
inhaled corticosteroids limb. More importantly, there was no difference in exacerbation
rates between these treatment groups. Another study compared'268' the addition of
salmeterol (50pg or lOOpg twice daily) to beclomethasone dipropionate 500pg twice
daily versus beclomethasone dipropionate lOOOpg twice daily in asthmatic patients, also
for 6 months. Similarly, there was greater improvements in morning and evening peak
flow rates in patients receiving the long-acting (32 agonist. There was no difference in
exacerbation rates and neither treatment improved bronchial hyperresponsiveness to
histamine. Pauwels et al'62' showed similar findings in the Formoterol and
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Corticosteroids Establishing Therapy (FACET) study. This was a four way parallel
study comparing budesonide lOOpg twice daily, budesonide lOOpg twice daily plus
formoterol 12pg twice daily, budesonide 400pg twice daily, or budesonide 400pg twice
daily plus formoterol 12pg twice daily. The addition of long-acting p2 agonist was
shown to reduce both mild and severe exacerbations when added to either the low or
high dose corticosteroid.
It is uncertain as to whether long-acting P2-agonists have anti-inflammatory activity.
There is in vitro evidence that they have effects on mast cell degranulation, vascular
permeability and inflammatory cell infiltration(269). A recent biopsy study(270) showed
inhaled formoterol to reduce the numbers of submucosal mast cells and eosinophils,
although the baseline values were not equal and there was an out-lying value which may
have influenced the results. Serum ECP levels have also been shown to be reduced with
inhaled salmeterol(271).
There is a body of evidence that long-acting P2-agonists may be detrimental in the long
term care of asthmatic patients. The concern is that, as their main action is at the bottom
of the inflammatory cascade, they may be treating symptoms and not inflammation.
Indeed they may mask the underlying inflammation, resulting in a delay in treatment of
asthmatic exacerbations(272). This is in keeping with the results from the FACET
study(62), which showed that although the combination of high dose inhaled budesonide
and formoterol achieved the best control of asthma. High dose (800pg per day)
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budesonide as monotherapy was superior to low dose (200pg per day) budesonide plus
inhaled formoterol in terms of severe asthmatic exacerbation rates. There is also
evidence to suggest that p2-agonists may, in fact, inhibit the anti-inflammatory effects of
corticosteroids on eosinophil survival in lung tissue'273), although other authors have
shown that p2 agonists do not compromise the ability of dexamethasone to suppress the
generation of cytokines from monocytes(274).
Another concern with p2-agonists is that they exhibit tolerance or tachyphylaxis to both
their bronchodilator and bronchoprotective properties'275-1, which is measured by
comparing the response after the first dose of long-acting p2 agonist with the response
after a prolonged period of treatment(276). This effect is as a result of receptor down
regulation and is more pronounced with long-acting p2 agonists than with short-acting
p2-agonists due to the duration of receptor occupancy. The degree of tachyphylaxis is
greater for the bronchoprotective than bronchodilator effects(275) and is more pronounced
with indirect than direct stimuli'277'. In view of the therapeutic benefit of long-acting p2
agonists in a large number of studies(266-268), it is felt by many physicians that
tachyphylaxis is not clinically relevant. Although it has been shown that patients
receiving long-acting p2-agonists require more short-acting p2 agonist to achieve a given
degree of bronchodilation during an acute exacerbation of asthma(278).
Long acting p2 agonists can be dispensed in either oral or inhaled preparation. The tablet
formulation is obviously easier to administer although there is a greater incidence of
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systemic adverse effects. The most common side effect is that of tremor, although they
should be used with caution in patients with hyperthyroidism, ischaemic heart disease
and arrhythmias. These adverse effects mean that some patients may not tolerate long-
acting P2 agonists.
1.5.2 Leukotriene receptor antagonists
Leukotrienes, originally referred to as slow-reacting substance of anaphylaxis, are
important mediators in the inflammatory cascade. On release from the nuclear
membrane by phospholipase A2, arachidonic acid is metabolised by the 5-lipoxygenase
pathway to produce leukotriene A4. This is then metabolised via a cascade of enzymes
to produce the cysteinyl leukotrienes - leukotriene C4, D4, and E4. These chemicals
have been shown to have major effects in the pathophysiologies of rhinitis and asthma.
They produce bronchial smooth muscle contraction, inflammatory cell chemotaxis,
mucus hyper-secretion and neuronal stimulation'279'. Furthermore, leukotriene, D4 has
been shown to be 1000 times more potent than histamine in terms of inducing airway
obstruction'280' and nasal responses'281'. Further evidence that leukotrienes are involved
in acute asthma is seen by the presence of high levels of urinary leukotriene E4 after an
exacerbation'282', and by the fact that the early and late asthmatic response can be
significantly attenuated with blockade by a leukotriene antagonist and antihistamine'283'.
Nakamura et al'284' have shown a reduced inflammatory cellular infiltrate in a biopsy
study and Pizzichini et al'285' have shown reduced eosinophil counts in the induced
sputum of asthmatic patients receiving leukotriene receptor antagonists.
The development of the 5-lipoxygenase inhibitor (zileuton) and antagonists of the
cysteinyl leukotriene receptor (montelukast, zafirlukast, and pranlukast) have therefore
been used in the management of asthma(259). All of the available drugs modifying the
leukotriene pathway are licensed in tablet form. This obviates any problems with inhaler
technique and lung delivery, although with zafirlukast there is a decrease in
bioavailability when taken with food. Zafirlukast also inhibits cytochrome P450 hepatic
microsomal enzymes at clinically therapeutic doses which may result in drug-
interactions^8^. However, both zafirlukast and montelukast appear to be generally well
tolerated and most side effects are mild e.g. gastrointestinal disturbance, rashes and
fatigue(287).
Several mulitcentre studies have shown leukotriene receptor antagonists to improve
clinical efficacy when compared to placebo. Altman et al(288) performed a dose-ranging
study with montelukast at doses of lOmg, lOOmg and 200mg given once daily; and
lOmg and 50mg twice daily. There was significant improvement with all doses
compared to placebo but no dose-response effect or relationship to dosing interval. Reiss
et al(2X9) reported significant improvement in terms of spirometry, symptoms, reliever
therapy usage and exacerbation rates with montelukast in patients with moderately
severe chronic asthma. Interestingly the effects were evident after therapy for 1 day, and
there was no evidence of tolerance. Similar results with montelukast in children and
adults have also been reported(290"292). Other authors have shown clinical efficacy with
zileuton, zafirlukast and pranlukast<293 295).
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There are only a few trials which have compared leukotriene receptor antagonist with
other forms of asthma therapy. A comparison between inhaled sodium cromoglycate and
zafirlukast(296), showed both drugs to have better control of asthmatic symptoms than
placebo. However, there was no difference between the active treatments. In a recent
study, Malmstom et al(297) compared 200pg twice daily beclomethasone dipropionate
and lOmg once daily montelukast in patients with moderately severe chronic asthma.
Both drugs were shown to have beneficial clinical effects compared to placebo in terms
of spirometry, peak flow, exacerbation rates and quality of life. However,
beclomethasone dipropionate was significantly better than montelukast. The only other
published data shows beclomethasone dipropionate to be more effective than
zafirlukast(298). This suggests that leukotriene antagonists may not be as potent as anti¬
inflammatory drugs, although there is evidence to suggest they have bronchodilator
properties(299).
Although the role of leukotriene receptor antagonists is not established, they are likely to
have their greatest use as second-line therapy in asthmatic patients receiving inhaled
corticosteroids, as inhaled corticosteroids seem to be more potent at controlling
inflammation. However, there are few published reports comparing leukotriene receptor
antagonists and other second-line therapy in the one study. The study by Busse et al(300)
showed salmeterol to be more effective than zafirlukast in terms of pulmonary function
and symptom control, whereas Turpin et al(301) showed that montelukast was superior to
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inhaled salmeterol in the prevention of exercise-induced bronchoconstriction. In a multi¬
centre trial of patients with persistent asthma, 80% ofwhom were receiving concomitant
inhaled corticosteroids, treatment with salmeterol produced significantly greater
improvements than zafirlukast in overall asthma control, as assessed by peak flow,
asthma symptoms and rescue (32 inhaler usage(300). This study, however, did not evaluate
the effects on bronchial hyperresponsiveness (e.g. methacholine challenge) or airway
inflammation.
There may be some cases for using leukotriene receptor antagonist as first-line agents.
For example patients who have aspirin sensitive asthma have been shown to have over
expression of leukotriene C4 synthase'302', and would benefit from these drugs'303'. It is
also recognised that after exercise there is an increase in excretion of leukotrienes in the
urine and this is attenuated by montelukast(304). Other studies have shown beneficial
effects of leukotriene receptor antagonists at controlling exercise induced asthma in
adults'292'304'305' and children'306'. Indeed, Bronsky et al'307) showed that the montelukast
caused dose-related protection against exercise-induced bronchoconstriction. Villaran et
al(3H8) compared the efficacy of montelukast and salmeterol in controlling exercise
induced asthma in 333 asthmatic patients, 25% of whom were taking low dose inhaled
corticosteroids, in terms of fall in FEVi and showed the leukotriene receptor antagonist
to be more effective after 8 weeks of therapy. Many patients do not like using inhalers
and prefer the convenience of taking medication in oral form. For these patients and
others with poor compliance, a once daily oral leukotriene receptor antagonist would be
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an effective first line therapy.
Given that asthma and allergic rhinitis both have similar pathophysiologies, it is likely
that leukotriene receptor antagonists may be effective in both conditions. Again there are
little data on this area of therapeutic intervention. Knapp et al(3()t)) showed that 5-
lipoxygenase inhibition reduced allergen induced nasal congestion and levels of
leukotrienes in nasal lavage fluid. Studies with leukotriene receptor antagonists have
also shown improved symptom control compared to placebo in seasonal allergic
rhinitis(310'3II). Malmstrom et al(3l2) showed that the addition of an antihistamine
(loratadine) to a leukotriene receptor antagonist (montelukast) exhibited an additive
effect to both treatments when given alone. However, there have been no studies
investigating the use of leukotriene receptor antagonists in patients with both allergic
rhinitis and asthma.
1.6 AIMS
The aim of this thesis is to perform a series of pilot studies to investigate aspects of anti¬
inflammatory medication used to treat allergic airways disease. Comparisons of
corticosteroids given by the inhaled or intra-nasal route are made using sensitive
measures of systemic activity. These include basal and dynamic tests of HPA-axis
activity and markers of bone metabolism. The dose-response effects of measures of
asthmatic control and airway inflammation are also assessed for inhaled budesonide.
The effects of long-acting [T agonists and leukotriene receptor antagonist are evaluated
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in comparison to inhaled corticosteroids as mono-therapy. Finally these drugs are







Patients with asthma and seasonal allergic rhinitis were recruited from respiratory
outpatient clinics at King's Cross Hospital, the Rhinology Clinic at Ninewells Hospital,
Dundee, and by advertisement within Ninewells Hospital and the local press. Healthy
subjects were recruited from the staff and students of the University of Dundee. All
patients fdled in a questionnaire giving details of past and present illnesses, history of
illness in family members, and any potential risk of blood borne infections. Prior to
recruitment into a study, all had a full physical examination and normal urinalysis;
haematological and biochemical profile, and were negative to hepatitis serology
markers. Female subjects of childbearing age were asked to provide a morning urine
sample for a human chorinoic gonoadotropin pregnancy test. All asthmatic patients were
non-smokers and had asthma according to American Thoracic Society criteria1202'.
Patients with seasonal allergic rhinitis conformed to international criteria04'. No subject
had had an exacerbation of asthma or rhinitis which required the use of antibiotics or
oral corticosteroids within 6 months prior to a study. None of the healthy volunteers
were receiving any regular medication.
2.2 ETHICAL APPROVAL
Ethical approval was granted for all studies by the Tayside Committee on Medical
Research Ethics. All subjects gave their written informed consent. The patients' and
healthy volunteers' General Practitioners were informed and invited to discuss their
views on each subjects' inclusion into a particular study.
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2.3 MASKING
All inhalers, nasal sprays, tablet bottles and nebuliser solutions were masked and sealed
in envelopes by a pharmacist along with instruction sheets at the beginning of each trial,
in order to blind the investigators and subjects to the study medication. Where possible,
an identical placebo was used. However, if this was not available all clues to the identity
of the medication and dose were removed as far as possible. For many of the
investigations, the subjects would not have seen the inhaler devices prior to the study,
i.e. for the non UK medication such as triamcinolone acetonide, flunisolide and the
Flovent formulation of fluticasone propionate. Likewise no patients would have seen the
American preparation of nasal fluticasone propionate (Flonase) or triamcinolone
acetonide (Nasacort) as these studies were performed prior to licensing in the UK.
Identical placebo Turbuhalers and Accuhalers were available. All studies using
Pulmicort Turbuhaler and Flixotide Accuhaler were, therefore, double blind. If an
identical placebo was not available a similar devices was used for placebo. For studies
which involved two different forms of medication e.g. inhalers and tablets, or inhalers
and nasal sprays, a corresponding placebo device was given during the active treatment
arm in order to make the study "double-dummy". For all studies, a randomisation code
was produced and kept by a third party observer.
2.4 INSTRUCTIONS
In each study the medications were given according to the manufacturers' packet insert
instructions. Prior to each study and at each visit, subjects were given detailed tuition, by
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a third party, in how to use their inhalers or nasal sprays. Nasal sprays were primed
according to the manufacturers' instructions prior to first use and discharged twice
before each treatment was administered. After each dose of inhaled corticosteroid, all
patients were instructed to rinse their mouth three times. In each study using a
pressurised metered dose inhaler, a Vitalograph aerosol inhalation monitor device
(Vitalograph, Bucks, UK) was used to check the subjects' co-ordination between
inspiration and actuation. Likewise, in each study using a Turbuhaler an appropriate
training device was used to ensure adequate peak inspiratory flow rate (Astra Draco,
Lund, Sweden). In every study, each subject received a detailed written instruction sheet
to follow while taking their inhaler at home and a simple tick chart was used as an aid to
compliance. Patients were required to exhibit at least 90% compliance in order for the
data to be considered evaluable.
2.5 SERUM/PLASMA CORTISOL
2.5.1 Basal measures
Patients attended the laboratory at least 30 minutes prior to the time of sampling. An
intravenous indwelling cannula was inserted into the ante-cubital vein and patients were
asked to rest, lying supine, for 30 minutes. After withdrawing dead space volume of 3
ml, a 5 ml blood sample was taken for Cortisol. At the request of individual volunteers,
topical anaesthetic cream (lignocaine gel) was applied to the arm 2 hours prior to
venepuncture. For serum samples, blood was allowed to clot at body temperature for 20
minutes. Serum and plasma samples were centrifuged at 4°C at 3300 rpm for 15
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minutes. The supernatant (serum or plasma) was aliquoted and stored at -20°C until
analysed in batches, in duplicate, at the end of each study.
Analysis of serum/plasma Cortisol was made by a commercially available radio¬
immunoassay (RIA). For the first two studies in Chapter 3 and the last in Chapter 5 an
Immunodiagnostic (Immunodiagnostic System Ltd, Boldon, Tyne & Wear UK) RIA kit
was used. For all other studies an Incstar (Incstar Ltd, Wokingham, Berkshire) RIA kit
was used. The Immunodiagnostic RIA kit had a within assay co-efficient of variation
(CV) of 7.1 and a between assay CV of 7.2 whereas the Incstar RIA kit had a within
assay CV of 4.3% and a between assay CV of 7.2%. The CV's were calculated from the
results of the studies performed in this thesis. Neither RIA had cross-reactivity with any
inhaled corticosteroid although they had an 11% cross-reactivity for oral prednisolone
(Chapter 4). A value of 150 nmol/1 (5.4mg/dl) was taken to be the lower limit of
normality for baseline serum or plasma Cortisol.
2.5.2 Dynamic Stimulation Testing
2.5.2.1 Low Dose ACTH Stimulation Test
Adrenocorticotrophic hormone (ACTH) (Synacthen, Ciba Laboratories, Horsham, UK)
was diluted to 0.5pg per ml by injecting the 250pg vial into a 500ml bag of 0.9% saline
solution. After mixing, 1 ml aliquots were withdrawn from the bag and used for
injection. Subjects received the injection immediately after a 0800 hr plasma/serum
sample. Two further samples for Cortisol were taken after 20 minutes and 30 minutes
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respectively, to evaluate the peak Cortisol response. A normal result was taken to be a
post stimulation serum or plasma Cortisol value greater or equal to 500 nmol/1 (18pg/dl).
It was not possible to evaluate an ACTH stimulation response in any study involving
patients with asthma or allergic rhinitis as it is contraindicated on the UK data sheet
(Synacthen, CIBA Laboratories) for use in asthmatic or atopic subjects because of
potential anaphylactic reactions. Indeed volunteers were screened for atopy with skin
prick testing prior to recruitment into studies using ACTH stimulation testing. Any
volunteer with Grade 1 reaction to skin testing with house dust mite, grass or tree pollen
was excluded.
2.5.2.2 Human Corticotropin Releasing Factor
A lOOpg bolus dose of human corticotropin releasing factor (hCRF) (Clinalfa AG,
Laufelfingen, Switzerland) was given immediately after a 0800hr plasma/serum sample.
Further samples for Cortisol analysis were taken 30 and 60 minutes following the
injection. The peak Cortisol response was used for the purpose of analysis for post hCRF
Cortisol response. A normal result was taken to be a post stimulation serum or plasma
Cortisol value greater or equal to 500 nmol/1 (18pg/dl).
2.6 URINARY CORTISOL.
2.6.1 10 Hour Overnight Urinary Cortisol
This sample consists of the total amount of urinary Cortisol excreted between 2200hrs
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and 0800 hrs the following day. Patients emptied their bladder, as normal, immediately
prior to commencing the sample, and collected all voided urine in the container
provided. Patients were asked to empty their bladder into the container at the end of the
period to finish the collection. A normal result was taken to be a value greater or equal
to lOnmol/lOhr (3.6pg/10hr).
2.6.2 24 Hour and Fractionated Urinary Cortisol
In the last two studies in Chapter 5, twenty-four hour collections of urine were obtained.
A daytime 12 hour collection (from 0800 hrs to 2000hrs) and nighttime (from 2000hrs to
0800hrs the following day) were obtained in a similar manner as described above
(section 2.6.1). The 24 hour urinary Cortisol measurement was calculated by the sum of
the two twelve hour samples. A normal result was taken to be a value greater or equal to
40nmol/24hr (14.4pg/24hr). An 8am spot collection was obtained by patients voiding a
sample at 0800hrs on request after drinking an adequate amount of water after rising in
the morning. This sample was included when calculating the daytime and 24 hour
samples. A normal result was taken to be a value greater or equal to 20nmol (7.2pg).
The volume of each collection was measured and duplicate aliquots were obtained and
stored at -20°C until analysis in batches at the end of each study. The urinary Cortisol
was extracted from urine using dichloromethane prior to analysis. Urinary Cortisol was
measured using a commercial RIA kit which has no cross reactivity for any inhaled
corticosteroid. For the first two studies in Chapters 3 and the last in Chapter 5, an
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Immunodiagnostic (Immunodiagnostic System Ltd, Boldon, Tyne & Wear UK) RIA kit
was used. For all other studies (last in Chapter 3, first two in Chapter 5, Chapters 4, 7
and 9) an Incstar (Incstar Ltd, Wokingham, Berkshire) RIA kit was used. The
Immunodiagnostic RIA kit had a within assay CV of 10% and a between assay CV of
7.2%, whereas the Incstar RIA kit had a within assay CV of 6.7% and a between assay
CV of 8.2%. The CV's were calculated from the results of the studies performed in this
thesis.
2.6.3 Urinary cortisol/creatinine ratio
Urinary Cortisol was corrected for creatinine excretion in all studies by calculating a
cortisol/creatinine ratio. This obviated any errors in volume measurement and is thought
to be more sensitive than an uncorrected value. However, as the excretion rates of both
Cortisol and creatinine are not constant it does not compensate for incomplete
collections. Urinary creatinine was measured on a Cobas-Bio autoanalyser (Roche
Products Ltd, Welwyn Garden City, UK). The within assay CV was 3.9% and the
between assay CV was 0.63%.
2.7 OSTEOCALCIN
Blood was taken at 0800hrs (at the same time as the sample for Cortisol) for osteocalcin
and allowed to clot at room temperature for 60 minutes, centrifuged at 3300 rpm and
stored at -20°C until analysis by radioiummoassay (Incstar Ltd, Wokingham, Berkshire,
UK). The within assay CV was 3.3%.
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2.8 EOSINOPHILIC CATIONIC PROTEIN
The samples of blood for ECP were collected in Vacutainer Hemogard SST silica gel
containing tube (Becton Dickinson Vacutainer systems Europe, France). After
collection, the samples were kept at room temperature for 60 minutes before being
centrifuged at 3300 rpm for 15 minutes. The serum was collected in a separate aliquot
bottle and frozen at -20°C until analysis at the end of the study. The ECP was measured
using a radioimmunoassay kit (Pharmacia and Upjohn Diagnostics AB, Uppsala
Sweden).
2.9 BLOOD EOSINOPHIL COUNT
Blood samples for measurement of eosinophil count were collected in ETDA containing
tubes. They were analysed using an automated haematology analyser (SE-9000
Haematology analyser, Sysmex UK Ltd, Bucks, UK).
2.10 SPIROMETRY
The forced expiratory volume in one second (FEVi), forced vital capacity (FVC) and the
forced expiratory flow between 25% and 75% of forced vital capacity or forced mid
expiratory flow rate (FEF25-75) were performed according to criteria of the American
Thoracic Society<66) using a Vitalograph compact spirometer (Vitalograph Ltd,
Buckinghamshire UK) with a pneumotachograph head and pressure transducer and on¬
line computer assisted determination of FEVi and FEF25-75. Forced expiratory
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manoeuvers were performed from total lung capacity to residual volume. The best test
FEVi value was taken from three consistent measurements (a coefficient of variation of
less than 5% was considered acceptable). The pneumotachograph head was calibrated
daily using a precision syringe (Vitalograph Ltd Buckinghamshire, UK).
2.11 TOTAL BODY PLESTHMOGRAPHY
2.11.1 Spirometry
A PK Morgan plethysmograph (PK Morgan, Kent, UK) with a pneumotachograph head
and pressure transducer was used to measure forced expiratory flow volume curves
(from total lung capacity to residual volume). Forced expiratory flow rates between 50%
and 75% (FEF2575) of forced vital capacity were determined by on line computerised
analysis. Patients were seated and wearing nose clips during the tests. The best of three
consecutive measurements were taken. The pneumotachograph head was calibrated
daily using a 5 litre precision syringe (PK Morgan, Kent, UK).
2.11.2 Airways Resistance
Airways resistance was measured in a constant-volume pressure-compensated whole
body plethysmograph (PK Morgan, Gillingham, Kent, UK) with subjects using nose-
clips panting at 2 Hz and a peak-to-peak flow of 2-3 1/sec. Airway resistance and
specific airways conductance was automatically calculated by an on-line computerised
analysis. The mouth pressure, box pressure and pneumotachograph head were calibrated
daily.
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2.12 BRONCHIAL CHALLENGE TESTING
2.12.1 Methacholine Challenge Test
A microprocessor controlled dosimeter was used to deliver lOpl of aerosol of
methacholine from 10 separate System 22 Turbo jet nebulisers (Medic Aid, Pagham,
West Sussex, UK), during an individually timed activation of approximately two
seconds at a driving pressure of 20 psi (138 kPa). Aerosol release into a mouthpiece was
activated by a pressure transducer during inspiration from functional residual capacity to
inspiratory capacity. Five inhalations (total of 50 pi) were taken for each incremental
dose and nose clip was used in all cases.
Airway narrowing was assessed by measurement of FEVi with a Morgan Spiroflow
pneumotachometer (PK Morgan Ltd., Gillingham, Kent, UK) with an Apple Macplus
PC running software by Collingwood Measurement Ltd. (Packington, Leicestershire,
UK). At each time point (5 minute intervals), the mean of the highest three of six FEVi
measurements was calculated. In order to avoid the discomfort of completing a FVC
manoeuvre each forced expiration was terminated after 1 second as indicated by an
audible signal from the computer. Baseline FEVi was taken to be the overall mean from
the 3 consecutive time points prior to methacholine administration.
Doubling concentrations of methacholine from 0.0625 to 32 mg/ml (doubling
cumulative doses of 3.125 to 3200pg) were administered at five minute intervals until a
67
fall in FEVi greater than or equal to 20% was recorded. The methacholine provocation
dose required to cause exactly 20% fall in FEV] (PD20) was calculated by computerised
interpolation of the steep part of the log dose-response curve for methacholine and
FEV 1. If the FEV 1 did not show a 20% drop when a cumulative dose of 3200 pg had
been inhaled, a censored PD20 value of 6400pg (double the maximum cumulative dose)
was used for that test for the purpose of statistical analysis.
2.12.2 Adenosine Monophosphate Bronchial Challenge
Fresh solutions of adenosine monophosphate (AMP) in a range of concentrations from
0.04mg/ml to 800mg/ml were made up in normal saline on each day of the study. A
nebicheck nebuliser controller (PK Morgan Ltd., Rainham, Kent, UK) was used with a
system 22 Acom nebuliser (Medic Aid Ltd., Pagham ,West Sussex, UK) with a driving
pressure of 20 psi (138KPa). The nebuliser was activated for 1.2 seconds from the
initiation of respiration. A mouthpiece was used with the nebuliser and the nose clipped
during the procedure. The mouthpiece was placed between the teeth of the subject who
exhaled to slightly below functional residual capacity and then inhaled slowly over 1 to
2 seconds toward total lung capacity, where the breath was held for 3 seconds before
taking the next breath.
Baseline pulmonary function was assessed by measurement of FEVi using a Vitalograph
compact spirometer (Vitalograph Ltd., Buckinghamshire UK) as described above (see
section 2.10). Subjects then inhaled five breaths of a normal saline control solution
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followed by sequential doubling concentrations of AMP given at 3 minute intervals.
FEVi was measured 1 minute after administrating saline and each concentration of
AMP. The test was terminated when a 20% fall in FEVi from the post-saline value was
attained. The PC20 was calculated using a computer assisted curve fitting package
(Biolab Assistant 1.1, University of Dundee, UK) and interpolation of the steep part of
the log dose-response curve. A value of 1600mg/ml (double the maximum) was assigned
if the FEVi did not fall below 20% of baseline value.
2.13 NITRIC OXIDE
2.13.1 Exhaled Nitric Oxide
Exhaled nitric oxide was measured using a chemiluminescence analyser (Model
LR2000; Logan Research, Rochester, UK) sensitive to NO from 2 to 5000ppb, with a
resolution of 0.3 ppb, and a response time of 2 seconds, which was designed for on-line
recording of exhaled NO concentration. The NO analyser also measured CO2,
(resolution 0.1%, response time 200ms) and sample pressure and volume in real-time.
The sampling rate for the analyser was 250ml/min and the analyser was calibrated
weekly using a cylinder of nitric oxide at concentration of 108ppb (BOC special gases,
Surrey research park).
Patients performed the test in the standing position without wearing nose clips.
Measurements of exhaled NO were made by exhalation from total lung capacity for 20-
30 seconds via a wide bore inert (Teflon) tube into the analyser with a flow of 15 1/min
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creating a mouth pressure of 70 mmH20 in order to cause elevation of the soft palate so
that the nasal cavities are partitioned from the remainder of the respiratory tract
preventing contamination of exhaled air. The mouth pressure was kept constant as
patients maintained a constant expiratory flow rate using a visual feedback system with a
light emitting diode visual display of expiratory flow measured by pressure and volume
sensors in the analyser. The conditions of temperature (20°C), flow rate (250ml/min)
and mouth pressure (70 mm H20) were standardised throughout the study.
The initial peak (corresponding to dead-space and nasal contaminated air) was ignored
and the value was taken at the plateau at the last part of exhalation. This plateau value,
corresponding to the plateau of end-exhaled C02, has been shown to represent lower
airways and alveolar sampling by direct sampling via a bronchoscope'313\ Three
measures of nitric oxide were taken after intervals of at least one minute and the results
were recorded.
2.13.2 Nasal Nitric Oxide
Nasal nitric oxide (NO) was determined using the same chemiluminescence analyser
(Model LR2000, Logan Research, Rochester, UK). Nasal NO was measured during
breath-holding as assessed by simultaneous measurement of exhaled carbon dioxide as
this method keeps the soft palate closed'314). Patients inserted the Teflon tubing in one
nostril and ambient room air (NO free) was drawn up one nostril, exiting from the other,
into the analyser. The analyser generated the negative pressure and kept a constant flow
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rate of 250ml/min. The value was taken as the plateau value of NO. A test was deemed
unacceptable if there was a rise in exhaled C02. Three measures of nitric oxide were
recorded.
2.14 DIARY CARD
2.14.1.1 Peak Expiratory Flow Rate
Peak expiratory flow (PEF) was measured using a portable Mini-Wright peak flow
meter (Clement Clark International Ltd., Harlow, Essex UK). Domiciliary measurements
were made twice daily at approximately the same time each day (+/- 1 hour) at 8am and
8pm. Patients withheld their inhaled short-acting (32 agonist reliever therapy for 6 hours
prior to measurement. The test was performed, while standing, by exhaling forcefully on
three occasions and recording the highest value. For a given study, each patient used the
same individual peak flow meter.
2.14.1.2 Nasal Peak Inspiratory Flow Rate
Nasal peak inspiratory flow rate (nPIFR) was measured using a portable inspiratory flow
meter (In-check' Clement Clarke International Limited, Harlow, Essex, UK) with a
purpose built facemask. Prior to testing, patients were asked to blow their nose to expel
secretions. All measurements were made in the sitting position, with a good seal round
the facemask and patients inspired forcefully from residual volume to total lung capacity
through their nose, with the mouth closed according to manufacturer's packet insert
instructions. Measurements were made twice daily, at approximately the same time each
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day +/- 1 -hour, at 8am and 8pm, throughout the study. Three maximal inspiratory efforts
were performed, the highest value being recorded by the patient. For a given study, each
patient used the same individual inspiratory flow meter.
2.14.2.1 Asthma Symptoms
Asthma symptom scores were recorded according to a four-point scale, with zero
indicating no symptoms and three indicating maximal symptoms, twice daily at 8am and
8pm. Patients recalled the extent of their symptoms over the preceding 12 hours.
2.14.2.2 Seasonal Allergic Rhinitis Symptoms.
Seasonal allergic rhinitis symptoms were recorded under four headings, namely nasal,
eye and throat symptoms, and the effect of their condition on their daily activity.
Symptom scores were documented according to a 4-point scale with 0 representing no
symptoms and 3 representing maximal symptoms. Under the heading of nasal
symptoms, patients recorded "runny nose", "blocked/stuffy nose", "itchy nose" and
"sneezing". For eye symptoms, patients recorded "itchy eyes", "watery eyes" and "red
eyes". Under the heading of throat symptoms, patients recorded "tickly throat".
Patients were also asked to record the extent to which their symptoms interfered with
their daily activity on an 11-point scale, with 0 representing no symptoms and 10
representing maximal symptoms.
2.14.3 Rescue Therapy Usage
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On a twice daily basis, at 0800hrs and 2000hrs, patients recorded the number of puffs of
rescue medication with inhaled reliever therapy (short-acting fl2 agonist or
anticholinergic inhalers) that they had taken during the preceding 12 hours. Patients also
recorded their requirement for use of ocular sodium cromoglycate eye drops in number
of drops used during the preceding 24 hours at 0800hrs.
2.15 ALLERGY TESTING
2.15.1 Skin Prick Testing
Patients withheld anti-histamine medication for 4 days prior to skin prick testing. This
was performed following a standard protocol (Bencard testing solutions, Welwyn
Garden City, UK) using extracts including grass, tree and weed pollen in addition to a
negative control. Results were read after 10 minutes, a positive reaction being defined
as a minimum weal diameter with erythema of 2mm greater than negative control.
2.15.2 Phadiotop Testing
Patients were assessed for the presence of atopy by multiple allergen testing of their
serum to a battery of inhaled allergens including mites, molds, trees, grasses weeds, cats
and dogs by radioallergosorbent testing (Uni Cap Phadiotop test, Pharmacia Upjohn
Ltd., Milton Keynes, UK).
2.16 POLLEN COUNT MEASUREMENT
Data were collected locally on a daily basis, (Scottish Crop Research Institute, Dundee,
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UK) using a 7 day recording volumetric spore trap (Burkard Manufacturing Co Ltd.,
Hertfordshire, UK).
2.17 STATISTICAL ANALYSIS
Each study was powered, where possible, as detailed. Data were entered into a computer
and checked in duplicate. All bronchial challenge data were log transformed as were
other data if they did not conform to a normal distribution. For bronchial challenge
testing, data from active treatment were compared to placebo or baseline in terms of the
fold difference. This comparison is commonly expressed as the number of "doubling
dose differences" from placebo. This is calculated as the log of the fold difference
divided by the logio of 2 (0.30103).
For all parameters (active treatments at each dose and placebos) comparisons were made
by an overall multifactorial analysis of variance (MANOVA) using treatment, dose,
subject and period as factors. Where a significant overall difference between treatments
and placebo was found multiple range testing was applied to identify where these
differences occurred. A value ofp<0.05 (two tailed) was considered to be significant and
95% confidence intervals for mean treatment differences or fold differences were
calculated.
The presence of dose related suppression was determined using least squares regression
analysis to evaluate the overall effects of all doses of each drug studied, where
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appropriate. In Chapter 4, parallel slope analysis was then used where possible and in
the presence of a significant fit for the common parallel slope a dose ratio was calculated
for relative potency.
The Area Under the Curve (AUC) plasma Cortisol was generated from the integrated 24
hour plasma sample profile using the trapezoidal method and the fractionated (overnight,
8am, daytime) components were also analysed separately. The fractionated (overnight, 8
am, daytime) and 24 hour urinary Cortisol collections were analysed after correcting for
urinary creatinine excretion.
The number of individual values of a measurement below the lower limit of normal was
analysed using the Chi- square test.
All data were analysed using a 'Statgraphics' software package (STSC Software Group,
Rockville, Maryland, USA).
2.18 MEDICATION
beclomethasone dipropionate (Vancenase AQ double strength, Schering Corporation,
Kenilworth, USA)
budesonide (Pulmicort pMDI, Astra Pharmaceuticals Ltd, Kings Langley, Herts, UK)
budesonide (Pulmicort Respules, Astra Pharmaceuticals Ltd, Kings Langley, Herts, UK)
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budesonide (Pulmicort Turbuhaler, Astra Pharmaceuticals Ltd, Kings Langley, Herts,
UK)
budesonide (Rhinocort Aqua, Astra Pharmaceuticals Ltd, Kings Langley, Herts, UK)
flunisolide (Aerobid, Forest Pharmaceuticals Inc, St Louis, USA)
fluticasone propionate (Flixotide pMDI, Allen & Hanburys, Uxbridge, UK)
fluticasone propionate (Flonase, Glaxo Wellcome Inc, USA)
fluticasone propionate (Flovent metered dose inhaler, Glaxo-Wellcome Inc, USA)
formoterol (Oxis Turbuhaler, eformoterol fumarate, Astra Pharmaceuticals Ltd, Kings
Langley, Herts, UK)
ipratropium bromide (Atrovent Forte, Boehringer Ingelheim, Bracknell, UK)
mometasone furoate (Nasonex, Schering-Plough Ltd, Hertfordshire, UK)
montelukast (Singulair, Merck Sharpe & Dohme Ltd, Herts, UK)
prednisolone (5mg tablets, Biorex Laboratories Ltd, Enfield, UK)
salbutamol (Ventolin Accuhaler, Allen & Hanburys Ltd, Uxbridge, UK)
salmeterol (Serevent Accuhaler, Allen & Hanburys Ltd, Uxbridge, UK)
sodium cromoglycate (Clariteyes, Sheering Plough, Welwyn City, UK)
triamcinolone acetonide (Azmacort oral inhaler, Rhone Poulenc Rorer Pharmaceuticals,
Collegeville, USA)




DOSE RESPONSE COMPARISON FOR
RELATIVE SYSTEMIC EFFECTS OF
INHALED CORTICOSTEROIDS
Study 1 A Comparison of the Systemic Effects of Inhaled Triamcinolone
Acetonide and Fluticasone Propionate Adult in Asthmatic
Patients
Study 2 A Comparison of the Systemic Effects of Inhaled Triamcinolone
Acetonide and Flunisolide in Healthy Adult Volunteers
Study 3 A Comparison of the Systemic Effects of Inhaled Fluticasone
Propionate Given By Two Devices with Different Lung Delivery
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3.1 INTRODUCTION
This chapter examines dose-response comparisons for relative systemic effects of
inhaled corticosteroids. There are three separate studies each of which look at different
aspects of systemic activity. The first is a dose-response study comparing triamcinolone
acetonide and fluticasone propionate in asthmatic patients, which assesses systemic
activity in terms of basal measures of adrenal function. The second evaluates
triamcinolone acetonide and flunisolide by assessing basal and dynamic adrenal function
using the ACTH stimulation test. As ACTH stimulation test now contra-indicated in the
UK for use in asthmatics (see section 2.5.2.1), healthy volunteers were recruited. The
third study evaluates the influence of the drug device on the degree of systemic activity,
again in healthy volunteers. None of the studies investigate the clinical efficacy of the
drugs or the therapeutic ratio.
A pilot study'3l5) was performed to compare the adrenal suppression of inhaled
fluticasone propionate and triamcinolone acetonide in twelve healthy volunteers. Both
drugs were given via their respective pressurised metered dose inhaler (pMDI) devices
at high doses within the manufacturers recommended dose range. The study was of a
single (investigator) blind randomised crossover design and compared a total daily dose
of 1625pg fluticasone propionate delivered via a pMDI, 1600pg daily of triamcinolone
acetonide delivered via a pMDI with integrated tube spacer, or placebo pMDI. All
treatments were given in two divided doses at 8.00 am and 10.00 pm over a 24 hour
period. Each drug treatment was separated by a 1 week washout. Blood samples were
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taken for 8.00am plasma Cortisol, i.e. 10 hours following the second dose. 10 hour
overnight urine collections were taken for urinary Cortisol and creatinine excretion. For
8.00 am plasma Cortisol (geometric mean, nmol/1) compared with placebo (353.1)
fluticasone propionate (137.7) produced significant (p<0.05) suppression (2.57-fold
difference: 95% CI 1.50 to 4.39), whereas triamcinolone acetonide (262.8) did not (1.34-
fold difference: 95% CI 0.77 to 2.34). Fluticasone propionate produced 1.91-fold greater
adrenal suppression (p<0.05) than triamcinolone acetonide (95% CI 1.10 to 3.33).
Individual subjects with abnormal low 8.00 am Cortisol values < 150nmol/l (< 5.4pg/dl)
were n=4 for fluticasone propionate and n=0 for triamcinolone acetonide (p<0.05).
Overnight urinary cortisol/creatinine ratio (geometric mean, nmol/mmol) did not show
any difference between fluticasone propionate (1.48) and triamcinolone acetonide
(1.60), with both producing significant suppression versus placebo (4.01): triamcinolone
acetonide 2.50 fold difference (95% CI 1.45 to 4.24), fluticasone propionate 2.71 fold
difference (95% CI 1.57 to 4.69). Therefore fluticasone propionate 1625pg per day
produced approximately two-fold greater adrenal suppression of 8.00 am plasma Cortisol
than triamcinolone acetonide 1600pg per day when given twice daily, and one third of
subjects with fluticasone had abnormal low 8.00 am Cortisol values <150nmol/l. There
were no differences between the drugs for urinary Cortisol excretion.
However, as this was a pilot study, there were several limitations to the study that may
result in the findings not being clinically relevant. Firstly, the subjects were healthy
volunteers and had normal airway caliber. As the systemic activity of inhaled
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corticosteroids like fluticasone propionate and triamcinolone acetonide with a high
degree of first-pass metabolism is mainly determined by the lung delivery, volunteers
with normal airway caliber will have greater systemic absorption. Thus the degree of
adrenal suppression compared to placebo is likely to be different between volunteers and
patients with airways obstruction. Furthermore there may be other differences between
patients with asthma and healthy volunteers including differences in muco-ciliary
clearance and attitudes towards taking medication. In short, it is only clinically relevant
to evaluate the response of drugs in patients who would normally be taking them.
Secondly the measurements were made after one day's dosing and therefore the blood
and tissue levels of the inhaled corticosteroids could not have reached steady state. As
the degree of adrenal suppression is related to steady-state drug levels, a single day's
dosing will not represent the clinical setting. In this respect Lonnebo et al(316) showed
that fluticasone propionate had greater systemic activity after repeated dosing compared
to after a single dose. Furthermore, as discussed above (see section 1.4.1), single dose
studies offer little information regarding the relative effects of two drugs. More
meaningful results are obtained from dose-response rather than single dosing studies
when comparing the relative systemic bioactivity of different inhaled corticosteroids.
For these reasons the study was repeated in the first study of this chapter in order to
compare fluticasone propionate and triamcinolone acetonide in a dose-response manner
at steady-state dosing interval in patients with asthma. The doses chosen represent low
medium and high treatments and were given by their respective pressurised metered
dose inhalers.
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The second study assesses the effects of inhaled corticosteroids on basal and dynamic
measures of HPA-axis activity. Although 8am serum Cortisol and overnight urinary
cortisol/creatinine ratio are recognised to be sensitive and reproducible markers of
systemic bioactivity, measuring adrenal suppression in terms of early morning serum
Cortisol concentration or urinary Cortisol excretion only gives information about the
basal adrenocortical activity. It is probably more clinically meaningful to look at the
effects of stress on the hypothalamic-pituitary-adrenal (HPA) axis, as this will indicate
the degree of adrenal reserve. The low dose ACTH (0.5pg) test was chosen, as there is
evidence that it may be more a sensitive method of detecting impaired adrenocortical
reserve than the standard (250pg) ACTH test (see section 1.3.4).
As well as comparing the relative systemic effects of inhaled corticosteroids with
different pharmacological properties, for example fluticasone propionate and
triamcinolone acetonide, it is also important to consider the influence of the lung
delivery via an inhaler device (see section 1.3.1). For example the two-fold difference
between these two drugs when delivered by their respective pressurised metered dose
inhalers, elicited in the pilot study'315), may be confounded by the respective device
delivery. Fluticasone propionate is a particularly good drug to use when investigating the
influence of the inhaler device, as the near complete first pass hepatic metabolism will




Study l:Twelve stable mild to moderate asthmatic patients (6 female) ofmean age (SE):
34.3 (2.9) years mean FEVi: 82.1 (2.0) % predicted, and FEF25-75 53.6 (5.5) % predicted,
completed the study. All patients were receiving less than or equal to 400pg per day of
inhaled corticosteroid. (Median dose: 250pg per day, range: 100 to 400pg per day).
Study 2: Twelve healthy volunteers (3 female) mean age (SE) 24.2 (2.4) years.
Study 3: Sixteen healthy volunteers (8 female) mean age (SE) 29.3 (2.3) years.
Study Design
Study 1: Patients were randomised to receive either triamcinolone acetonide 100 pg per
actuation (dose delivered to patient as Azmacort oral inhaler with integrated spacer
device, Rhone Poulenc Rorer Pharmaceuticals Inc., USA) or Fluticasone propionate
llOpg per actuation (dose delivered to patient as Flovent metered dose inhaler, Glaxo-
Wellcome Inc., USA). Six patients received fluticasone propionate first in sequence and
the other six patients received triamcinolone acetonide first in sequence. Each drug
sequence was given over a total of 9 days in twice daily divided doses at 8am and 10pm.
The doses were as follows given sequentially each for three days: TAA: 2 puffs bid, 4
puffs bid and 8 puffs bid (i.e. total daily dose of 400pg, 800 pg, 1600pg, respectively);
FP: 2 puffs am/1 puff pm, 4 puffs am/3 puffs pm, 7 puffs bid (i.e. total daily dose of
330pg, 770pg, 1540 pg, respectively). Prior to each 9 day drug sequence (i.e. either
fluticasone propionate or triamcinolone acetonide) patients received the respective
82
matching placebo inhaler (pressurised metered dose inhaler (pMDI) or oral inhaler) 2
puffs bid also for three days. The patients' usual inhaled corticosteroid therapy was
discontinued during the placebo and treatment periods. There was also a 12 day
washout between each of the 9 day treatment sequences where patients received their
usual maintenance inhaled corticosteroid therapy. Each inhaler was discharged twice
prior to inhalation and each inhalation was followed by mouth rinsing. Spirometry was
also measured at each visit to ensure the FEVi did not vary by more than 15% between
treatments.
Study 2: Subjects were randomised to receive either: Triamcinolone acetonide 100 pg
per actuation (as Azmacort with integrated actuator/spacer, Rhone Poulenc Rorer
Pharmaceuticals, Inc, Collegeville, USA) or Flunisolide 250 pg per actuation without
spacer (as Aerobid, Forest Pharmaceuticals, Inc, St Fouis, USA). These drugs were used
according to manufacturer's labeling. Six patients received triamcinolone acetonide
(TAA) first and the other six received flunisolide (FN) first in sequence. Each drug was
given for six days (each dose for 3 days) in twice daily doses at 0800 h and 2200 h
mouth rinsing. The dosing sequence was as follows each given sequentially for 3 days:
TAA 4 puffs BID and 8 puffs BID (i.e. total daily dose of 800 pg and 1600 pg
respectively); FN 2 puffs BID and 4 puffs BID (i.e. total daily dose of 1000 pg and
2000 pg respectively). The total daily dose of each drug was chosen to reflect the
lowest (L) and highest (Fl) recommended dose according to the manufacturers' labeling.
Prior to the first treatment sequence each patient received a placebo treatment sequence
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2 puffs BID for three days. The placebo device used corresponded to the first treatment
device (Flunisolide pMDI without spacer or Azmacort with integrated actuator/spacer).
There was a 10 day washout between treatments. Each inhaler was discharged twice
prior to inhalation and each inhalation was followed by mouth rinsing.
Study 3: Volunteers were randomised into a 3-way crossover study comparing placebo
inhaler [PL]; 2mg of fluticasone propionate dry powder (Flixotide Accuhaler 250pg per
actuation, Allen & Hanburys Ltd, Uxbridge UK) [DP]; or a pressurised metered dose
inhaler (pMDI) (Flixotide 250pg per actuation) with a Volumatic spacer
[pMDI+spacer], Each treatment was given at 1800hrs, under supervision. All data were
log transformed followed by multifactorial analysis of variance and Bonferroni's
multiple range testing.
Measurements
Measurements were made after each dose level of both treatments and after both the run-
in and washout placebo for Serum Cortisol, 10 Hour Overnight Urinary Cortisol
excretion, Overnight Urinary Cortisol/Creatinine Ratio (Study 1) and for 8am Serum
Cortisol, Low Dose Synacthen Test, Overnight Urinary Cortisol/Creatinine, 8am urinary
cortisol/creatinine (Study 2). In Study 3, subjects attended the following day for
measurement of 8am serum Cortisol and collected all urine passed between 10pm on the
day of dosing until 8am on the following day for analysis of Cortisol and creatinine.
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Statistical Analysis
All three studies were designed with sample size of 12 with 80% power (beta error =0.2)
to detect a 20% difference in 8.00am Cortisol (the primary end point) between treatments
with the alpha error set at 0.05 (two-tailed). Comparisons between treatments were made
by an overall multifactorial analysis of variance (MANOVA), followed by Duncan's
multiple-range testing in the first study and Bonferroni's multiple-range test in the other
two studies. In addition, a comparison was made to assess any carryover effect between
the active treatment periods by comparing values for placebo in order of sequence. The
presence of dose related suppression was determined using least squares regression
analysis to evaluate the overall effects of all three dose levels for each drug in the first
study. Data were log transformed prior to analysis so as to normalise their distribution in
the first study only.
The number of individual values for overnight urinary Cortisol < 3.6pg (10 nmol) and
early morning urinary Cortisol < 7.2pg (20 nmol); 8am serum Cortisol < 5.4pg/dl (150
nmol/1) and serum Cortisol response to ACTH < 18pg/dl (500 nmol/1), were analysed
using the Chi-Square test in Study 2, whereas only those values for overnight urinary





There were no significant carryover effect between the first and second placebo using
either of the parameters measured: 8am serum Cortisol 574.4 vs 539.1 nmol/1 and
overnight corrected urinary cortisol/creatinine ratio 5.0 vs 5.3 nmol/mmol. There were
no significant differences between the FEVi values (as % predicted) comparing placebo
(PL) with low (L) medium (M), high (H) doses of each drug: PL (92.3); TAA: (L: 96.6,
M: 94.9, H: 94.5); FP (L: 96.6, M: 92.3, H:95.0).
8 am Serum Cortisol:
Regression analysis showed there was significant dose-related suppression with
fluticasone propionate (p<0.001) but not with triamcinolone acetonide [Figure 3.1]. At
the highest dose there was a 2.33 fold ratio between FP and PL (p<0.05), and a 2.03 fold
ratio between TAA and FP (P<0.05). There was no significant difference between TAA
and PL at any dose. Compared with PL there were significant (p<0.05) differences with
medium and high doses of FP but at no dose of TAA. Geometric means (SE) were as
follows (nmol/1): PL: 574.4 (33.1); FP: L: 505.1 (28.9), M: 419.1 (41.8), H: 246.8
(44.4); TAA: L: 554.9 (32.0), M: 538.0 (53.6); H: 500.8 (90.0).
Overnight Urinary Cortisol:
Regression analysis for overnight corrected urinary cortisol/creatinine excretion showed
fluticasone propionate to cause significant (p<0.005) dose related suppression whereas
86
this was not significant with triamcinolone acetonide [Figure 3.1] At the high dose there
was a significant (p<0.05) 2.69 fold ratio between FP and PL and a 1.9 fold ratio
between FP and TAA. There were significant (p<0.05) differences from placebo for
medium and high doses of FP and for the medium dose of TAA. Geometric means (SE)
were as follows (nmol/mmol): PL: 5.0 (.07); FP: L: 4.2 (0.6), M: 2.2 (0.3), H: 1.9 (0.5);
TAA: L: 4.3 (0.6), 3.3 (0.4), 3.5 (1.0). For doses < lOOOpg per day the number of
individual results with an abnormal low value for urinary Cortisol excretion (< 10
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Figure 3.1
Geometric means with standard error ofmean for placebo (PL); triamcinolone acetonide
(TAA) at 400 pg per day, 800pg per day, and 1600pg per day; and fluticasone
propionate (FP) at 330 pg per day, 770pg per day, 1540 pg per day for 8am serum
Cortisol (top) and overnight corrected urinary cortisol/creatinine excretion (bottom).
Regression analysis showed significant dose-related suppression for fluticasone
propionate (* p<0.001) for serum Cortisol and (* p<0.005) for urinary cortisol/creatinine






























Individual values for uncorrected overnight urinary Cortisol excretion for all 3 dose
levels of each drug. For doses < lOOOpg per day individual abnormal low levels
(<10nmol/10hr) were: 10/24 (42%) for fluticasone propionate (FP) vs 3/24 (13%) for
triamcinolone acetonide (TAA) (p<0.005).
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Study 2:
There were no significant carryover effects between placebo and washout values in
sequence for any of the parameters measured: a) Pre ACTH serum Cortisol 481.8 vs
513.7 nmol/1, b) post-ACTH 666.3 vs 668.9 nmol/1, c) overnight corrected urinary
cortisol/creatinine ratio 6.4 vs 5.7 nmol/mmol, d) 8am corrected urinary
Cortisol/creatinine ratio: 39.0 vs 39.5 nmol/mmol. Mean values (after placebo or
washout) prior to starting treatment with either flunisolide and triamcinolone acetonide
respectively were also not significantly different (FN vs TAA): a) Pre ACTH serum
Cortisol 502.0 vs 493.6 nmol/1, b) post ACTH 676.2 vs 659.0 nmol/1, c) overnight
corrected urinary cortisol/creatinine ratio 6.3 vs 5.8 nmol/mmol, or d) 8am corrected
urinary cortisol/creatinine ratio 40.9 vs 36.0 nmol/mmol.
Pre-ACTH 8 am serum Cortisol:
There were no significant differences, between placebo (481.8 nmol/1) and any of the
other treatments: L TAA (519.9 nmol/1), L FN (545.8 nmol/1), H TAA (388.7 nmol/1), H
FN (481.4 nmol/1) [Figure 3.3]. There was 1 subject who had a value less than 5.4pg/dl
(150 nmol/1) (with L FN)
Post ACTH Serum Cortisol
There was no significant difference between placebo (666.3 nmol/1) and any of the other
treatments L TAA (686.0 nmol/1), L FN (699.2 nmol/1), H TAA (591.4 nmol/1) H FN
(617.0 nmol/1) [Figure 3.3], When analysing the number of individual values less than
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18|iig/dl (500 nmol/1) for both dose levels there was no significant difference between
the drugs: 3/24 for TAA vs 2/24 for FN [Figure 3.4], None of the post-stimulated
Cortisol levels were below 14.4pg/dl (400 nmol/1).
Overnight corrected urinary cortisol/creatinine excretion:
Compared with placebo (6.4 nmol/mmol) there was significant suppression (p<0.05) for
the high dose H TAA (2.3 nmol/mmol) and FI FN (2.6 nmol/mmol) but not at the low
dose L TAA (4.5 nmol/mmol) or L FN (4.2 nmol/mmol). There was no significant
difference between the two drugs [Figure 3.5], When analysing individual values for
both dose levels for overnight urinary Cortisol less than 3.6pg (10 nmol) there were no
differences between the two drugs: 13/24 for TAA vs 11/24 for FN.
Early morning corrected urinary cortisol/creatinine excretion
Compared with placebo (39.0 nmol/mmol) there was significant suppression (p<0.05)
with the high dose of both drugs (H TAA: 26.6 nmol/mmol, FI FN 26.5 nmol/mmol) but
no significant suppression with the low doses (L TAA 36.5 nmol/mmol, L FN 37.2
nmol/mmol) [Figure 3.5]. When analysing values less than 7.2 pg (20nmol) for both
dose levels for early morning urinary Cortisol, there was no difference between the






























Means with standard error for placebo (PL), triamcinolone acetonide 800 pg per day
(TAA-L) and 1600pg per day (TAA-H); flunisolide lOOOpg per day (FN-L) and 2000pg
per day (FN-H) for pre and post ACTH stimulation serum Cortisol. Neither drug had
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PL TAA-L TAA-H FN-L FN-H
Individual values for placebo (PL), triamcinolone acetonide 800 pg per day (TAA-L)
and 1600pg per day (TAA-H); flunisolide lOOOpg per day (FN-L) and 2000pg per day
(FN-H) for pre ACTH stimulation for (a) 8am plasma Cortisol (There was only 1
abnormal low value (with FN-L) below 150nmol/l) (b) post ACTH stimulation plasma






















































PL TAA-L TAA-H FN-L FN-H
Means with standard error for placebo (PL), triamcinolone acetonide 800pg per day
(TAA-L) and 1600pg per day (TAA-H); flunisolide lOOOpg per day (FN-L) and 2000pg
per day (FN-H) for (a) overnight and (b) early morning corrected urinary




There were no significant differences between PL and DP for any measurement [Table
3.1]. However, there were significant differences (p<0.05) between pMDI+spacer versus
DP [Table 3.1]. The geometric mean fold difference (95% CI for difference) between
DP versus pMDI+spacer were: 5.48-fold (2.90-10.34) for urinary Cortisol, 7.68-fold
(4.10-14.39) for urinary cortisol/creatinine ratio, and 5.57-fold (2.97-10.43) for serum
Cortisol. For serum Cortisol the number of subjects with an abnormal low value




Geometric means (within treatment 95% confidence intervals) for placebo inhaler (PL),
2mg nominal dose of fluticasone propionate delivered via a pressurised metered dose
inhaler and spacer (pMDI+spacer), and via a dry powder Accuhaler device (DP) for 10
hour overnight urinary Cortisol (OUC), overnight urinary cortisol/creatinine ratio
(ONCC) and 8am serum Cortisol (8am). Asterisk denotes significant (p<0.05) difference






























Placebo pMDI+spacer Dry Powder
Figure 3.6
Scatter plot showing individual values for 8am serum Cortisol for placebo and
fluticasone propionate delivered via a metered dose inhaler and spacer (pMDI+spacer)
and dry powder device. The number of subjects with an abnormal low value




In the study comparing inhaled fluticasone propionate and triamcinolone acetonide,
fluticasone produced significant dose-related suppression of 8am serum Cortisol and
overnight corrected urinary cortisol/creatinine excretion, whereas inhaled triamcinolone
did not. At the highest dose this amounted to a two fold difference between the two
drugs. This is in keeping with the findings of the pilot study in normal volunteers(315)
which also showed a two fold difference between these inhaled corticosteroids in terms
of overnight urinary cortisol/creatinine and 8am serum Cortisol.
These results for adrenal suppression at steady-state are similar to those found with
budesonide versus fluticasone propionate given by pressurised metered dose inhalers at
steady-state, in asthmatics(23l) and healthy volunteers"83'. This is perhaps not surprising
given the similar pharmacological and pharmacokinetic properties of triamcinolone
acetonide and budesonide. Indeed when compared on a microgram equivalent basis in a
dose-response study (400-1600pg per day) there was no significant difference between
the two drugs at any dose for measures of serum or overnight urinary Cortisol1317).
Furthermore, in keeping with this study, there was no significant difference with placebo
and triamcinolone acetonide at any dose.
In the study comparing flunisolide and triamcinolone acetonide, fractionated overnight
and early morning collections of urinary Cortisol corrected for creatinine excretion were
measured, as these have been shown to be as sensitive as a full 24 hour uncorrected
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urinary Cortisol collection1185). When looking at overnight and early morning corrected
urinary cortisol/creatinine excretion, the results from this study are also in keeping with
those ofMclntyre et al(185), who showed that this collection is more sensitive than early
morning serum Cortisol. Mclntyre et al(185) also showed that high dose (2000pg/ day)
but not low dose (800 pg per day) inhaled beclomethasone dipropionate produced
significant suppression of both overnight and early morning corrected urinary
cortisol/creatinine. This study showed that only the highest recommended doses of both
drugs (TAA 1600pg per day and FN 2000pg per day) produced suppression of basal
adrenocortical activity, as measured by corrected urinary cortisol/creatinine, although
these effects were not associated with any blunting of Cortisol response to ACTH
stimulation. It also demonstrated that fractionated overnight and early morning urinary
Cortisol excretion, corrected for creatinine, were more sensitive than either a spot 8am
serum Cortisol sample or the Cortisol response to low dose ACTH stimulation.
It is interesting to compare the results for overnight urinary Cortisol creatinine ratio from
the first two studies. Both compared triamcinolone acetonide at a dose of 800pg twice
daily via the same inhaler device after the same duration of therapy. However, in the
first study there was no significant difference between placebo and triamcinolone,
however, there was a significant difference in the second study. This is most likely due
to the fact that in the first study asthmatic patients were studied and healthy volunteers
were recruited into the second. This highlights the importance of evaluating asthmatic
patients who would be normally taking the drugs in order to make absolute statements.
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More importantly it highlights the fallacy of making direct comparisons between two
studies with different samples.
The finding of a 2:1 ratio of adrenal suppression with high dose fluticasone and
triamcinolone acetonide are in keeping with a chronic dosing study by Brus(318) which
assessed the AUC24 Cortisol suppression of lOOOpg twice daily of a number of inhaled
corticosteroids in healthy volunteers. This showed that fluticasone caused 79%
suppression compared to 25% suppression with triamcinolone acetonide. However, the
reported suppression of flunisolide (7%) by Brus(318) is contrary to the second study in
this chapter which showed no difference between these two drugs. The study in this
thesis could have been limited by power and with further patients a significant difference
may have been found.
In a study comparing placebo, triamcinolone acetonide (200pg four times daily and
400pg twice daily) and fluticasone propionate (88pg and 220pg twice daily) versus
prednisolone (lOmg), high dose triamcinolone acetonide caused significantly more
suppression than placebo or low dose fluticasone propionate using 8 hr AUC(319). This is
in contrast to the results of the first study in this chapter. The difference is hard to
explain as both studies employed asthmatic patients of similar severity and both used
sensitive endpoints. The duration of the study was different with 9 days in this study and
28 days in the study by Li et al(319). The most likely difference is due to patient inhaler
technique. In the study by Li et al(319), patients were "instructed in the proper use of a
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metered dose inhaler", however, in all of the studies in this thesis the patients had their
inhaler technique checked, using a metered dose inhaler training device, at each visit.
This is likely to result in better lung delivery and systemic effects of fluticasone.
Intensive training is likely to have less of an effect on triamcinolone acetonide as a result
of its integrated spacer-actuator attachment.
Sorkness et al(320) compared fluticasone propionate (lOOpg and 500pg twice daily) and
triamcinolone acetonide (300pg and 500pg twice daily) in one study and fluticasone
propionate (lOOpg and 250pg twice daily) with flunisolide (500pg twice daily) in a
second study and found no difference between active treatments and placebo in terms of
the 6 hour ACTH stimulation test. This probably reflects the insensitivity of the 6 hour
ACTH stimulation test
Surprisingly, there are only limited published data on the HPA-axis effects of inhaled
triamcinolone acetonide and flunisolide. In a parallel group study of steroid naive mild
asthmatics, sequential cumulative doubling doses of triamcinolone acetonide (800-3200
pg per day) and flunisolide (1000-4000pg per day) were administered with dose
increments at weekly intervals021'. In terms of 24 hour uncorrected urinary Cortisol
excretion, triamcinolone acetonide had no detectable effect at 800pg per day but
produced 7% suppression at 1600pg per day, as compared to 13% and 15% suppression
with lOOOpg per day and 2000pg per day respectively of flunisolide. The authors
concluded that relative potencies of the triamcinolone acetonide, flunisolide and
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beclomethasone dipropionate appeared to be approximately equivalent for both topical
and systemic effects. In another study of healthy volunteers(322), 3.5 days treatment with
triamcinolone acetonide 2000pg per day and flunisolide 2000pg per day produced no
significant effect on uncorrected 24 hour urinary Cortisol excretion.
The low dose (0.5 pg) ofACTH was chosen in the present study as this is known to be a
better reflection of the physiological stress response, as compared with the high (250 pg)
dose of ACTH(I88). However, after 3 days of treatment with twice daily dosing, there
was no blunting of the Cortisol response to ACTH stimulation. It is possible that, with
more prolonged treatment, it is possible that blunting of the Cortisol response to ACTH
stimulation may occur as a consequence of adrenocortical atrophy. However, it has been
shown that after 3 days of inhaled budesonide lOOOpg twice daily, there is evidence of
an attenuated Cortisol and ACTH response to stimulation with a lOOpg bolus of
corticotropin releasing hormone(323).
The results above look at mean figures but it is probably more clinically relevant to look
at the individual systemic response to inhalation of corticosteroid. When looking at
clinically relevant treatment doses less than lOOOpg per day, in the first study it can be
seen that there were three times as many individual results with an abnormal low values
for overnight urinary Cortisol excretion with fluticasone propionate than triamcinolone
acetonide. However, there was no significant difference between the number of low
values when comparing triamcinolone acetonide and flunisolide with either 8am or
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overnight urinary Cortisol. This is important to the physician when prescribing inhaled
corticosteroids to individual patients as there is no simple way of distinguishing which
patients will or will not have abnormal urinary Cortisol levels at a given dose. In this
respect it is known that there is good correlation between urinary Cortisol excretion and
serum Cortisol response to ACTH stimulation in patients receiving inhaled corticosteroid
therapy0 s8).
This study has also shown that, for adrenal suppression, fluticasone via pMDI plus
spacer exhibited approximately 5-fold greater systemic activity than the same dose
delivered via a dry powder device, and consequently a 5-fold increase in lung delivery
given the linearity of the dose-response curve for fluticasone at this dose. This is
explained by in vitro impactor data showing that, for fluticasone propionate, a pMDI
delivers twice the respirable fraction of a dry powder device0 72\ and the use of a spacer
doubles the lung delivery compared to a pMDI alone(324'325).
The difference in lung delivery of fluticasone propionate, when delivered by a pMDI or
Accuhaler, are in keeping with the Dose of Inhaled Corticosteroids with Equisystemic
Effects (DICE) study sponsored by the Asthma Clinical Research Network (Reported by
M. Craft at the American Academy of Asthma Allergy and Immunology Meeting, San
Diego, March 2000). The study investigated the dose of each inhaler and steroid
combination required to cause a 10% fall in 12hr AUC serum Cortisol and found
fluticasone propionate via pMDI could be given at a quarter of the dose to cause the
same suppression as fluticasone propionate dry powder. In another study(326), comparing
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lmg twice daily of fluticasone propionate via a pMDI or Accuhaler, a potency ratio of
1:0.32 was determined for effects on AUC plasma fluticasone propionate.
It is important to highlight the fact that triamcinolone acetonide was compared on a
microgram equivalent basis with both fluticasone propionate and flunisolide. There are
several reasons for doing this. Firstly, at the time of performing the study there were no
dose-response studies assessing either the systemic activity or clinical efficacy of these
drugs on the steep part of the dose response curve. The only data which provided
information regarding the potency of these drugs were from in vitro studies which have
limitations as discussed above (see section 1.3.2). As it was not possible to know the
relative clinical effectiveness, it is a sensible starting point to compare on a 1:1 dose
ratio. Secondly, clinicians often change patients from one drug to another drug without
making any change of dose. Thirdly, these dose-response studies enable comparisons to
be made between different doses of different corticosteroids as well as within dose
comparisons. For example, comparisons can be made between a low dose of one drug
and a high dose of another. Furthermore, potency of the drug is only one variable in the
propensity for adverse effects and, as has been shown in the third study, drug delivery is
at least as important. In this respect, the Azmacort pMDI with integrated tube spacer
delivers approximately two fold greater respirable fraction than Flixotide pMDI, as
shown by data from respective in vitro studies using an Anderson sampler (69% v
34%)<172i. Flowever, as the results from this study produced dose response curves which
were not parallel, it was not possible to calculate potency ratios. Further studies are
required to be performed comparing fluticasone propionate with higher doses of
104
triamcinolone in order to create parallel curves and produce a potency ratio.
CHAPTER 4
DOSE RESPONSE COMPARISON FOR
RELATIVE SYSTEMIC EFFECTS OF
INHALED AND ORAL CORTICOSTEROIDS
Study 1 A comparison of the systemic effects of oral prednisolone and
inhaled fluticasone propionate in adult asthmatics
Study 2 A comparison of the systemic effects of oral prednisolone and
nebulised budesonide in adult asthmatics
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4.1 INTRODUCTION
In the previous chapter, studies compared the systemic bioactivity of different inhaled
corticosteroids in terms of measures of adrenal function. Significant differences were
shown between a potent inhaled corticosteroid (fluticasone propionate) and less potent
inhaled corticosteroids (triamcinolone acetonide and flunisolide) in terms of twice daily
and once daily dosing. There was no significant difference between two inhaled
corticosteroids of similar potency (triamcinolone acetonide and flunisolide) in terms of
basal and dynamic measures ofhypothalamic-pituitary adrenal axis activity.
Although it is important to compare the effects of different inhaled corticosteroids and
their devices of lung delivery, it is equally relevant to compare inhaled corticosteroids
with oral corticosteroids. As physicians are aware of the adverse effects of long term
oral corticosteroids, comparisons of oral and inhaled corticosteroids may allow a
tangible awareness of the effects of inhaled corticosteroids.
Some patients with chronic severe asthma and chronic obstructive airways disease are
not adequately controlled with conventional inhaled corticosteroid therapy and require
maintenance treatment with oral corticosteroids such as prednisolone. However, long-
term systemic adverse effects are a problem even when using the minimal effective
maintenance dose of oral prednisolone. Although all inhaled corticosteroids are
associated with dose-related systemic adverse effects(168), it is assumed that high-dose
inhaled corticosteroids have a better therapeutic index than oral prednisolone. For these
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reasons high-dose nebulised budesonide has been advocated as an alternative to patients
who would otherwise be treated with maintenance daily oral prednisolone'327'328'. In
order to obviate compliance problems with multiple actuations of metered-dose inhalers
(pMDI), nebulisers are an alternative option for the delivery of high doses of inhaled
corticosteroids to the lung. The problem of poor inhaler technique, which often occurs
with pMDI's, is also avoided with nebulisers, as there is no need to co-ordinate actuation
with inhalation. When this study was performed, budesonide (Pulmicort Respules, Astra
Pharmaceuticals, UK) was the only suspension formulation of corticosteroid which was
licensed in Europe for delivery via a nebuliser in the treatment of asthmatic patients.
However, fluticasone propionate suspension (as Flixotide Nebules, Glaxo-Wellcome,
Uxbridge, UK) has recently become available for nebulisation.
Prednisolone is the most widely used oral corticosteroid and is often used as a reference
standard in terms of adverse and beneficial effects of anti-inflammatory medication.
Fluticasone propionate is a potent inhaled corticosteroid for use in asthma. Dose-
response studies have been performed comparing systemic adverse effects of inhaled
(183 231 ^fluticasone propionate with other inhaled corticosteroids (Chapter 3p ' but there are
no published dose-response data comparing systemic effects of oral prednisolone and
inhaled fluticasone propionate.
Two studies have compared inhaled budesonide with oral prednisolone. In both of these
studies, one in asthmatic'1%) and the other in healthy volunteers'209', budesonide was
given via a large volumatic spacer. It was therefore considered important to perform a
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direct comparison of these two therapies, i.e. oral prednisolone and nebulised
budesonide, which are commonly used to treat chronic severe asthmatics. From these
studies the milligram equivalent potency ratio for Cortisol suppression for prednisolone
vs budesonide has been calculated to be 7.6:1 for steroid dependent asthmatics(196) and
5:1 for healthy volunteers'-209'. Given that the glucocorticoid potency of fluticasone
propionate is twice that of budesonide(151'152) a putative milligram equivalence ratio of
11:1 was chosen for comparing oral prednisolone versus inhaled fluticasone propionate
and dose ratio of 5:1 for comparing nebulised budesonide and oral prednisolone. Neither




Twelve (6 female) stable mild to moderate asthmatic patients were recruited into both
studies.
Study 1: mean age (SE): 28.8 (3.3) years mean forced expiratory volume in one second
(FEVi): 94.7 (3.6) % predicted, and mid-expiratory flow (FEF25-75): 65.5 (6.1) %
predicted. (Median dose: 300pg per day, range: 100 to 800pg per day). Eight patients
were taking beclomethasone dipropionate (2 patients on lOOpg per day, 3 patients on
200pg per day, 2 patients on 400pg per day and 1 patient on 500pg per day); and 4
patients were taking budesonide (1 patient on 200pg per day, 3 patients on 800pg per
day).
Study 2: mean age (standard deviation): 34.7 (10.1) years mean FEV): 88.3 (13.2) %
predicted, and FEF25-75 54.8 (18.4) % predicted. Medication: beclomethasone
dipropionate: n=9, fluticasone propionate: n=l, budesonide: n=2. (Median dose: 400pg
per day, range: 100 to lOOOpg per day).
Study Design
In, both studies a double-blind, double-dummy placebo controlled randomised crossover
design was used. Spirometry was also measured at each subsequent visit, although
efficacy was not an end point due to the short duration of treatment. Patients were
randomised to receive either oral prednisolone (Pred) 5mg per tablet (Biorex
Laboratories Ltd, Enfield, UK), or inhaled fluticasone propionate (FP) O.llmg per
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actuation (as Flovent metered dose inhaler, Glaxo-Wellcome Inc, USA) via a 750ml
Volumatic spacer (Allen and Hanburys, UK) in study one; or nebulised budesonide
(BUD) as 0.25 mg/ml and 0.5mg/ml (as Pulmicort Respules, Astra Pharmaceuticals Ltd.,
UK) given via a Ventstream nebuliser (Medicaid Ltd., UK) with mouthpiece with a
Portaneb compressor (Medic-aid Ltd., Pagham, UK) delivering air at 6 1/min in Study 2.
Each drug sequence was given over a total of 12 days with six patients receiving FP or
BUD first in sequence and the other six patients receiving prednisolone first in sequence.
FP and BUD were given twice daily divided doses at 8am and 10pm whereas
prednisolone was given orally once daily at 8am. The doses were given sequentially as
follows each for four days; Pred: 1 tablet once daily, 2 tablets once daily, 4 tablets once
daily (i.e. 5mg per day, lOmg per day and 20mg per day respectively); FP: 2 puffs twice
daily, 4 puffs twice daily, 8 puffs twice daily (i.e. 0.44 mg per day, 0.88mg per day and
1.76mg per day respectively); BUD 2ml of 0.25mg/ml bid, 2ml of 0.5mg/ml bid, 4ml of
0.5mg/ml bid (i.e. 1 mg per day, 2 mg per day and 4 mg per day respectively). Patients
received placebo tablets whilst taking FP/BUD, and inhaled placebo (MDI plus
Volumatic spacer)/nebulised placebo (0.9% sterile saline) when taking Pred, using the
corresponding number of tablets or number of puffs/volume of solution in order to make
the trial double-dummy. Prior to each 12 day drug sequence (i.e. either FP, BUD or
Pred) patients received 1 placebo tablet per day and 2 puffs bid of placebo MDI (via
Volumatic spacer)/2ml vial of 0.9% saline via nebuliser, both for four days. The
patients' usual inhaled corticosteroid therapy was discontinued during the placebo and
treatment periods. There was also a 7 day washout between each of the 12 day treatment
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sequences where patients received their usual maintenance inhaled corticosteroid
therapy.
Each inhaler was discharged twice prior to use and patients used the spacer according to
the manufacturers' instructions, breathing from residual volume to total lung capacity.
Patients were instructed to use single puffs without delay, with each dose being followed
by mouth rinsing. Prior to the study, each individual spacer was initially pre-washed in
detergent, left to dry and then coated with 20 puffs. Each dose of budesonide was
nebulised to residual volume (approximately 0.5-1.0ml) associated with sputtering over
a period of 10 minutes. Patients were instructed to breathe at tidal volume until delivery
was complete.
Measurements




Peripheral Blood Eosinophil Count.
Statistical Analysis
The studies were designed with sample size of 12 with 80% power (beta error =0.2) to
detect a 20% difference in 8.00am Cortisol (the primary end point) between treatments
with the alpha error set at 0.05 (two-tailed). Osteocalcin was analysed geometrically in
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order to normalise its distribution, as was eosinophil count in the second study.
The presence of dose-related suppression was determined using least squares regression
analysis to evaluate the overall effects of all three dose levels for each drug. In the first
study, regression analysis was applied to investigate whether for either drug, FP or Pred,
there was a significant dose-response relationship, as percentage suppression for each of
the three end points. For a given end point parallel slope analysis was then applied to
both drugs together. In the presence of a significant fit for the common parallel slope
with both drugs, a dose ratio was calculated for relative potency on a milligram
equivalent basis. This was only possible for effects on Cortisol.
In addition, all active treatments and both placebos were compared by an overall
multifactorial analysis of variance (MANOVA) using treatment, dose, subject and
period as factors, followed by Bonferroni's multiple range testing to obviate multiple
pair-wise comparisons. The Bonferroni's multiple range test was set with 95%





There were no significant differences between the FEVi values (as % predicted)
comparing placebo (PL) with low (L) medium (M) or high (H) doses of each drug: PL
89.4 Pred L:91.5, M:92.0, H:90.1; FP L:91.3., M:96.2. H:94. 1; or FEF25-75 values (as %
predicted): PL: 65.3, Pred L:62.2, M:64.4. H:61.4; FP L:56.3, M:69.2, H:65.6.
There were no significant carryover effects between the first and second placebos in
sequence using any of the systemic parameters measured: 8am plasma Cortisol 415.2 vs
395.5 nmol/1 eosinophils 0.33 vs 0.30 x 109/litre, or osteocalcin 1.0 vs 1.2 nmol/1. There
were also no significant differences between the placebos prior to each treatment
sequence (Pred vs FP): 8 am plasma Cortisol 420 vs 390 nmol/1, eosinophils 0.27 v 0.36
x 109/litre, or osteocalcin 1.12 vs 1.0 nmol/1.
Dose-response relationships
Mean values for each of the three parameters for both FP and pred are shown in Table
4.1 With FP there was significant suppression at M and H for 8am plasma Cortisol, at H
dose only for osteocalcin, and at no dose for blood eosinophil count. This shows that the
effects of FP are greater on Cortisol compared to osteocalcin or eosinophils.
Regression analysis showed significant dose-response relationships for percentage
suppression with each end-point for both drugs: Pred (8am plasma Cortisol p<0.005
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eosinophils p<0.05, osteocalcin p<0.001); FP (8am plasma Cortisol p<0.01, eosinophils
p<0.05, osteocalcin p<0.05). This showed a dose-ratio for relative potency of 8.5:lmg
(95% CI 5.7 to 11.2) in terms of milligram equivalence for comparison of Pred:FP
[Figure 4.1]. It was not possible to calculate a dose-ratio for either eosinophil count or
osteocalcin.
Response ratios showed no significant differences at any dose level for effects on 8am
plasma Cortisol or eosinophils but a significant difference in osteocalcin at medium and
high doses [Table 4.2]
Individual data [Figure 4.2] showed no significant difference in the numbers of
individual results with abnormal low values for 8am Cortisol (<150 nmol/1 or <5.4pg/dl)
comparing all doses of both drugs: FP (n=9/36) vs Pred (n=15/36) (p=0.2 1).
There was no significant correlation between 8am plasma Cortisol and the degree of
airway calibre as FEVi % predicted, with either FP or Pred at any dose level.
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TABLE 4.1
Mean (SE) for prednisolone (Pred) and fluticasone propionate (FP) and pooled placebo
for: 8 am plasma Cortisol, osteocalcin and eosinophils at low, medium and high dose
levels. Asterisk denotes significant difference from placebo.


































Response ratios shown as fold difference (95% CI for difference) for prednisolone
(Pred) v fluticasone propionate (FP) for: 8am plasma Cortisol, osteocalcin and
eosinophils at low, medium and high doses. Confidence intervals which exclude unity
show a significant (p<0.05) difference between the two drugs at a given dose level.












1.2 (0.5-2.8) 1.1 (0.5-2.5) 1.5 (0.6-3.4)
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1.1 (0.9-1.3) 1.2(1.0- 1.6) 1.4(1.1 -1.7)
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1.3 (0.7-2.5) 1.1 (0.6- 1.9) 1.5 (0.8-2.7)
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Dose of steroid (mg/day)
Figure 4.1
Log dose-response plot for 8am plasma Cortisol suppression to show dose-ratios for
relative potency. Doses of oral prednisolone (Pred) were 5mg per day, lOmg per day and
20mg per day. Doses of inhaled fluticasone propionate (FP) were 0.44mg per day,
0.88mg per day and 1.76mg per day. Parallel fitted slope analysis was used to calculate
the equivalent dose of prednisolone causing the same degree of suppression as compared
to lmg of fluticasone. The relative dose ratio for Pred vs FP was calculated at 8.5:1 mg
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Individual values for 8 am plasma Cortisol with each treatment. Horizontal bars represent
mean values. The interrupted line represents the lower end of the normal reference range
at <150nmol/l (or <5.4pg/dl). There was no significant difference between fluticasone
and prednisolone in terms of the number of abnormal values: n=9/36 for fluticasone vs
n=15/36 for prednisolone (p=0.21).
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Study 2
There were no significant carryover effects between the first and second placebos given
in sequence using any of the parameters measured: 8am plasma Cortisol 420.0 vs 373.4
nmol/1, eosinophils 0.35 vs 0.31 x 109/litre, or serum osteocalcin 0.62 vs 0.55 nmol/1.
There were also no significant differences between the placebos prior to each treatment
(i.e. prior to Pred or prior to BUD): 8 am plasma Cortisol 406.9 vs 386.6 nmol/1,
eosinophils 0.36 v 0.31 10 x 109/litre, or serum osteocalcin 0.61 vs 0.56 nmol/1.
There were no significant differences between the FEVi values (as % predicted)
comparing placebo (PL) with low (L) medium (M), high (H) doses of each drug: PL
86.8%, Pred L:84.3%, M:78.1%, H:85.4%; BUD L:89.6%, M:90.43% H:92.3%; or
FEF25-75 values (as % predicted): PL: 48.5% Pred L:47.1%, M:42.6%, H:47.7%; BUD
L:52.3%, M:51.2%, H:56.3%.
8am Plasma Cortisol:
Regression analysis showed there was significant (p<0.0001) dose-related suppression
with Pred but not with BUD (p=0.53) [Figure 4.3]. Compared with PL (p<0.0005)
[Figure 4.4]
Eosinophils:
Regression analysis showed there was a significant (p<0.001) dose-related suppression
for Pred but not with BUD [Figure 4.3]. There were significant (p<0.05) differences
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from placebo for medium and high doses of Pred but at no dose of BUD. There were
significant differences between the two drugs at the highest dose level only which
amounted to a 1.87 fold difference (95% CI 1.16 to 3.00).
Osteocalcin:
Regression analysis showed there was a significant (p<0.05) dose-related suppression
for Pred whereas this was not significant with BUD [Figure 4.3]. There were significant
(p<0.05) differences from placebo for medium and high doses of Pred but at no dose of
BUD. There were significant differences between the two drugs at the medium and
highest dose levels. At the highest dose level this amounted to a 1.62 fold difference
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Figure 4.3
Geometric means with standard errors for pooled placebo (PL); budesonide (BUD) at
lmg per day, 2 mg per day and 4 mg per day 400; and prednisolone (Pred) at 5mg per
day, lOmg per day for 8am plasma Cortisol (top), blood eosinophils (middle) and serum
osteocalcin (bottom). Regression analysis showed significant dose-related suppression
for prednisolone (*** p<0.0001) for plasma Cortisol, (** p<0.001) for blood eosinophils
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Figure 4.4
Individual values for 8 am plasma Cortisol for pooled placebo (PL); budesonide (BUD)
at lmg per day, 2 mg per day and 4 mg per day 400; and prednisolone (Pred) at 5mg per
day, lOmg per day. The interrupted line represents the lower limit of the normal
reference range at <150nmol/l (5.4pg/dl).
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4.4 DISCUSSION
These results in asthmatic patients showed that there were no significant differences in
the degree of Cortisol suppression exhibited by oral prednisolone and inhaled fluticasone
propionate, when administered on an 11:1 mg equivalent nominal basis. Furthermore,
there was no significant difference in the number of individual low values (<150nmol/l
or 5.4pg/dl) between oral prednisolone and fluticasone propionate when all doses were
compared. When the same data were fitted by parallel slope analysis, an 8.5:1 mg
relative potency ratio for oral prednisolone compared with fluticasone propionate was
found. It should be pointed out that the potency ratios for effects of fluticasone
propionate and prednisolone were calculated on the raw data and not on the mean
responses. Only after it was shown that the log-dose response curves were linear and that
the curves were parallel was it possible to go on to calculate potencies. This was
performed according to the dose-response equation and confidence intervals were
generated.
Unfortunately the potency ratio for fluticasone propionate and prednisolone in terms of
their effects on osteocalcin or eosinophils could not be calculated as the data did not lie
on the steep part of the dose response curve for observed effects. However, it could be
argued that it would not be clinically relevant to evaluate doses of fluticasone propionate
greater than 1.76mg per day as this is the highest recommended dose by the
manufacturers. The findings with fluticasone propionate are in keeping with Jennings et
al(209) and Toogood et al(1%), using budesonide who also showed greater suppression
124
with Cortisol compared with the effects on eosinophils or osteocalcin. This is reassuring
in that the bone appears to be less sensitive than the adrenal gland to the systemic effects
of inhaled fluticasone propionate. In this respect Hodsman et al(208) showed that
budesonide had less of an effect on bone metabolism than prednisolone for a given
change in adrenal function.
The results of the studies for prednisolone are in keeping with those of Toogood et al(1%)
and Jennings et al(209), who also showed dose-related suppression with oral prednisolone
for all the measured parameters including 8am plasma Cortisol, blood eosinophils and
serum osteocalcin. However, this was not the case for nebulised budesonide, which
showed no significant dose-related suppression. It can be seen from the graphs of dose-
response curves that for all of the endpoints, nebulised budesonide caused very little
suppression even at the highest dose of 4mg per day. If higher doses of budesonide had
been used, it may have been possible to detect systemic activity, but the doses chosen
represented those most commonly used in clinical practice. Although it is sometimes
necessary to prescribe doses greater than 4mg per day, and indeed nebulised Pulmicort is
licensed as such, this is rarely done in normal practice.
The explanation for the lack of detectable systemic effects with budesonide is unlikely to
be due to differences in asthmatic severity between this and previous studies0 96'209). As,
in the previous studies both severe steroid dependant asthmatics'196) and healthy
volunteers<209) were involved. The duration of treatment was shorter in this study but, as
the effects of corticosteroids on adrenal suppression may become detectable within 12
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hours of a single dose(232), this is unlikely to account for the observed differences.
Furthermore steady-state blood levels would be achieved within the 4-day dosing period.
The patients in this study received budesonide via a nebuliser as this is a common way
of delivering high doses of inhaled medication, whereas in the previous studies a
pressurised metered-dose inhaler plus large volume spacer was used. The lack of
detectable systemic activity with steroids delivered by a nebuliser has previously been
reported in a study where a single 4mg dose of inhaled budesonide, given via a
Sidestream nebuliser (Medic-aid Ltd., Pagham, UK), had no effect on 9am serum
cortisol(329).
The Ventstream nebuliser was specifically chosen because of its superior in vitro and in
vivo performance characteristics compared with other conventional jet nebulisers(330'331).
Indeed the Ventstream has been shown to produce 80% of respirable particles with a
diameter <5p,m, as well as increasing the lung dose to the patient by boosting respiratory
delivery and minimising expiratory wastage(330). For example, in comparison to a
Hudson updraft II nebuliser, the Ventstream nebuliser produces 25% more respirable
particles in vitro and a two-fold improvement in lung delivery in vivo<330). It is,
therefore, not possible to justifiably explain the lack of systemic bioactivity with
budesonide solely on the basis of poor nebuliser performance, although it is likely that
the lung dose and hence systemic bioavailability would probably be greater from a large
volume spacer. Clark and Lipworth(231 ] have previously shown that chronic dosing with
2mg per day of budesonide given by metered-dose inhaler to asthmatic patients,
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produces no significant detectable activity on 8am plasma Cortisol or overnight urinary
cortisol/creatinine excretion.
The inter-individual variability in systemic activity, which can be seen by the dispersion
of the values in Figure 4.2 and 4.4, may be related to effects of airway calibre inhaler
technique or glucocorticoid receptor responsiveness. The high degree of first-pass
metabolism of the swallowed dose of the inhaled corticosteroids will result in the
systemic bioactivity being predominantly determined by the lung bioavailability, as
there is no first-pass metabolism in the lung(l69). It is important, therefore, to assess
whether airway calibre was altered by fluticasone and budesonide treatment, as this
might conceivably result in attenuated systemic bioavailability as a result of reduced
lung delivery. In this respect, there were no differences in either FEVi or FEF25-75
between the inhaled corticosteroids and prednisolone. Altered lung delivery is, therefore,
unlikely to explain their relative systemic effects. The efficacy of the corticosteroids was
not an end point in this study because the duration of treatment was not long enough to
evaluate beneficial effects. Furthermore, the patients reported here, had well controlled
mild to moderate asthma, and were therefore probably at the top of the dose-response
curve for corticosteroid efficacy(168).
Great care was also taken to eliminate possible differences in inhaler technique when
using the spacer or nebuliser. Indeed it was evident that even with oral prednisolone
there was considerable variability in suppression, suggesting that factors other than
inhaler technique and lung bioavailability are important in determining systemic
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bioactivity. For example even at a high dose of 20mg per day of prednisolone there are
clearly a proportion of patients who are relatively insensitive to adrenal suppression.
This is more likely to represent tissue specific differences in glucocorticoid metabolism
or possibly individual glucocorticoid receptor responsiveness'175'.
It is also worth noting that the dosing schedules of the two drugs may have influenced
the diurnal profile for adrenocortical activity, in that prednisolone was given once daily
in the morning and the inhaled corticosteroids were in the morning and evening. Enteric
coated prednisolone was specifically chosen, as this is the most commonly prescribed
formulation in the local area. In a study evaluating the pharmacokinetic profile of enteric
coated prednisolone, there was a lag in absorption such that there was an appreciable
concentration remaining at 24 hours after dosing(332). Furthermore, the corresponding 24
hour plasma Cortisol profile showed that the lowest value coincided with the time point
at 24 hours after dosing.
When considering the effects of fluticasone and budesonide it has been shown that
suppression of a spot 8am plasma Cortisol sample closely mirrors the effects on an
integrated 24 hour plasma Cortisol profile (see Chapte(182'182'182)r 4). This is perhaps not
surprising as the maximal degree of diurnal HPA-axis suppression coincides with peak
levels as measured at 8am. This is especially true for fluticasone propionate as the peak
to trough variability is much less than other steroids'333', reflecting the long elimination
half life of 14.4 hours'138', and the time of dosing is therefore not as important with
respect to Cortisol suppression. Indeed, it has been shown that significant adrenal
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suppression occurs with fluticasone when administered with a 24 hour dosing
interval(334). Thus, the suppressive effects of fluticasone propionate and enteric coated
prednisolone are likely to be comparable on 8am and 24 hour Cortisol measurements.
The patients recruited into the studies were all taking up to lOOOpg per day of inhaled
corticosteroid which represented their lowest possible effective maintenance dose.
These patients can therefore be considered as mild to moderate with an average FEV i of
88% predicted and FEF25-75 of 55% predicted, and would not be regularly requiring the
high doses which were studied. However, it is conceivable that such patients may
experience an exacerbation of their asthma and require a course of oral prednisolone and
subsequently require higher doses of maintenance inhaled steroid. However, it is
reassuring to know that even in asthmatics without severely impaired airway calibre,
there was only minimal systemic response to high-dose nebulised budesonide.
In a study investigating the efficacy and systemic effects of prednisolone (30mg per day)
and fluticasone (2mg per day and 0.5mg per day), it was shown that there was no
significant difference between high dose fluticasone propionate (100% suppression of
serum Cortisol) and prednisolone (150%)(335). However, in that study the clinical
response was greater with high dose fluticasone propionate than prednisolone.
As the effect on adrenal function is so great with fluticasone propionate it may be
considered that some of the clinical efficacy is due to a systemic prednisolone like
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effect. However, this has been shown not be the case in a study by Lawrence et al(336),
who demonstrated that it was the topical effect of fluticasone propionate which
contributed to its activity. Fluticasone propionate was given orally at a dose which
resulted in greater plasma levels than when given via the inhaled route. However, the
clinical efficacy was greater with inhaled than oral fluticasone propionate. Furthermore
Noonan et al(224) showed, in a sixteen week study, that in prednisolone dependant
asthmatic patients taking fluticasone propionate 2mg/day, nearly 90% could be weaned
off their oral corticosteroids. Indeed compared to baseline this group of patients had an
average increase in FEVi of 0.52 litres despite a reduction in systemic activity. They
found that 73% of cases had a subnormal morning plasma Cortisol value (<7pg/dl)
compared with 91% of cases before starting fluticasone (initial mean prednisone dose
was 10.2mg/day).
O'Reilly et al(337) showed that fluticasone propionate 2mg per day via pMDI and spacer
was superior to 4mg of nebulised budesonide and equivalent to 2mg nebulised
budesonide in terms of peak expiratory flow rate. Furthermore, fluticasone propionate




COMPARISON FOR RELATIVE SYSTEMIC
EFFECTS OF INHALED AND INTRA¬
NASAL CORTICOSTEROIDS
Study 1 A comparison of systemic effects of intra-nasal triamcinolone
acetonide, fluticasone propionate and beclomethasone
dipropionate in healthy volunteers
Study 2 A comparison of the systemic effects of intra-nasal budesonide,
mometasone furoate and triamcinolone acetonide in patients with
allergic rhinitis
Study 3 A comparison of the additive systemic effects of intra-nasal plus




This chapter contains three separate studies which examine the systemic adverse activity
of intra-nasal corticosteroids. There is no intention to offer any information regarding
the clinical efficacy of the corticosteroids. The first assesses fluticasone propionate,
triamcinolone acetonide and beclomethasone in healthy volunteers using 8am serum
Cortisol and overnight urinary Cortisol. The second examines triamcinolone, mometasone
furoate and budesonide in patients with allergic rhinitis using integrated 24 hour AUC
serum Cortisol and osteocalcin. The third study examines the additive effects of intra¬
nasal corticosteroids on top of inhaled corticosteroids in patients with asthma.
Intra-nasal corticosteroids have generally been regarded as being safe and free from
systemic adverse effects*238'239'241'338). They have been shown to have greater efficacy
than anti-oral histamine medication(57). Although the doses of intra-nasal corticosteroids
for treatment of allergic rhinitis are small compared to inhaled corticosteroids, intra¬
nasal administration of corticosteroids is associated with a high level of systemic
bioavailability, probably due to the abundant vascularity of the nasal mucosa and
lipophilicity of modem drugs(175). The use ofmodem aqueous pump sprays is associated
with high intra-nasal deposition*339-*, although this may be partially off set by rapid
nasociliary clearance into the throat. Furthermore, there is no first-pass inactivation in
the nose, and so absorption of the unchanged drug occurs directly into the systemic
circulation. It is now increasingly recognised with inhaled corticosteroids that detectable
systemic activity occurs at doses less than lOOOpg per day (see Chapter 3) particularly
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with fluticasone propionate due to its specific pharmacological and pharmacokinetic
properties069'. The question therefore ensues as to whether the same effects occur with
nasal corticosteroids when given in clinically recommended doses.
The first study in this chapter is designed, therefore, to compare the systemic activity of
intra-nasal triamcinolone acetonide, beclomethasone dipropionate and fluticasone
propionate in terms of effects on HPA-axis activity. Both basal and dynamic measures
of HPA-axis activity were chosen, namely overnight urinary Cortisol excretion and
Cortisol response to stimulation with a physiological dose ofACTH (0.5pg).
There are several reasons why the results of this study may not reflect what happens in
clinical practice. Firstly, it may be more clinically relevant to assess the effects of intra¬
nasal medication in patients with rhinitis who would normally be taking such treatment.
There may be a difference in the absorption through the nasal mucosa in patients and
healthy volunteers. The absorption is likely to be decreased due to nasal obstruction and
nasal secretions, and potentially increased by the hyperaemia associated with nasal
inflammation.
Another concern is the measure of adrenal activity used in the first study. Adrenal
suppression is commonly used as a marker for the systemic bioactivity of inhaled and
intra-nasal corticosteroids'175' and can be assessed by both fractionated or 24 hour
measurements of urine and plasma Cortisol. As Cortisol secretion varies according to the
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diurnal circadian rhythm, spot samples are usually taken between 8.00am and 9.00am in
order to coincide with the physiological peak blood levels. However these do not take
account of the changes during the day and night, and have been shown to be less
sensitive than a full 24 hour urine collection(175'184). Thus, the second study used a 24-
hour AUC marker rather than a spot serum 8am sample.
Furthermore, the first study only assessed the effects of intra-nasal corticosteroids on
HPA-axis activity. As has been shown in Chapter 4, the bioactivity of corticosteroids is
not the same in all tissues. Therefore a second study was performed in patients with
rhinitis to assess the comparative systemic bioactivity of budesonide, mometasone
furoate and triamcinolone acetonide using sensitive markers of adrenocortical activity,
bone formation and blood count. All drugs were given via aqueous formulations once
daily at the usual clinically recommended dose.
Given the frequency of patients with rhinitis and asthma it would seem necessary to
investigate the side effect profile when these drugs are prescribed concomitantly. The
aim of the third study was therefore to evaluate the integrated 24 hour and fractionated
profiles for serum and urinary Cortisol in asthmatic patients receiving inhaled
corticosteroids given alone or in conjunction with aqueous formulations of intranasal
corticosteroids. Triamcinolone acetonide (TAA) and fluticasone propionate (FP) were
chosen for investigation as examples of corticosteroids with different pharmacological
and pharmacokinetic properties, and both were given within the manufacturer's licensed




Study 1: Sixteen healthy non-allergic volunteers (9 female) of mean age (SE) 30.7 (2.7)
years.
Study 2: Twenty patients (12 female) with rhinitis of mean age (SE) 35.7 (3.5) years
completed the study. All but 3 patients were taking intra-nasal corticosteroids (12 taking
beclomethasone dipropionate 200pg bid, 3 taking fluticasone propionate 200pg od, one
taking budesonide 200pg od, and one taking flunisolide lOOpg bid). Nine patients were
taking oral anti-histamines and two were taking inhaled salbutamol on an as required
basis. A skin prick test was performed in all patients which revealed a Grade 2 or greater
(>6mm) wheal and flare reaction to grass or tree pollen in 16 patients and to house dust
mite in 8 patients. One patient with perennial rhinitis also had a positive skin prick test
to house dust mite.
Study 3: Twelve patients (6 female) mean age (SE): 25.9 (3.5) years mean FEV): 84.0
(4.0) % predicted, mean mid forced expiratory flow rate (FEF25-75) 56.1 (6.0) %
predicted, and a median dose of inhaled corticosteroids of 500pg per day (range 200pg
per day-1200pg per day). One patient was also receiving intranasal corticosteroid at a
dose of 200pg per day.
Study Design
In all studies a single (investigator) blind randomised placebo controlled design was
used. The first two studies were four-way crossover and used the Williams Design
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whereas the last was a 2-way crossover study.
Study 1: Subjects received four different randomised intra-nasal treatments with either:
triamcinolone acetonide (TAA) 55jLig per actuation (as Nasacort AQ, Rhone Poulenc
Rorer Pharmaceuticals, Inc, Collegeville USA); fluticasone propionate (FP) 50pg per
actuation (as Flonase, Glaxo Wellcome Inc, USA) or beclomethasone dipropionate
(BDP) 84pg per actuation (as Vancenase AQ double strength, Schering Corporation,
Kenilworth, USA), or placebo. Each treatment was given once daily, 2 squirts up each
nostril, at 8am, for four days.
Study 2: Subjects received four different randomised intra-nasal treatments with either:
TAA 220pg od (as Nasacort AQ 55pg per actuation, Rhone Poulenc Rorer Ltd., East
Sussex, UK); mometasone furoate (MF) 200pg od (as Nasonex 50pg per actuation,
Schering-Plough Ltd., Hertfordshire, UK) or budesonide (BUD) 200pg od (as Rhinocort
Aqua lOOpg per actuation, Astra Pharmaceuticals Ltd., Herts, UK) or placebo. Each
treatment was given once daily at 8am for four days. BUD was administered as one
squirt up each nostril, whereas MF, TAA and PL were administered as 2 squirts up each
nostril.
In both of these studies was also an initial non-randomised 4 day placebo run-in prior to
the randomised treatment block. The initial non-randomised placebo was compared to
the randomised placebo in order to assess for any carryover effect in the randomised
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treatment block. Each of the four randomised treatments were separated by a 7 day
washout period.
Study 3: The drug treatment phase consisted of 5 days of active inhaler plus placebo
nasal spray, followed by 5 days of active inhaler plus active nasal spray. Patients were
randomised to receive either triamcinolone acetonide first or fluticasone propionate first.
Triamcinolone acetonide was given as Azmacort integrated spacer actuator lOOpg per
actuation and Nasacort AQ 55pg per actuation, Rhone-Poulenc Rorer Inc, USA.
Fluticasone propionate was given as Flovent metered dose inhaler llOpg per actuation
without spacer and Flonase 50pg per actuation, Glaxo-Wellcome Inc, USA. As each
inhaler was given at a dose of 8 puffs bid and each nasal spray was 2 puffs up each
nostril once daily, the doses of each drug were as follows: Azmacort 1600pg per day,
Nasacort AQ 220pg per day, Flovent 1760pg per day and Flonase 200pg per day. Both
inhaled and intranasal drugs were prescribed according to manufacturers'
recommendations including priming of the nasal sprays. Azmacort oral inhaler has an
integrated actuator-spacer device, whilst the Flovent metered dose inhaler is not licensed
for use with a spacer. The above inhaled corticosteroid doses refer to the dose delivered
ex-actuator, in accordance with US product labeling, and are therefore less than the
nominal dose (ex-value). For example Flovent llOpg per puff ex-actuator dose is
equivalent to Flixotide 125pg per puff ex-valve dose, whilst Azmacort lOOpg per puff
ex-actuator/spacer is equivalent to 200pg per puff ex-value.
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Patients were randomised in blocks to receive one of two treatment sequences: 1)
nPL+inhPL, nPL+inhTAA, nTAA+inhTAA, washout, nPL+inhPL, nPL+inhFP and
nFP+inhFP or 2) nPL+inhPL, nPL+inhFP, nFP+inhFP, washout, nPL+inhPL,
nPL+inhTAA, nTAA+inhTAA. Where nPL=nasal placebo, inhPL=inhaled placebo,
inhTAA=inhaled triamcinolone actonide 800pg twice daily, nTAA=intra-nasal
triamcinolone acetonide 200pg once daily, inhFP=inhaled fluticasone propionate 880pg
twice daily and nFP=intra-nasal fluticasone propionate 220pg once daily. Each patient
took both an active or placebo inhaler (8 puffs bid) and an active or placebo nasal spray
(2 squirts via each nostril once daily) on all 15 days of each arm of the trial.
There was a 10 day washout period between each of the 15 day treatment sequences
where patients received their usual maintenance inhaled corticosteroid therapy. Prior to
each 10 day drug period with the active drug (i.e. either fluticasone propionate or
triamcinolone acetonide), patients received the respective matching placebo inhaler and
placebo nasal spray for 5 days (making a total of 15 days for each treatment sequence).
The patients' usual inhaled and intranasal corticosteroid therapy was discontinued
during the placebo and treatment periods.
Measurements
Measurements were made after each 4 day period with active treatment or placebo in the
first two studies; and after both placebos, inhaled alone or inhaled plus nasal treatment
for both corticosteroids in the third study.
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In Study 1 8am Serum Cortisol, Low dose Synacthen test, Overnight Urinary Cortisol
and Overnight Urinary Cortisol/Creatinine Ratio were measured. In the other two studies
24 hour area under curve and fractionated (8am, overnight, daytime) serum plasma
Cortisol and 24 hour and fractionated (8am, overnight, daytime) urine cortisol/creatinine
ratio were measured. In the second study only 8am serum osteocalcin and 8am blood
eosinophil count were measured.
Statistical Analysis
The first study was designed with sample size of 16 with 90% power (beta error = 0.1)
to detect a 20% difference in overnight urinary Cortisol between treatments with the
alpha error set at 0.05 (two-tailed). The other two studies were designed with sample
sizes of 20 and 16 with 80% power (beta error = 0.2) to detect a 20% difference in 24
hour integrated AUC plasma Cortisol and 8am plasma Cortisol respectively between
treatments with the alpha error set at 0.05 (two-tailed).
In order to normalise its distribution, all data were analysed by logarithmic
transformation in the first and third studies; and urinary cortisol/creatinine data only in
the third study.
In the first two studies, comparisons were made of all three treatments and both placebos
(randomised and non-randomised) by an overall analysis of variance with subject,
treatment and period as factors. In the third study Comparisons between all 4 active
treatments and both placebos were made by a multifactorial overall analysis of variance,
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with subject, drug, treatment and period as factors. Bonferroni's multiple-range testing
was then applied in order to obviate multiple pair-wise comparisons, so as to assess
where there were significant differences between treatments and the randomised
placebo. The Bonferroni's range test was set with 95% confidence intervals and hence
any significant differences are only reported at the p<0.05 level. 95% confidence
intervals for the mean treatment differences were also calculated. In the third study, a
comparison was also made between the first and second placebos given in sequence
within the study design to check for any carry-over effect between the two drug
sequences. In addition, a comparison was made of the two placebos given before FP and
TAA irrespective of the treatment sequence.
In the third study, individual values for low 24 hour urinary Cortisol excretion <40nmol
(<14.4pg) and 8am serum Cortisol <150nmol/l (<5.4pg/dl) were analysed using the Chi-
Square test. A value of <40nmol for 24 hour urinary Cortisol excretion and <150nmol/l




There was no significant carryover effect between the non-randomised placebo and
randomised placebo respectively using any of the parameters measured (as geometric
means ± SE): Overnight urinary Cortisol: 17.1 ± 2.3 vs 20.8 ± 2.8 nmol, pre ACTH
serum Cortisol: 547.5 ± 23.2 vs 574.0 ± 24.3 nmol/1, or post-ACTH 781.2 ± 32.6 vs
761.0 ±31.7 nmol/1. The randomised placebo was used for all comparisons with the
three active treatments.
Overnight urinary Cortisol excretion.
Compared with PL (20.8 ± 2.8 nmol) there was statistically significant (p<0.05)
suppression with FP: (11.8 ± 1.6 nmol) but not with TAA (16.0 ±2.1 nmol) nor with
BDP (16.5 ± 2.2 nmol) [Figure 5.1], This amounted to a ratio of 1:1.75 for PL versus
FP (95% CI 1.01 to 3.03). There was a ratio of 1:1.30 for PL versus TAA (95% CI 0.75
to 2.25) and a ratio of 1:1.26 for PL versus BDP (95% CI 0.73 to 2.18). There were no
significant differences between the three active treatments. There was also a trend
towards suppression of overnight urinary cortisol/creatinine ratio (nmol/mmol) but this
was not statistically significant: PL (5.2 ± 0.5), TAA (5.0 ± 0.5), BDP (4.3 ± 0.4) and
FP (4.3 ± 0.4). Individual values for overnight urinary Cortisol are depicted in Figure
5.1. This shows that there was considerable inter-individual variability in the propensity
for suppression.
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Pre-ACTH 8am Serum Cortisol: [Figure 5.2]
There were no significant differences between placebo (574.0 ± 24.3 nmol/1) and any of
the other treatments: TAA: (572.3 ± 24.2 nmol/1), BDP: (590.6 ± 25.0 nmol/1), FP:
(581.9 ± 24.6 nmol/1). There were no patients who had an individual value less than 150
nmol/1 for any drug.
Post ACTH Serum Cortisol [Figure 5.2]
There were no significant differences between placebo (761.0 ±31.7 nmol/1) and any of
the other treatments TAA: (767.8 ± 32.0 nmol/1), BDP: (749.6 ±31.2 nmol/1) FP: (769.7

























































TAA 220 BDP 336 FP 200 PL
Dose of intranasal steroid (|jg once daily)
Figure 5.1:
a) Geometric mean (and SE) and b) individual values for overnight urinary Cortisol
excretion with intra-nasal administration of placebo (PL), triamcinolone acetonide
220pg once daily (TAA-220), beclomethasone dipropionate 336pg once daily (BDP
336) and fluticasone propionate 200pg once daily (FP 200). Asterisk denotes significant


























































TAA 220 BDP 336 FP 200 PL
Dose of intranasal steroid (pg once daily)
Figure 5.2
(a) Geometric means and SE for pre and post ACTH stimulated serum Cortisol and (b)
individual values for post ACTH stimulated serum Cortisol for placebo (PL),
triamcinolone acetonide 220pg once daily (TAA-220), beclomethasone dipropionate
336pg once daily (BDP 336) and fluticasone propionate 200pg once daily (FP 200).
There were no patients with post stimulated Cortisol less than 500nmol/l for any drug.
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Study 2
There was no significant carryover effect between the non-randomised placebo and
randomised placebo respectively using any of the parameters measured [Table 5.1].
Plasma Cortisol.
There was no significant difference between the randomised placebo and any of the
active treatments in terms of fractionated or 24 hour measurements [Figure 5.3], From
the 24 hour plasma Cortisol profile, it can be seen that the normal circadian diurnal
rhythm was unaltered with all drugs and the curves were virtually super-imposable with
that ofplacebo [Figure 5.4]. Inspection of individual data shows a considerable degree of
inter-individual dispersion and there were no individual values for 8am Cortisol
<150nmol/l (<5.44pg/l) with any of the treatments[Figure 5.5].
Urinary Cortisol
There was no significant difference between the randomised placebo and any of the
active treatments in terms of fractionated or 24 hour uncorrected urinary free Cortisol
[Table 5.2] or for fractionated and 24 hour cortisol/creatinine [Figure 5.6]. There were
two values with TAA for 24 hour urinary Cortisol of <40nmol (14.4pg) and one value
with MF for overnight urinary Cortisol of <10 nmol (3.6pg)[Figure 5.5].
Osteocalcin
There was no significant difference between randomised PL (1.3 ± 0.1) and any of the
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three active treatments (BUD: 1.2 ±0.2, MF: 1.3 ±0.2, TAA: 1.2 ±0.2).
Blood Eosinophil Count
There was no significant difference between randomised PL (0.29 ± 0.05) and any of
the three active treatments (BUD: 0.27 ±0.04, MF: 0.25 ±0.04, TAA:0.24 ±0.04).
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Table 5.1
Means (SE) for first placebo (PL-1) in sequence and randomised placebo (PL-R) for 24
hour and fractionated plasma Cortisol and urinary cortisol/creatinine ratio, for blood
eosinophil count and for serum osteocalcin. There were no significant differences
between the two placebo values for any tissue marker.
PL-1 PL-R PL-1 PL-R
Overnight 3071.0 2719.2 overnight urinary 9.2 6.9
plasma Cortisol (248.1) (238.6) cortisol/creatinine (1.0) (0.8)
(nmol.hr/1) ratio (nmol/mmol)
8am plasma 545.1 585.3 8am urinary 18.0 19.1
Cortisol (37.8) (42.2) cortisol/creatinine (2.2) (2.3)
(nmol/1) ratio (nmol/mmol)
Daytime 3414.4 3593.6 Daytime urinary 9.8 (0.6) 10.4
plasma Cortisol (250.5) (365.7) cortiso1/creatinine (0.6)
(nmol.hr/1) ratio (nmol/mmol)
24 hour plasma 6485.4 6312.9 24 hour urinary 119.8 114.7
Cortisol (467.9) (564.4) cortisol/creatinine (7.8) (6.7)
(nmol.hr/1) ratio (nmol/mmol)
Osteocalcin 1.5 1.3 Blood eosinophil 0.29 0.29
(nmol/1) (0.2) (0.2) count (x 109/l) (0.04) (0.05)
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Table 5.2
Means (SE) for budesonide (BUD), mometasone furoate (MF), triamcinolone acetonide
(TAA) and randomised placebo (PL) for 24 hour and fractionated (Overnight, 8am and
daytime) urinary Cortisol (nmol). There was no significant difference between any of the
active treatments and placebo.
PL BUD MF TAA
24 Hour urinary
Cortisol
114.7(6.7) 96.8 (6.1) 107.7 (6.3) 102.2 (6.0)
Overnight urinary
Cortisol
40.4 (4.4) 39.3 (4.4) 36.0 (3.9) 46.0 (5.0)
8am urinary
Cortisol
8.1 (1.4) 10.0(1.8) 11.3 (2.0) 8.9(1.6)
Daytime urinary
Cortisol
67.4 (4.3) 54.7 (3.6) 67.2 (4.3)' 56.4 (3.6)
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Figure 5.3
Arithmetic means with standard error for placebo (PL), budesonide 200p.g once daily
(BUD 200), mometasone furoate 200p.g once daily (MF 200), and triamcinolone
acetonide 220pg once daily (TAA 220), for effects on 24 hour AUC and fractionated
(overnight, 8am and daytime) plasma Cortisol. There was no significant difference
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Figure 5.4
Means for 24 hour profile of plasma Cortisol for placebo (PL), budesonide 200pg once
daily (BUD), mometasone furoate 200pg once daily (MF), and triamcinolone acetonide
220pg once daily (TAA), for effects on 24 hour AUC and fractionated (overnight, 8am




































































BUD 200 MF 200 TAA 220
Corticosteroid (pg/day)
Figure 5.5:
Individual values for a) 8am plasma Cortisol and b) overnight urinary Cortisol for
placebo (PL), budesonide 200pg once daily (BUD 200), mometasone furoate 200pg
once daily (MF 200), and triamcinolone acetonide 220pg once daily (TAA 220), for
effects on 24 hour AUC and fractionated (overnight, 8am and daytime) plasma Cortisol.
There were no valued below 150nmol/l for 8am plasma Cortisol and only one value (for
MF) below lOnmol for overnight urinary Cortisol.
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Figure 5.6:
Geometric means with standard error for 24 hour and fractionated (overnight, 8am
daytime) corrected urinary cortisol/creatinine ratio for placebo (PL), budesonide 200pg
once daily (BUD 200), mometasone furoate 200pg once daily (MF 200), and
triamcinolone acetonide 220pg once daily (TAA 220), for effects on 24 hour AUC and
fractionated (overnight, 8am and daytime) plasma Cortisol. There were no significant
differences between placebo and any of the three active treatments.
152
Study 3
There were no significant carryover effects between the first and second placebos given
in sequence using any of the parameters measured [Figures 5.7, 5.8, 5.11]. Placebo
values prior to treatment (irrespective of sequence) with either FP and TAA were also
not significantly different (FP vs TAA): a) 24 hour serum Cortisol 6880 vs 7280
nmol.hr/1, b) fractionated serum Cortisol (overnight: 2590 vs 2760 nmol.h/1, 8am 587 vs
608 nmol/1, daytime: 4240 vs 4460 nmol.h/1), c) 24 hour corrected urinary
cortisol/creatinine excretion 7.0 vs 6.4 nmol/mmol, or d) fractionated urine collections
corrected for creatinine (overnight: 3.9 vs 3.8 nmol/mmol, 8am: 16.1 vs 16.5 nmol/mmol
and daytime: 9.3 vs 9.1 nmol/mmol). Mean FEV) values showed a significant difference
between both placebo and inhaled alone for both treatments but no difference between
the two drugs for either inhaled alone or combined inhaled and intranasal: PL: 2.98L,
inhTAA+nPL: 3.18L, inhFP+nPL:3.29L, inhTAA+nTAA: 3.05L, inhFP+nFP:2.94L.
Serum Cortisol:
Inspection of the 24 hour serum Cortisol time profile shows that the normal diurnal
circadian rhythm was abolished by FP [Figure 5.7]. With TAA there was blunting of the
8 am early morning Cortisol peak although the normal diumal circadian rhythm
remained preserved. For both 24 hour and fractionated serum Cortisol there was a
significant (p<0.05) difference between placebo and all of the other 4 active treatments.
There was a significant difference (p<0.05) between FP and TAA for both inhaled
medication alone and inhaled plus nasal medication [Figure 5.8 and 5.9]. For 8 am
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serum Cortisol for all active treatments, there was a significant (p<0.0005) difference in
the number of individual values between FP [17/24 (71%)] and TAA [3/24 (12%)] with
an abnormal low level <150nmol/L [Fig 5.10]. The addition of intranasal corticosteroid
did not produce any further significant suppression ofmean serum Cortisol values.
Urinary cortisol/creatinine:
For 24 hour and fractionated measurements there was a significant (p<0.05) difference
between placebo and all of the other active treatments and a significant difference
(p<0.05) between FP and TAA for both inhaled medication alone and inhaled plus nasal
medication. [Figure 5.9 and Figure 5.11]. The 95% CI for a within-subject differences
showed less variance for urine than for serum measurements [Figure 5.9], For 24 hour
urinary Cortisol excretion [Figure 5.10], there was a significant (p<0.0005) difference
between those treated with FP [17/24 (71%)] and TAA [4/24 (16%)], when analysing
the number of individual values with an abnormally low level <40nmol. The addition of
nasal corticosteroid did not produce any further significant suppression of mean or
urinary cortisol/creatinine values. However, the addition of intranasal FP resulted in 3























Geometric means for 24 hour profile of serum Cortisol for first and second placebo (PL 1
and 2), inhaled triamcinolone acetonide with nasal placebo (inhTAA+nPL), inhaled
fluticasone propionate with nasal placebo (inhFP+nPL), inhaled plus nasal triamcinolone
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Figure 5.8
Geometric means with standard error for 24 hour and fractionated serum Cortisol for first
and second placebo (PL 1 and 2), inhaled triamcinolone acetonide with nasal placebo
(inhTAA+nPL), inhaled fluticasone propionate with nasal placebo (inhFP+nPL), inhaled
plus nasal triamcinolone acetonide (inhTAA+nTAA), inhaled plus nasal fluticasone
propionate (inhFP+nFP). There was a significant(p<0.05) difference between all 4 active
treatments and both placebos. Asterisk denotes a significant (p<0.05) difference between
FP and TAA for inhaled alone or inhaled plus nasal medication.
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Figure 5.9
Ratio for TAA:FP (with 95% confidence intervals) for 24 hour, overnight, daytime and
8am urinary cortisol/creatinine excretion (open) & serum Cortisol (closed). 95%
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Figure 5.10
Individual values for a) 8am serum Cortisol and b) 24 hour urinary Cortisol for first and
second placebo (PL 1 and 2), inhaled triamcinolone acetonide with nasal placebo
(inhTAA+nPL), inhaled fluticasone propionate with nasal placebo (inhFP+nPL), inhaled
plus nasal triamcinolone acetonide (inhTAA+nTAA), inhaled plus nasal fluticasone
propionate (inhFP+nFP). For all 4 active treatments the numbers of individual patients
with an abnormal 8am serum Cortisol <150nmol/l (<5.4pg/dl) were: FP 17/24 (71%),
and TAA 3/24 (12%) (p<0.0005). The corresponding numbers of individual patients
with an abnormal 24 hour urinary Cortisol excretion <40 nmol (<14.4pg) were FP 17/24
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Figure 5.11
Geometric means with standard error for 24 hour corrected urinary cortisol/creatinine
excretion and fractionated (overnight, 8am and daytime) corrected urinary
cortisol/creatinine for first and second placebo (PL 1 and 2), inhaled triamcinolone
acetonide with nasal placebo (inhTAA+nPL), inhaled fluticasone propionate with nasal
placebo (inhFP+nPL), inhaled plus nasal triamcinolone acetonide (inhTAA+nTAA),
inhaled plus nasal fluticasone propionate (inhFP+nFP). Asterisk denotes significant
(p<0.05) difference between TAA and FP for inhaled or inhaled alone plus nasal
medication. There was a significant difference between all 4 active treatments and both
placebos for 24 hour and fractionated measurements.
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5.4 DISCUSSION
In the first study, suppression of overnight urinary Cortisol occurred with fluticasone
propionate, triamcinolone acetonide and beclomethasone dipropionate, although this was
only statistically significant for fluticasone propionate. The presence of detectable
adrenal suppression does not necessarily imply that the observed effects are clinically
relevant, although it is evident from the scatter plot (Figure 5.1b) that individuals differ
in their susceptibility to the systemic adverse effects of intra-nasal corticosteroids. It is
important to point out that this degree of suppression would not result in an acute
adrenal crisis if patients were to abruptly stop their treatment or be exposed to acute
stress. Indeed, there was no blunting of the Cortisol response for any of the three drugs to
low dose (0.5p,g) ACTH stimulation test.
Although steady-state drug levels would have been reached in this study, it is possible
that an impaired response to ACTH stimulation might have occurred after more
prolonged treatment as a consequence of impaired adrenal reserve due to adrenocortical
atrophy. However, previous long-term studies with clinically recommended doses of
inhaled FP, TAA and BDP have shown no evidence ofHPA-axis suppression in terms of
a bolus or 6 hour infusion with high dose (250pg) ACTH(238'239'241).
The results with suppression of overnight urinary Cortisol are in keeping with other
studies which have shown systemic bioactivity with intra-nasal fluticasone propionate in
terms of significant effects on serum osteocalcin(237). The fact that intra-nasal
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corticosteroids cause detectable systemic activity is not surprising as there is no first-
pass inactivation in the nose, resulting in extensive systemic absorption of unchanged
active drug'175'. Whether beclomethasone dipropionate undergoes partial
biotransformation to active and inactive metabolites in the nose, as in the lung, is not
clear.
These results are in contrast to a study by Vargas et al'340' where 200pg fluticasone
propionate resulted in no significant change in morning plasma Cortisol. In the same
study fluticasone propionate 400pg bid resulted in significant plasma Cortisol
suppression but no blunting of the 250pg ACTH stimulation test. Studies have shown no
difference from placebo in terms of plasma Cortisol levels after 2 weeks'34'', 4
weeks'139'342' and 1 year'342'343' of therapy with fluticasone propionate. Van As et al(241)
performed a dose tolerance study of fluticasone propionate and showed no suppression
of plasma Cortisol or 24 hour urinary Cortisol up to 1600pg per day in patients with
seasonal allergic rhinitis. The study in this chapter investigated healthy volunteers and it
is likely that nasal deposition and bioavailability might be altered in the presence of
rhinitis, due to effects of inflammation and associated secretions.
Haye et al(344) performed a study comparing intra-nasal fluticasone propionate and
beclomethasone dipropionate and showed that fluticasone propionate provided greater
control of patients nasal blockage, discharge and eye watering after 1 year of therapy in
patients with perennial allergic rhinitis. However, there was no significant difference
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between the treatments in terms ofmorning plasma Cortisol levels.
In the second study, the results showed no significant systemic bioactivity in terms of
markers of adrenal function, blood count and bone metabolism in patients with allergic
rhinitis. In particular, no suppressive effects were seen with the use of the sensitive
measurement of 24 hour integrated plasma Cortisol. Because the study was powered to
detect 20% adrenal suppression, a smaller degree of suppression may not have been
detected although this is unlikely to be of clinical relevance. Regardless, there were no
trends to suggest that an increase in sample size would have shown a significant effect in
any of the sensitive endpoints used. Great care was taken to ensure adequate nasal spray
technique and compliance was checked with each patient at each visit and the 24 hour
Cortisol samples were taken in controlled conditions.
The findings of both studies, in healthy volunteers and patients with rhinitis, are in
keeping with each other as neither showed significant suppression with triamcinolone
acetonide. Studies have reported no significant suppressive effect with budesonide at a
dose of 400pg per day, in terms of early morning plasma Cortisol in adults with
vasomotor rhinitis(345) and overnight urinary Cortisol in children with seasonal allergic
rhinitis(346). In terms of blood eosinophil count, Edsbacker et al(347) showed detectable
but clinically non-significant suppression with budesonide at a dose of lOOpg. Knutsson
et al(237) demonstrated significant suppression with budesonide in terms of osteocalcin,
early morning serum Cortisol and 24 hour urinary Cortisol but this was at higher doses of
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400pg od and 400pg bid administered to healthy volunteers. However, in the same study
it was shown that there was no impaired response to dynamic stimulation with an insulin
tolerance test. Pipkorn et al(345) also showed no impaired response to budesonide 400pg
od in terms of the 6 hour cosyntropin test. In contrast two studies in children have shown
evidence of growth suppression with intra-nasal budesonide pMDI or dry powder inhaler
400pg per day, as assessed by knemometry(348'349).
These findings with mometasone furoate are also in keeping with those of Brannan et al
who found, in two separate studies, no suppression with once daily intra-nasal
mometasone furoate at doses of 200pg and 400pg in adults(238), and 50 to 200pg in
children(350). Although 24 hour urinary free Cortisol was investigated in children, the
main endpoint for adrenal suppression in both studies was the 6 hour 250pg cosyntropin
stimulation test.
Mometasone furoate is more potent than both budesonide and triamcinolone as shown
by in vivo inhibition of T-cell cytokine production(351). It is difficult to explain its lack of
systemic bioactivity in terms of glucocorticoid potency, first-pass metabolism or in
terms of sensitivity of tissue markers. The explanation may be due to the fact that all of
the corticosteroids studied had short plasma elimination half lives (BUD 2.3 hrs, TAA
3.6 hrs, MF 5.8 hrs)(159'165) and therefore at steady-state with once daily dosing,
significant degree of blood accumulation is unlikely to occur. It is known that adrenal
suppression, unlike clinical efficacy, is proportional to plasma concentration. In this
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respect, the adrenocortical suppression with fluticasone propionate, which has a longer
elimination half life (14.4hrs)(158), is greater with steady-state than single dosing(316) and
fluticasone propionate has been shown to cause more suppression than other
corticosteroids when given by the intra-nasal (Chapter 8) or inhaled route (Chapter
3)(23l). Another possibility for the lack of effects is that the aqueous delivery device may
be less efficient for MF resulting in a lower degree of nasal bioavailability, although
there are no published data for Nasonex nasal formulation. Deposition data using
positron emission tomography delivery scanning showed that the thixotropic formation
of triamcinolone acetonide produced 80% delivery to the target tissues in the nose and
sinuses(338).
When assessing the combined effects of intra-nasal corticosteroids and inhaled
corticosteroids, it was shown for 24 hour and fractionated measurements of serum
Cortisol and corrected urinary cortisol/creatinine excretion, that both inhaled fluticasone
propionate and triamcinolone acetonide produced significant adrenal suppression versus
placebo. Inspection of the 24 hour serum Cortisol profile for fluticasone propionate
shows that the normal circadian diurnal rhythm was abolished. This flattening of the 24
hour profile with fluticasone propionate has also been reported by Boorsma(l83) in
healthy subjects taking lOOOpg bid of fluticasone propionate (pMDI without spacer)
with 87% suppression in AUC for plasma Cortisol. Interestingly in the asthmatic
patients in this study the degree of suppression for AUC was calculated at 81% with
inhaled fluticasone propionate (pMDI without spacer) at a dose of 880pg bid. Although
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triamcinolone acetonide showed significant suppression, the diurnal pattern remained
intact with a Cortisol rise at 8am.
From the 24 hour serum profile, it can be seen that the addition of intra-nasal to inhaled
medication had a small non-significant additive effect with triamcinolone acetonide.
With fluticasone propionate, however, there was no evidence of any additional
suppression with intra-nasal corticosteroids which can be explained by the near maximal
suppression with the inhaled drug alone. In other words the ceiling of the dose response
curve had been attained with inhaled fluticasone propionate alone prior to addition of
intra-nasal fluticasone propionate. It is evident from inspection of the scatter-plots for
8am serum Cortisol and 24 hour urinary Cortisol excretion that the majority of patients
receiving inhaled fluticasone propionate alone or with intranasal fluticasone propionate,
had suppression below that of accepted normality(l76). In contrast there were only a
minority of abnormal individual low values for inhaled alone or with intranasal
triamcinolone acetonide. Although the mean data showed no significant additive
suppression with intranasal fluticasone propionate, it was evident from the individual
data for 24 hour urinary Cortisol that there were a further three abnormal values with
combination therapy as compared to inhaled fluticasone propionate alone. This in turn
suggests that the bioavailability from the nasal moiety may contribute to the overall
systemic burden in certain susceptible patients(175).
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CHAPTER 6
DOSE RESPONSE EVALUATATION OF
THE THERAPEUTIC INDEX FOR




The preceding chapters have assessed the dose-response effect for systemic bioactivity
and adverse effects of inhaled and intra-nasal corticosteroids. They have shown that
inhaled corticosteroids exhibit dose-related systemic adverse effects. Furthermore, intra¬
nasal corticosteroids may also exhibit systemic adverse effects in some patients and this
is especially the case when given in addition to inhaled corticosteroids. However, the
unwanted systemic side effects represent only half of the picture, and it is necessary to
consider the therapeutic benefit of these drugs. This is required in order to calculate a
therapeutic ratio. In this respect, it is clear that the therapeutic ratio is of greater clinical
importance as this represents the trade off between harmful and beneficial effects of a
drug.
Inhaled corticosteroids are widely accepted as first-line anti-inflammatory therapy for
the treatment of persistent asthma(352). Current asthma management guidelines suggest
that the dose of inhaled corticosteroids should be titrated according to the patients'
symptoms or lung function(134'353). However, measurements of lung function reflect the
consequences of the inflammatory cascade rather than quantifying the degree of
underlying inflammation per se. In other words it is theoretically possible for patients to
have bronchodilation, for example with inhaled p2.adrenoceptor agonists, but still have
uncontrolled airways inflammation. There is concern that this may result in a delay in
treatment of an asthmatic exacerbation(272).
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As discussed above (see section 1.2), there are a number of techniques for assessing
asthmatic disease. These include patients' symptoms and spirometry. However the
degree of underlying airway inflammation can be assessed non-invasively by
quantifying bronchial hyperresponsiveness(84). Methacholine bronchial challenge, which
correlates with airway eosinophil numbers(76), is thought to be less clinically relevant
than adenosine monophosphate, which more closely mimics bronchial hyperreactivity
due to mast cell activation and inflammatory mediator release(79). However, there are no
data comparing these types of challenge in a dose-ranging study with inhaled
corticosteroids.
Exhaled nitric oxide production is induced by inflammatory cytokines and therefore may
also be a marker of underlying airway inflammation(94). Both peripheral blood
eosinophil count and their state of activity, as measured by serum ECP concentration,
are also considered to be sensitive surrogate markers of asthmatic inflammation^08'112).
However, as all of the current available markers of asthmatic disease control assess
different parts of the inflammatory cascade they should not be considered in isolation
but must be considered together.
It is also recognised that inhaled corticosteroids cause dose-related systemic effects on
tissues such as the adrenal gland and bone. In particular, sensitive measures of basal
adrenocortical activity such as overnight urinary Cortisol excretion may be used to detect
potential systemic bioactivity of inhaled corticosteroids^75). This study is therefore a
dose-ranging evaluation of an inhaled corticosteroid on symptoms, lung function,
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markers of airway inflammation as well as systemic adverse effects.
Budesonide was used as an example of a commonly used inhaled corticosteroid which
could be administered by breath actuated dry powder reservoir device in order to
improve lung delivery and compliance. The doses were chosen to reflect the clinically
recommended dose range (400-1600pg per day) for this drug. Kraan et al(251) showed
that two weeks of treatment with inhaled budesonide was adequate to achieve near
maximal response in terms of effects on bronchial challenge and lung function. Hence
the medication was administered for 3 weeks at each dose sequentially over a total




Twenty-six (13 female) mild to moderate asthmatic patients were recruited into the
study, mean (SE) age 34.7 (2.3) years, FEVj 84.8 (3.0) % predicted, FEV25.75 55.5 (3.4)
% predicted. All patients were taking maintenance inhaled corticosteroids (median dose
800pg per day; range 200-1600pg per day) (beclomethasone n=19, budesonide n=6,
fluticasone n=l). All patients were required to be responsive at screening to
methacholine and adenosine monophosphate challenge testing with a provocation
dose/concentration producing 20% fall in FEVi of less than 500pg (geometric mean
PD2o MCh 32.8pg) and 200mg/ml (geometric mean PC20 AMP 35.8mg/ml) respectively.
Two patients were taking oral theophylline therapy and two patients were taking long
acting P2 therapy prior to entry into the initial placebo run-in. All but one patient were
shown to be atopic by Phadiotop testing.
Design
The study was conducted as an open label study. Patients had an initial placebo run-in
period of 10 days where they received a placebo Turbuhaler one puff twice daily at 8am
and 8pm. Following this patients received budesonide as Pulmicort Turbuhaler 200pg
per actuation (Astra Pharmaceuticals, Kings Langley, UK) in three consecutive doubling
dose increments each of 3 weeks (i.e. a total of 9 weeks): 1 puff bid, 2 puffs bid, 4 puffs
bid at 8am and 8pm:- i.e. a total daily dose of 400pg, 800pg, and 1600pg. Patients
attended the laboratory after the run-in placebo period (at baseline) and after each 3
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week period of inhaled budesonide. After 3 weeks of high dose inhaled budesonide
patients returned to the laboratory, on the day following the fourth visit, for a fifth
occasion when spirometry and bronchial challenge testing were repeated 20 minutes
after inhalation of a bolus dose of 400pg inhaled salbutamol (Ventolin Accuhaler, Allen
& Hanburys Ltd., Uxbridge, UK).
Patients withheld all other treatment with long-acting p2-agonists, cromones,
theophylline or leukotriene antagonists throughout the study. Patients received their
usual short acting p2 agonist on an as required basis but were asked to withhold this for
12 hours prior to attending the laboratory.
Measurements




8am serum eosinophilic cationic protein
8am peripheral blood eosinophil count
Overnight urinary Cortisol excretion






Domiciliary twice daily peak expiratory flow rate
Also in a subgroup of 15 patients:
hCRF stimulation test
Statistical Analysis
The study was designed with at least 80% power to detect a 1.0 doubling dose difference
(2.0 fold) in AMP PC20 and MCh PD2o(354>, with the alpha error set at 0.05 (two-tailed).
For domiciliary peak expiratory flow the mean values of the last 7 days of each
treatment period were analysed, whereas for asthma symptom scores the sum of the last
7 days of each treatment period were used.
Overall comparisons between treatment levels were made by multifactorial analysis of
variance (MANOVA) using subject and treatment as factors. This was followed by
Bonferroni multiple range testing (set at 95% CI) to assess which doses were different
from baseline, in order to obviate multiple pair-wise comparisons. Consequently
statistical comparisons are only denoted as being significant (p<0.05) or not significant
in order not to confound the alpha error. Regression analysis was applied to investigate
whether for each endpoint there was a significant overall dose-response relationship for
all three doses of budesonide. In order to permit quantitative comparisons between the
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different endpoints, the response after placebo run-in and after each dose level was
calculated as the percentage of maximal achievable response occurring at the highest




There was a significant difference between placebo compared with medium and high
doses of budesonide for mean spirometry values (FEVi, FEF25-75, and PEF). The mean
percentage change from baseline was greater for FEF25-75 than for PEF or FEV] at all
dose levels [Figure 6.1]. For AMP and MCh challenge there were significant overall
dose response effects and all doses of budesonide were significantly different from
placebo [Table 6.1]. There was a greater doubling dose shift for AMP than for MCh
challenge across the dose range [Figure 6.2], A 400pg bolus dose of inhaled salbutamol
produced further improvements in both MCh, AMP and lung function over and above
the response with budesonide 1600pg per day [Table 6.1, Figure 6.1, Figure 6.2],
Differences from placebo were significant at all 3 doses of budesonide for nitric oxide
and diary card data, but only at the medium and high doses for eosinophil markers.
When expressed as a percentage of maximal response [Figure 6.3], there was a plateau
in the dose-response curve for nitric oxide at 400pg per day, for spirometry at between
400pg per day and 800pg per day and for ECP and AMP at between 800pg per day and
1600mg per day.
Systemic effects
Markers of HPA-axis activity showed a significant overall dose-response relationship,
with 8am plasma Cortisol exhibiting no plateau in response within the evaluated dose-
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range[Table 6.2], The proportion of individuals with a stimulated plasma Cortisol
response (post hCRF) less than 500nmol/l were: baseline (7%); 400pg per day (13%),
800pg per day (40%), 1600pg per day (66%) and for overnight urinary Cortisol less than
20nmol/10hr were: baseline (15%); 400pg per day (12%); 800pg per day (42%);
1600pg per day (43%). With osteocalcin there was no evidence of a significant dose-
response relationship with none of the doses being statistically significant from placebo
[Table 6.2],
Therapeutic index
To evaluate the therapeutic index (airway/systemic ratio) patients were categorised into
those who did (overnight urinary Cortisol <20nmol/10hr) or did not (overnight urinary
Cortisol >20nmol/10hr) have a marked systemic response and/or those who did (AMP >
2 doubling dose shift) or did not (AMP <2 doubling dose shift) have a marked airway
anti-inflammatory response with inhaled budesonide [Figure 6.4], The proportion of
patients with a marked airway response together with a minimal systemic response was
46% at low dose and 52% at high dose. The proportion of patients with a marked airway
response together with a marked systemic response increased from 4% at low dose to
38% at high dose.
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Table 6.1
Mean (SE) for forced expiratory volume in 1 sec (FEVi), forced mid-expiratory flow
rate (FEF 25-75), peak expiratory flow rate (PEF) as percentage predicted (%pred); and
for adenosine monophosphate (AMP) bronchial challenge test as provocative
concentration causing a 20% fall in FEVi (PC20) and methacholine (MCh) bronchial
challenge testing as provocative dose causing a 20% fall in FEVi (PE>2o)- Values are
shown after placebo (baseline), 400pg per day, 800mg per day, 1600pg per day of
inhaled budesonide and following a bolus dose of 400pg inhaled salbutamol. The 'p'
values for the significance of the slope of the overall dose response curve are also
shown. An asterisk denotes a significant difference compared to placebo run-in
(baseline). Values for AMP and MCh are geometric means.
Visit FEV, FEF 25-75 PEF AMP MCh
% pred % pred % pred PC20 PD20
% % % mg/ml Pg
Baseline 78.0 53.1 89.3 23.7 17.7
(3.2) (3.5) (3.8) (7.4) (5.4)
400|ug 81.4 56.5 92.9 133.8 * 48.8 *
(3.1) (3.0) (3.1) (40.2) (14.3)
800pg 84.9* 61.9* 96.8 * 300.8 * 58.2 *
(3.0) (3.8) (2.7) (92.0) (16.1)
1600pg 84.5 * 59.3 * 97.5 * 502.2 * 119.3 *
(3.1) (3.3) (3.3) (146.3) (44.3)
Post salbutamol 89.5 * 66.1 * 100.7 * 1322.8 * 525.0 *
(3.3) (4.3) (3.6) (227.1) (144.9)




Mean (SE) for exhaled nitric oxide (NO), blood eosinophil count (EOS), serum
eosinophilic cationic protein (ECP), morning domiciliary peak expiratory flow rate
(PEFam), evening domiciliary peak expiratory flow rate (PEFpm), asthma symptom
scores (Symp), 8am plasma Cortisol (8am Cortisol), overnight urinary Cortisol (OUC),
and osteocalcin (O'cal) after placebo (baseline), 400pg per day, 800pg per day and
1600pg per day of inhaled budesonide. The 'p' values for the significance of the slope of
the overall dose response curve are also shown. Asterisk denotes a significant difference
compared to placebo run-in (baseline).







ppb xl09/l nmol/1 1/min 1/min units nmol/1 nmol/
lOhr
nmol/1
baseline 19.1 0.41 20.1 390.7 410.0 13.2 528.9 61.1 0.97
(2.2) (0.05) (3.5) (16.9) (19.1) (1.4) (39.0) (9.5) (0.11)
400pg 9.2 * 0.35 15.9 433.4* 440.8 * 7.3 * 528.6 40.0 0.92
(0.9) (0.04) (1.7) (17.8) (18.1) (1.7) (36.1) (4.4) (0.12)
800p.g 8.8 * 0.31 * 12.8 * 443.8 * 455.2 * 6.6 * 461.4 28.4* 0.85
(1.0) (0.04) (2.0) (16.0) (15.7) (1.9) (38.2) (3.1) (0.12)
1600pg 7.2 * 0.26 * 10.2 * 461.3 * 506.7 * 3.4* 366.9 * 24.9* 0.87
(0.6) (0.03) (1.2) (17.0) (45.0) (1.1) (36.1) (3.2) (0.10)
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Figure 6.1
Percentage change from placebo run-in (baseline) for laboratory based spirometry data
(FEVi,FEF25-75,PEF) after three weeks each at low, medium and high doses of
budesonide and after bolus 400pg dose of inhaled salbutamol (i.e. at the end of the
1600p,g per day budesonide period). There was a significantly greater percentage change













400 800 1600 Salbutamol
Dose of inhaled budesonide (jjg/day) 400pg
Figure 6.2
Doubling dose shift from placebo run-in (baseline) for adenosine monophosphate and
methacholine bronchial challenge testing at each dose of budesonide and after a bolus of
salbutamol. There was a significantly shift with adenosine than methacholine which was
























1 1 1 1
Baseline 400/jg 800|jg 1600/jg
Dose of inhaled budesonide (jjg/day)
Figure 6.3
Anti-asthmatic efficacy parameters plotted together as percentage of maximum
achievable response after placebo (at baseline), 400pg per day, 800pg per day, 1600pg
per day of inhaled budesonide for FEVi (V), serum eosinophilic cationic protein (ECP:















A Overnight urinary cortisol>20nmol,AMP>2 doubling concentrations 46% 50% 52%
B Overnight urinary Cortisol <20nmol,AMP>2 doubling concentrations 4% 29% 38%
C Overnight urinary Cortisol <20nmol,AMP<2 doubling concentrations 8% 13% 5%
D Overnight urinary Cortisol >20nmol,AMP<2 doubling concentrations 42% 8% 5%
Figure 6.4
Pie charts for proportion of individual patients at each dose level with A) overnight
urinary Cortisol (OUC) > 20nmol/l and adenosine monophosphate bronchial (AMP)
challenge > 2 doubling doses (dd) B) OUC <20 nmol and AMP > 2 dd C) OUC <20
nmol and AMP <2dd black) D) OUC >20nmol and AMP <2 dd.
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6.4 DISCUSSION
The results from this study indicate that, in patients with mild to moderate atopic
asthma, the mean responses for lung function parameters were optimised at a dose of
400pg - 800pg per day of inhaled budesonide. For parameters of asthmatic
inflammation, including serum eosinophil cationic protein and bronchial hyperreactivity
to methacholine and adenosine monophosphate bronchial challenge, maximal effects
were obtained at a dose of 800mg - 1600pg per day. The relevance of these findings is
that the underlying inflammation may be inadequately controlled if the dose of inhaled
budesonide is titrated according to the patients' lung function.
It should be noted that with nitric oxide, in contrast to other markers of inflammation,
there was a plateau in response at 400pg per day. This is in keeping with Jatakanon et
al(355) who showed that exhaled nitric oxide was normalised at 400pg per day. However,
this may reflect the sensitivity of nitric oxide to inhaled corticosteroids (see section
1.2.3) rather than absolute control of inflammation and highlights the importance of
assessing more than one marker of inflammation(356).
Inhaled corticosteroids have been shown to exhibit dose-related systemic bioactivity
which has lead to concern regarding the potential long term adverse effects of high dose
therapy (Chapters 3 and 4). In the present study, there was dose related suppression of
adrenocortical activity, as assessed by mean values for overnight urinary Cortisol or
plasma Cortisol pre and post hCRF stimulation. However, it is more important to
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consider the effects of increasing the dose of inhaled corticosteroid on the overall
therapeutic index, rather than adverse or beneficial effects in isolation. In this respect,
the proportion of individuals with a good airway anti-inflammatory response (an AMP
challenge greater than 2 doubling doses) at high dose was 90%, compared to 50% at low
dose although this was offset by greater adrenal suppression at the high dose (38%).
Unfortunately as only one drug was investigated, the study had to be of an open label
design. However, when performing the investigations measuring clinical response, for
example the bronchial challenge tests or nitric oxide measurements, it was not known
which dosing schedule the patient was on as the examiner did not refer back to the
results of previous visits.
This study was of an escalating dose design. In other words, the patients received
doubling doses of drug at each limb of the study without a washout period. As discussed
elsewhere (see section 10.6) this may result in a time-effect as well as a dose-effect on
treatment response. Ideally the order of the dose-steps should have been randomised and
there should have been a washout period in between each dose. However, this would
have significantly lengthened the duration of the study and increased the patient drop¬
out rate.
Another weakness of this design is the way in which the doses were given. The study
was designed so that the concentration of each inhaler remained constant and patients
took 1 puff twice daily followed by 2 puffs twice daily then 4 puffs twice daily. This
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may have altered patient compliance and they could have expected their symptoms to
improve if they were under the impression that they were receiving increasing doses of
the drug. It would have been better to have taken two puffs twice daily throughout the
study and use inhalers of lOOpg, 200pg and 400p.g per actuation.
The duration of each treatment period was also relatively short. As is discussed
elsewhere (see section 10.11), it is possible that there may have been a greater response
to bronchial challenge testing had the duration of each treatment period be longer.
However, the effect of dose is likely to have contributed to a greater extent than the
effect of duration of treatment on the bronchoprotector response to methacholine.
The results of this study are in keeping with those of Busse et al(357) in a parallel study
comparing 200pg, 400pg 800pg and 1600p.g per day of inhaled budesonide via a
Turbuhaler. After 12 weeks of therapy there was no significant difference between the
response of 400pg per day and 1600p,g per day in terms of change in mean in FEV)
from baseline, indicating a plateau in response. There was also no dose-response effect
in terms of symptom control, with all doses being statistically superior to placebo but no
significant difference between doses. In another study with triamcinolone acetonide via
a spacer, in mild to moderate asthmatic patients, there was also a plateau in response for
symptoms and lung function at 400pg per day(358).
The results for bronchial hyperreactivity are similar to those of Kraan et al(251) who
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showed a significant difference in terms of methacholine bronchial challenge between
200jig per day and 800pg per day of inhaled budesonide in a two-way parallel study.
Measurements were made after 2, 4, 6 and 8 weeks and the difference between these
doses remained significant throughout the study. The dose-response effect of budesonide
Turbuhaler has also been reported by Jatakanon et al(355) in mild asthmatics although
their data was a composite of two separate parallel group studies in patients receiving 4
weeks with either lOOpg per day (n=8), 400pg per day (n=7) or 1600pg per day (n=10).
They found a dose-response effect for methacholine bronchial challenge PC20 and
induced sputum eosinophil cell counts with no evidence of plateau.
More recently, Taylor et al(359) showed a dose-response effect with lOOpg, 400pg and
1600pg per day of inhaled ciclesonide in terms of adenosine monophosphate bronchial
challenge testing but not in terms of induced sputum ECP levels. Pedersen et al(247)
showed a dose response effect between 100 and 400pg per day of budesonide via a
spacer for the effects on exercise protection, but there were no improvements in
symptoms, domiciliary peak expiratory flow or (32-agonists use with doses greater than
1 OOpg per day.
When comparing the effects of adenosine monophosphate and methacholine bronchial
challenge test, the results of this study indicate that adenosine monophosphate is more
sensitive in terms of changes with inhaled corticosteroids and with inhaled (32 agonists.
This is in keeping with a study by O'Connor et al(360\ who have also shown greater
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effect of inhaled budesonide on adenosine 5'-monophosphate than on sodium-
metabisulfite bronchial challenge in patients with mild asthma. Furthermore, Egbagbe et
al(361) showed terbutaline to have a greater effect on adenosine monophosphate than
histamine bronchial challenge, which is also in keeping with the results of this study.
It has been suggested that unchecked long-term inflammation leads to the development
of chronic irreversible air-flow limitation(26l). Patients with mild-intermittent asthma
have evidence of ongoing airway inflammation and may show improvement in
inflammatory markers when receiving inhaled corticosteroids*362*. Studies in children1363*
and in adults*364'365* have shown that a delay in instituting treatment with inhaled
corticosteroids may result in an attenuated response to inhaled steroid therapy. It is clear,
therefore, that patients have a better outcome when inhaled corticosteroid treatment is
commenced early in the course of the disease. For the same reasons, it is also possible
that patients will also fare better if the dose of inhaled corticosteroid is sufficient to
optimise suppression of airway inflammation.
Previous studies with inhaled corticosteroids and long-acting p2-agonists are shown to
have additive effects on lung function and exacerbation rates*62*. Further improvement in
bronchial hyperreactivity were found with a p2-agonist on top of high dose inhaled
budesonide. These effects of p2-agonists on bronchial hyperreactivity are due to
functional antagonism on smooth muscle, although it is considered that effects on AMP
challenge are also due to direct inhibition ofmast cell P2 adrenoceptor*366*.
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In keeping with the steep dose response with spirometry and shallow for bronchial
challenge, Noonan et al(248) found a significant increase with both fluticasone propionate
lOOpg per day and 200pg per day versus placebo, but no difference between the two
doses. However, with methacholine challenge, there was significant improvement with
fluticasone propionate 200mg per day between both lower dose fluticasone propionate
and placebo, and there was no difference between fluticasone propionate lOOpg per day
and placebo. Therefore, the addition of methacholine challenge testing allowed
definition of a dose-response relationship that was not apparent with spirometry.
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CHAPTER 7
A COMPARISON OF TOPICAL
BUDESONIDE AND ORAL MONTELUKAST




It has been shown in the previous chapter, that patients may have underlying airway
inflammation even when their symptoms are controlled and their lung function is
normal. It was also suggested, however, that inhaled corticosteroids exhibit dose-related
adverse systemic effects and indeed a high dose may confer a reduced therapeutic index.
For this reason, alternatives to inhaled and intra-nasal corticosteroids need to be
considered as a therapeutic option either to be used as monotherapy or as second-line
therapy in conjunction with corticosteroids. The aim of these second-line anti¬
inflammatory therapies should be to control symptoms and improve quality of life.
However, as asthma and allergic rhinitis are inflammatory conditions these treatments
are also required to control airways inflammation which is thought to be the underlying
mechanism producing the symptoms (see section 1.1)
Methods used to infer the degree of airway inflammation were exhaled and nasal nitric
oxide and adenosine monophosphate bronchial challenge(79'94'. Domiciliary peak
expiratory flow rate and peak inspiratory nasal flow were used, and patients recorded
their asthma symptom and seasonal allergic rhinitis symptoms in terms of eye, throat
and nasal symptoms, which is in keeping with international guidelines(14). Nasal peak
inspiratory flow rate has been shown to exhibit comparable results to
rhinomanometry(367) and has recently been reported to correlate well to patients
subjective measure of seasonal allergic rhinitis symptoms(65).
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Topically delivered inhaled and intra-nasal corticosteroids are widely recognised to be
effective anti-inflammatory treatment for allergic rhinitis and asthma(134'136). Leukotriene
receptor antagonists, however, have also been shown to have anti-inflammatory
properties and to have beneficial effects on asthma disease control(286). They have
recently been licensed as monotherapy for use in mild asthma and as second line therapy
for more severe asthma.
As both asthma and allergic rhinitis are mediated by similar inflammatory
mechanisms(36), it is likely that leukotriene receptor antagonists will also have anti¬
inflammatory activity in allergic rhinitis(368). Indeed there are data showing symptomatic
benefit with such treatment^ l0'312). Orally administered leukotriene antagonists act
systemically and thus, in theory, both conditions may be treated simultaneously.
The aim of this study was to evaluate whether an oral leukotriene receptor antagonist
would be efficacious in patients with seasonal allergic rhinitis and asthma, and also how
it would compare to inhaled and intra-nasal corticosteroids. In keeping with most
treatment regimens for allergic rhinitis, and to maximise compliance, treatment was
administered once daily. Budesonide and oral montelukast were used as these are the





Twelve patients with seasonal allergic rhinitis and asthma (9 female), mean (SE) age
34.7 (2.3) years, FEV] 84.8 (3.0) % predicted were recruited into the study. Six patients
were taking inhaled corticosteroids (budesonide 400pg per day n=2; beclomethasone
500pg per day n=2, 400pg per day n=l, 200pg per day n=l), 3 were taking intra-nasal
corticosteroids (beclomethasone 400pg per day) and 5 were taking oral antihistamines
(loratadine lOmg per day n=3, cetirizine lOmg per day n=2). All patients were required
to be responsive to adenosine monophosphate challenge testing with a provocation
concentration producing 20% fall in FEVi of less than 200mg/ml (geometric mean
29mg/ml). All patients had a positive skin prick test to grass or tree pollens and 9
patients also had positive skin prick test to house dust mite.
Design
The study was of a randomised placebo controlled, single-blind, double dummy, cross¬
over design. Patients were recruited during June and July 1998 when grass and tree
pollen levels are usually high in Tayside. Patients were randomised to receive the
following all given once daily at 0800hrs: A) 400pg inhaled budesonide dry powder (as
Pulmicort Turbuhaler™, Astra Pharmaceuticals Ltd., UK as 2 puffs of 200pg per
actuation) plus 200pg intranasal aqueous budesonide (as Rhinocort Aqua™ , Astra
Pharmaceuticals Ltd., UK as 1 squirt of lOOpg in each nostril) plus placebo tablets; or
B) lOmg oral montelukast (as Singulair™, Merck Sharp & Dohme Ltd., Herts, UK) plus
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placebo nasal spray and placebo Turbuhaler. Prior to each treatment, and at cross over,
patients had a one week treatment period with placebo Turbuhaler (2 inhalations),
placebo nasal spray (2 squirts in each nostril) and placebo tablets all taken at 0800hrs.
Six patients started with oral montelukast and 6 patients started with topical budesonide.
Measurements
The following measurements were made after both placebo and each active treatment
periods:
Adenosine Monophosphate Challenge Testing
Exhaled and Nasal Nitric Oxide
Spirometry




The study was powered at the 80% level to detect a 1.0 doubling dose difference (2.0
fold) in adenosine monophosphate PC20 with the alpha error set at 0.05 (two-tailed). On
each day a total seasonal allergic rhinitis symptom score was calculated as the sum of
each patients' individual nose, eye and throat symptom scores. Daily tree, grass and
weed pollen count data were summed to provide a daily pollen score for each day of the
study. For all domiciliary diary and pollen data, mean values for the 7 day placebo
periods and for the last 7 days of active treatment period were analysed. Overall
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comparisons between active treatments and placebos were made by multifactorial
analysis of variance (MANOVA) using subject, treatment and period as factors.
Analysis of co-variance was used to account for any influence of pollen level. This was
followed by Bonferroni multiple range testing (set at 95% CI) in order to obviate
multiple pair-wise comparisons. Consequently comparisons are only denoted as being
significant (p < 0.05) or not significant in order to not confound the alpha error. Least
squares regression analysis was used to assess the correlation between morning and




There were no significant carryover effects between the first (run-in) and second
(washout) placebo values in sequence with any of the measurements [Table 7.1].
Consequently all comparisons were made with reference to the run-in placebo.
Lower Airway Efficacy Markers
There was a significant difference between both treatments and placebo and also a
significant difference between active treatments for effects on adenosine monophosphate
bronchial challenge - the primary endpoint [Figure 7.1a]. Geometric mean differences
(95% CI for difference) were 6.4 fold (2.2 to 18.6) for placebo vs budesonide, 2.9 fold
(1.0 to 8.4) for placebo vs montelukast, and 2.1 fold (1.1 to 4.5) for budesonide vs
montelukast. For exhaled nitric oxide [Figure 7.1b] there were also significant
differences (95% CI for difference) between placebo vs montelukast: 7.9ppb (0.8 to
15.6) and placebo vs budesonide 8.7ppb (0.9 to 16.4). For spirometry data, asthma
symptom scores, peak expiratory flow, and rescue agonist usage there were similar
numerical trends for improvements with both budesonide and montelukast compared to
placebo, although these differences were not statistically significant [Table 7.2].
Upper Airway Efficacy Markers
For nasal nitric oxide [Figure 7.2a] there was a significant difference (95% CI for
difference) for placebo vs budesonide 369.3 ppb (15.4 to 723.2) but not with
montelukast. Likewise for domiciliary morning nasal peak flow there was significant
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difference with placebo vs budesonide 36.8 1/mm (15.9 to 57.5) but not with
montelukast [Figure 7.2b]. Both active treatments produced significant effects on eye
symptoms and total seasonal allergic rhinitis symptoms (i.e. nose, eye and throat
symptoms) compared to placebo whilst only budesonide significantly affected nasal
symptoms and daily activity scores [Table 7.2].
Correlations
There were significant correlations between asthma symptoms and morning PEF (r=-
0.25, p<0.0001) and evening PEF (r=-0.16, p<0.001); and between nasal symptoms and
morning nasal PIFR (r=-0.33,p<0.0001) and evening nasal PIFR (r=-0.33,p<0.0001).
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Table 7.1
Mean (SEM) values for 1st (run-in) and 2nd (washout) placebo in sequence for adenosine
monophosphate bronchial challenge PC20 (AMP), exhaled nitric oxide (NO), FEV),
morning peak expiratory flow rate (PEFR), evening peak expiratory flow rate, asthma
symptoms, rescue inhaler usage, nasal nitric oxide, morning nasal peak inspiratory flow
rate (PIFR), evening peak inspiratory flow rate, total seasonal allergic rhinitis symptoms
(SARS), nasal symptoms, eye symptoms, throat symptoms, ocular sodium cromoglycate
use (Ocular cromoglycate), and effects of symptoms on patients' daily activity (Daily
Activity). Values for AMP PC20 are given as geometric mean.
First PL Second PL First PL Second PL
AMP 23.5 (6.4) 34.5 (8.4) Nasal Nitric Oxide 949.8 (97.5) 797.5 (87.8)
(mg/ml) (PPb)
Exhaled Nitric Oxide 17.4 (2.0) 13.6(1.8) Morning PIFR 98.8 (5.3) 110.4 (4.7)
(PPb) (1/min)
FEV1 89.3 (2.6) 90.3 (2.2) Evening PIFR 114.4 (6.6) 122.1 (5.8)
(% predicted) (1/min)
Morning PEFR 399.2 (7.7) 398.4 (6.4) SARS 6.7 (0.9) 4.3 (0.7)
(1/min) (units)
Evening PEFR 393.6 (20.4) 425.4 (17.8) Nasal Symptoms 4.5 (0.6) 2.9 (0.5)
(1/min) (units)
Asthma symptoms 1.2 (0.2) 0.8 (0.2) Eye Symptoms 2.4 (0.4) 1.4 (0.4)
(units) (units)
Rescue inhaler 2.0 (0.5) 1.9(0.4) Throat Symptoms 0.6 (0.2) 0.7(0.1)
(Puffs/day) (units)





Mean (SEM) values after run-in placebo (PL) and after active treatment with budesonide
(BUD) or montelukast (MON). Data are for FEVi, morning peak expiratory flow rate
(PEFR), evening PEFR, asthma symptoms, rescue inhaler usage, effects of symptoms on
patients' daily activity (Daily Activity), evening peak inspiratory flow rate (PIFR), total
seasonal allergic rhinitis symptoms (SARS), nasal symptoms, eye symptoms, throat
symptoms, and ocular sodium cromoglycate use (Ocular cromoglycate). Asterisk
denotes a significant (p<0.05) difference between active treatments and placebo.
Treatment PT, BUD MON Treatment PL BUD MON
FEVI 89.3 94.3 91.3 Evening PIFR 114.4 135.7 124.0
(% predicted) (2.6) (2.1) (2.1) (1/min) (6.6) (5.6) (5.5)
Morning PEFR 399.2 424.3 401.1 SARS 6.7 1.8 * 3.5 *
(1/min) (7.7) (6.2) (6.1) (units) (0.9) (0.7) (0.7)
Evening PEFR 393.6 441.7 432.5 Nasal 4.5 1.3 * 2.8
(1/min) (20.4) (17.3) (16.8) Symptoms
(units)
(0.6) (0.5) (0.5)
Asthma 1.2 0.5 0.9 Eye Symptoms 2.4 o * 0.9 *
Symptoms (0.2) (0.2) (0.2) (units) (0.4) (0.3) (0.3)
(units)
Rescue inhaler 2.0 0.7 1.5 Throat 0.6 0.4 0.6
(Puffs/day) (0.5) (0.4) (0.4) Symptoms
(units)
(0.2) (0.1) (0.1)
Daily Activity 2.3 1.2 * 1.5 Ocular 0.7 0.2 0.3



















































(a) Geometric mean (SE) for adenosine monophosphate bronchial challenge PC20 for
placebo (PL), inhaled and intra-nasal budesonide (BUD) and oral montelukast (MON).
(b) Means (SE) for exhaled nitric oxide (ppb). Asterisk denotes significant (p<0.05)











































Means (SE) for (a) morning nasal peak inspiratory flow rate (1/min) and (b) nasal nitric
oxide (ppb) for placebo (PL), inhaled and intra-nasal budesonide (BUD) and oral




This study has shown that in patients with concomitant seasonal allergic rhinitis and
asthma, the use of oral montelukast or inhaled plus intra-nasal budesonide both exhibited
beneficial effects on markers of lower airway inflammation (adenosine monophosphate
bronchial challenge and exhaled nitric oxide). However, only inhaled plus intra-nasal
budesonide therapy showed a significant improvement on upper airway parameters
(nasal nitric oxide and nasal peak inspiratory flow rate). Both active treatments exhibited
significant improvements in total seasonal allergic rhinitis symptoms and on eye
symptoms alone, whilst budesonide improved nasal symptoms and daily activity scores.
The results with exhaled nitric oxide are in keeping with those of Kharitinov et al(369),
who showed that altering the dose of budesonide by 200pg per day resulted in detectable
changes in exhaled nitric oxide production. They showed budesonide 800pg per day
given via a Turbuhaler caused significant suppression of nitric oxide compared with
placebo'369'. There are also data to suggest that leukotriene receptor antagonists reduce
exhaled nitric oxide when given in addition to inhaled corticosteroids'106'. More recently
Bisgaard et al(107) showed that montelukast reduced exhaled levels in asthmatic children
by 20%, also after 2 weeks of therapy, and this effect was independent of concurrent
steroid treatment. Regarding nasal nitric oxide production, studies have demonstrated
suppression with intranasal corticosteroids'97'.
There are conflicting data on the effects of leukotriene receptor antagonist, given as
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monotherapy, on bronchial hyperreactivity. In a dose-response study for 12 weeks,
montelukast exhibited a 1.3 fold protection against methacholine challenge although this
was not significant compared to placebo(2y2). In a randomised, double blind, crossover
study, zafirlukast 20 mg bid and fluticasone propionate lOOpg bid for 2 weeks exhibited
1.7 fold and 2.8 fold protection respectively against histamine challenge(370). In a
subgroup analysis of a randomised crossover trial, there was 2.4-fold protection against
methacholine hyperreactivity after 2 weeks of zafirlukast 20mg bid compared to
placebo"71'. Studies with pranlukast have also shown protection against methacholine
and allergen challenge, and, in one study, a reduction in bronchial mucosal inflammatory
cells(284'372'373). As leukotrienes are inflammatory mediators, it is not surprising that
montelukast exhibited bronchoprotection with adenosine monophosphate although the
effect was less than that of budesonide (a 6.4 and 2.9 fold difference from placebo
respectively).
Montelukast was shown to have significant beneficial effects on allergic rhinitis
symptom scores in this study, which is in keeping with Malmstrom et al(312), Donnelly et
al(3ll) and Grossman et al(3l0). The superiority of an intra-nasal corticosteroid to a
leukotriene receptor antagonist has previously been shown in a study comparing 20mg
twice daily oral zafirlukast to 200pg intra-nasal beclomethasone dipropionate(374). Nasal
biopsies taken after 6 weeks of treatment showed decrease in eosinophilia with
beclomethasone dipropionate, compared to pre-season biopsies, but not with zafirlukast.
However, in that study, there was no significant difference with zafirlukast and placebo
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in terms of patients symptom scores(374).
Mild asthmatic patients were investigated as leukotriene antagonists and once daily
budesonide are only recommended as monotherapy in such patients. As a result the
patients in this study had near normal spirometry with a mean FEV) of 91% predicted
and therefore it was not surprising to see little improvement in lung function. Likewise
with asthma symptom scoring there was no significant improvement with either
treatment although there was a numerical trend with topical budesonide having better
symptom control and less P2 agonist use than montelukast or placebo. This study was
powered on bronchial challenge testing, but had more severe patients been investigated
or used greater numbers of patients these differences may have been significant.
Although bronchial challenge testing and nasal peak inspiratory flow were the only
parameters to show significantly greater efficacy with the corticosteroid than the
leukotriene antagonist, there was a similar numerical trend for other upper and lower
airway markers. It is conceivable, therefore, that such differences would have become
significant with a larger sample size. The primary end point was adenosine
monophosphate bronchial challenge and the study was therefore powered on this
measure. The sample size had been calculated to be adequate to detect a one doubling
dose difference, as this was deemed clinically relevant. Indeed a significant difference
was detected between placebo and active treatments and between both active treatments.
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It would still have been more satisfactory to include a larger number of patients into the
study. However, this study was performed during the pollen season which is particularly
short in Dundee and therefore there was only a limited time to recruit patients. Also the
entry criteria were fairly tight. Patients had to be suffering from both allergic rhinitis and
asthma and they had to have a provocation dose of adenosine monophosphate causing a
20% fall in FEVi of less than 200mg/ml. They also had to have relatively mild disease
as indicated by a pre-recruitment inhaled corticosteroid dose of less than or equal to
400pg per day.
Previous studies have also shown fluticasone propionate to have better control of
symptoms and lung function than zafirlukast as monotherapy(375). This is probably due
to the greater anti-inflammatory potency of corticosteroids, which have a broad
spectrum of activity on the inflammatory cascade, rather than on one of the
inflammatory mediators'99'.
There was also a significant correlation between nasal peak inspiratory flow rates and
nasal symptoms in this study. Although previous studies have shown comparative results
between nasal peak inspiratory flow rate, and rhinomanometry or acoustic




A COMPARISON OF INHALED
FORMOTEROL AND BUDESONIDE ALONE





Having shown that leukotriene receptor antagonists exhibit beneficial effects in terms of
disease control, surrogate measures of inflammation and patients symptoms, it was
important to also consider the properties of long-acting P2 agonists. As discussed
previously (see section 1.5.1), long-acting P2-agonists such as salmeterol and formoterol
are used on a regular basis as second-line controller therapy in addition to inhaled
corticosteroids in order to improve symptomatic control of asthma and exacerbation
rates. However, in view of the concerns that the use of regular long-acting p2-agonists
may potentially mask an increase in underlying inflammatory processes, it was
important to assess the anti-inflammatory properties of long-acting P2 agonists and
inhaled corticosteroids.
Pauwels et al<62) reported the results of the FACET study which evaluated the effects of
adding inhaled formoterol to both lower and higher doses of the inhaled budesonide.
They found beneficial effects with both high dose budesonide alone, and with the
addition of inhaled formoterol to low or high dose budesonide. Furthermore, the addition
of formoterol improved symptoms and lung function and did not increase the number of
exacerbation rates. In order to mirror that study(62), the effects of low and high doses of
formoterol and budesonide were evaluated when given alone or in combination.
Measurements of lung function and surrogate inflammatory markers (adenosine
monophosphate bronchial challenge, exhaled nitric oxide and serum eosinophilic
cationic protein) were made as well as patients symptoms scores(112). However, it was
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felt important to consider, at the same time, whether the effects on inflammatory
markers or lung function mirrored the patients' preference for monotherapy or
combination therapy. Patients with stable mild to moderate asthma who were already
using regular inhaled corticosteroids were recruited in line with the accepted asthma
management guidelines.
As stated above budesonide and formoterol were chosen in order to reflect the FACET
study. They are both made by the same company and are dispensed by the same delivery
device, the Turbuhaler, which is a dry powder reservoir inhaler. This was more
convenient for the patients to be studied and reduced the influence of lung delivery on




Fifteen stable atopic asthmatic patients (7 female) mean (±SE) age 32.4 (3) years, all
taking inhaled corticosteroids mean dose 473 (57)pg per day were randomised. The
subjects had mild to moderate asthma and were using inhaled corticosteroids in a dose of
less than lOOOpg per day. Baseline spirometry showed mean FEV) 2.74 (0.20) L, 75.2
(2.8) percent predicted and FEF25-75 2.29 (0.23) 1/s, 52.4 (4.0) percent predicted at
recruitment. All patients were required to be atopic on Phadiotop testing, and to be
responsive to adenosine monophosphate (AMP) with a geometric mean provocation
concentration producing a 20% fall in FEV) (PC20) of less than 200mg/ml. One subject
was using oral theophylline therapy and one was taking long-acting p2-agonist therapy
with formoterol.
Protocol
The study had a placebo controlled, double-blind, double-dummy, cross-over design.
The subjects attended the laboratory for the initial screening visit in the morning
between 9am and 11am and all the subsequent visits were performed within the same 2
hour window. The patients withheld their long-acting p2-agonist therapy for 48 hours
and oral theophylline therapy for 72 hours and short-acting p2-agonist therapy for at
least 12 hours prior to this screening visit. An adenosine monophosphate (AMP)
bronchial challenge test was performed. The patients who had a provocative
concentration of AMP producing a 20% fall in FEV) (PC2o) of less than 200mg/ml,
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entered the run-in phase. From the start of the run-in until the end of the trial all therapy
with theophylline, long-acting p2-agonists and inhaled corticosteroids were stopped.
Inhaled ipratropium bromide 2 puffs (Atrovent Forte, 40pg per puff, Boehringer
Ingelheim, Bracknell UK) was used as required for symptomatic relief purposes as 1st
line rescue, with inhaled salbutamol as 2nd line rescue. During subsequent visits the
subjects withheld ipratropium bromide or salbutamol for at least 12 hours as well.
At the start of the initial 1 week placebo run-in the patients were given a placebo
budesonide Turbohaler® (Astra Pharmaceuticals, Kings Langley UK) along with a
placebo formoterol Turbohaler® to use both on a regular once daily basis at 8pm. The
patients were taught in the correct technique for using the Turbohaler® by making sure
that they were able to generate an inspiratory flow of at least 60 L/min using a
Turbohaler® training device (Astra Draco, Lund Sweden).
The subjects attended the laboratory for the next visit after the 7-day placebo run-in
period having taken the last dose of the placebo Turbuhalers at 8pm the previous
evening. The patients collected their overnight urine for a 10 hour Cortisol collection
from 10pm till 8am prior to attending the department. At this first study visit the
patients had 5ml of blood taken for the measurement of ECP followed by measurement
of exhaled nitric oxide. After that the subjects performed baseline spirometry followed
by AMP challenge. The subjects were then given their randomised treatments with
either a) inhaled formoterol 12pg 1 puff once daily (as Oxis Turbohaler, eformoterol
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fumarate 12 |ug per puff, Astra Pharmaceuticals, Kings Langley UK) along with a
placebo Turbohaler® 1 puff or b) inhaled budesonide 400pg 1 puff once daily (as
Pulmicort Turbohaler, budesonide 400pg per puff, Astra Pharmaceuticals, Kings
Langley UK) along with a placebo Turbohaler® 1 puff or c) inhaled formoterol 12pg 1
puffwith inhaled budesonide 400pg 1 puff both once daily. Both inhalers were taken as
1 puff at 8pm each night for the first 2 weeks. The subjects were also instructed to
record the best of three values for their morning and evening peak flows the latter prior
to taking the evening medication in a diary card using a Mini-Wright peak expiratory
flow meter (Clement Clarke Ltd., Harlow UK). The subjects also recorded the total
number of puffs of ipratropium bromide or salbutamol rescue therapy taken for each
day.
The subjects attended the laboratory for the next visit after two weeks of each
randomised treatment, 12 hours after taking the 14th dose of their randomised treatment,
bringing along their overnight urinary Cortisol collection and diary cards. The same
process was repeated for the measurement ofNO, spirometry and AMP challenge except
that a sample for ECP was not collected at this occasion. The patients were then
instructed to start taking 2 puffs from the same randomised inhalers each evening for a
further 2 weeks and to record their peak flow and rescue inhaler use in a new diary card.
The subjects then returned to the laboratory after further two weeks, 12 hours after
taking their 28th dose (14th dose of the 2 puffper day period). At this third visit a sample
for ECP was collected along with measurement of exhaled NO, spirometry and AMP
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challenge.
The subjects then entered a 7 day washout period where they again used the two placebo
Turbuhalers at night. The same process was repeated with the next randomised
treatment for 2 weeks (1 puff) and 4 weeks (2 puffs). This was again followed by a
further 7-day placebo washout period and a subsequent randomised 4 week treatment




Adenosine Monophosphate Bronchial Challenge
Measurement ofEosinophilic Cationic Protein
Measurement of Exhaled Nitric Oxide




The study was powered at 80% to detect a 1 doubling dose (2-fold) difference in AMP
PC20- The data for PC20, exhaled nitric oxide and eosinophilic cationic protein were all
log transformed to normalize their distribution, prior to analysis. The parameters were
analysed as geometric mean values and as fold differences (with 95% confidence
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intervals). The first visits for all three randomised treatments (i.e. after placebo run-in or
placebo washout periods) were compared according to their order in sequence. In
addition the first visits for all 3 treatments were compared irrespective of sequence - i.e.
prior to fonnoterol alone, budesonide alone and formoterol + budesonide respectively.
A pooled placebo was then calculated and used for comparison with active treatments.
The statistical analysis was performed for within treatment effects (i.e. comparing each
active treatment at 2 and 4 weeks to pooled placebo) and between treatment effects (i.e.
comparing the 3 active treatments at 2 weeks and 4 weeks). The statistical analysis was
performed by multifactorial analysis of variance (MANOVA) using subject, treatment,
visit and sequence as factors. This was followed by Bonferroni multiple-range testing
(set at 95% CI) to obviate multiple pair-wise comparisons, in order not to confound the
overall alpha error (p<0.05, two-tailed). Hence all parameters are described as being
significant (p<0.05) or not according to the Bonferroni test. The patient preference was
analysed +using Friedman's Rank test.
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8.3 RESULTS
All subjects completed the study. Two subjects complained of hoarseness of voice, both
during the steroid limbs. They were reminded of mouth washing after inhalation and
they did not complain of the symptoms during the subsequent limbs. The urinary free
Cortisol did not show any significant difference pooled placebo and active treatments (as
mean (SE)); PL: 24.6 nmol (2.6), FM12: 20.1 nmol (3.3), FM24: 22.6 (5.4), BUD400:
29.4 nmol (6.2), BUD800: 22.6 nmol (5.1), FM12+BUD400: 27.5 nmol (5.7),
FM24+BUD800: 18.2 nmol (2.5).
Domiciliary Diary Cards
The domiciliary peak flow recordings [Figure 8.1] showed significant improvements
with BUD + FM together as compared to FM or BUD alone. For morning peak flow (as
mean over 4 weeks); FM+BUD 473 1/min vs. FM 460 1/min (95% CI for difference 2 to
22), vs. BUD 453 (95% CI for difference 9 to 29). Similarly for evening peak flow;
FM+BUD 486 vs. FM 472 (95% CI for difference 5 to 22), vs. BUD 476 (95% CI for
difference 1 to 19). Rescue use of salbutamol was much less than for ipratropium
bromide. The rescue inhaler usage of ipratropium bromide was significantly lower after
FM+BUD as compared to FM but not compared to BUD, whilst for salbutamol usage
was significantly lower after FM+BUD as compared to BUD but not compared to FM.
Baseline spirometry
The pre-challenge spirometry [Figure 8.2] showed significant improvements in FEVi
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and FEF25-75 with all active treatments as compared to baseline but there were no
significant differences between treatments [Table 8.1].
Placebo visits
All parameters did not show any significant differences when comparing the visits after
placebo according to sequence, or irrespective of sequence according to treatments (i.e.
placebo prior to FM, prior to BUD, or prior to FM+BUD) [Table 8.2]
Adenosine monophosphate bronchial challenge
The adenosine monophosphate bronchial challenge test [Figure 8.3] showed that all
active treatments afforded significantly better protection as compared to placebo [Table
8.3]. There was a dose-response effect in terms of a significant difference between low
and high doses of FM+BUD for visit 2 vs. visit 3: i.e. FM12+BUD400 vs.
FM24+BUD800 - a 2.4-fold difference (95% CI 1.0 to 5.5-fold).
There were no significant differences between the three low-dose treatments at visit 2
after 2 weeks. For high-dose treatment after 4 weeks there was significantly better
bronchoprotection with both BUD containing regimens compared to FM alone: FM24
vs. BUD800 - a 2.5-fold difference (95% CI 1.1 to 5.4-fold), vs. FM24+BUD800 - a 3.2-
fold difference (95% CI 1.5 to 7-fold). There was no significant difference between
BUD alone and BUD plus FM at either 2 or 4 weeks. Individual rank order for effects
on AMP PC20 showed significant (p=0.004) differences with both BUD containing limbs
compared to FM alone.
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Exhaled nitric oxide [Figure 8.3]
For FM alone there were no significant differences at either dose compared to placebo.
Both doses of BUD alone or combination therapy exhibited significantly lower NO
levels compared to placebo [Table 8.3]. For BUD alone at both doses and for
combination therapy at high dose there were significant reductions in exhaled NO
compared to FM alone: FM12 vs. BUD400 a 1.7-fold difference (95% CI 1.2 to 2.4-
fold), FM24 vs. BUD800 a 2.1-fold difference (95% CI 1.1 to 3.4-fold), and FM24 vs.
FM24+BUD800 a 1.8-fold difference (95% CI 1.1 to 2.9-fold). Individual rank order
for effects on exhaled nitric oxide showed significant (p=0.004) differences with both
BUD containing limbs compared to FM alone.
Eosinophilic cationic protein
There was no significant reduction in ECP (measured only at visit 3) after FM treatment
compared to placebo (95% CI for fold difference included unity), while there were
significant reductions in ECP after both BUD containing limbs [Table 8.3].
Patient preference
The patients preferred the combined treatment as their first choice followed by FM alone
and then BUD alone in rank order: FM + BUD > FM > BUD p<0.0005 [Figure 8.4].
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Table 8.1
Spirometry prior to adenosine monophosphate challenge comparing the active
treatments to the mean placebo. The values are arithmetic mean (SE). Asterisk denotes
significant (p<0.05) difference between active treatment and placebo.
FEV, FEVi FEF25-75 FEF25-75
(1) (% predicted) (1/s) (% predicted)
Placebo 2.7 73.3 2.3 53.3
(0.25) (4.4) (0.3) (7.7)
FM 3.0 * 82.2 * 2.8 * 65.3 *
(12pg) (0.2) (4.4) (0.2) (4.4)
FM 3.1 * 83.6 * 2.9 * 68.4*
(24pg) (0.3) (4-9)" (0.3) (6.1)
BUD 3.0 * 82.2 * 2.8 * 64.5 *
(400pg) (0.2) (4.4) (0.3) (5.2)
BUD 2.9 * 80.7 * 2.7 * 63.3 *
(800pg) (0.2) (4.4) (0.2) (5.3)
FM+BUD 3.0* 81.9 * 2.8 * 65.0 *
(12pg+400pg) (0.2) (4.1) (0.3) (5.6)
FM+BUD 3.0* 83.2 * 2.9 * 66.8 *
(24pg+800pg) (0.2) (3.4) (0.3) (5.5)
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Table 8.2
Measurements at visit 1 after placebo prior to each of the randomised treatments. The
values for spirometry are arithmetic means (SE) and the values for PC20, NO and ECP
are geometric means (SE). There were no significant differences in placebo values for
each treatment
FM BUD FM+BUD
FEV, 2.69 2.67 2.70
(1) (0.23) (0.27) (0.25)
FEV! 73.8 72.3 73.8
(% predicted) (4.9) (4.6) (4.6)
FEF25-75 2.37 2.30 2.32
(1/s) (0.24) (0.28) (0.28)
FEF25-75 54.8 52.6 52.8
(% predicted) (4.9) (5.1) (5.2)
AMP PC20 22.1 15.9 13.8
(mg/ml) (7.5) (8.0) (9.3)
Nitric oxide 14.7 13.1 18.1
(PPb) (2.9) (2.2) (3.8)
ECP 12.3 13.5 14.6
(Pg/1) (1.8) (2.2) (3.2)
216
Table 8.3
Comparison of inflammatory markers between active treatments and mean placebo All
values are geometric means with fold differences from placebo (95% confidence
intervals for fold-difference which include unity are non-significant). Asterisk denotes
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1.9-fold difference






(95% CI 4.6 to 22.5)
7.4 *
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(95% CI 5.7 to 30.6)
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1.8-fold difference
(95% CI 1.4 to 2.4)
9.9 *
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(95% CI 1.1 to 1.9)
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FM BUD FM+BUD FM BUD FM+BUD
Figure 8.1
Overall means (SE) for the 4 week treatment period for a) rescue inhaler usage of
ipratropium bromide (1st line) and salbutamol (2nd line) and b) domiciliary peak
expiratory flow rate for morning and evening recordings for formoterol (FM),
budesonide (BUD), and combination (FM+BUD). Asterisk denotes as significant
(p<0.05) difference from combination therapy.
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PL 2wks 4wks 2wks 4wks 2wks 4wks
FM BUD FM + BUD
Figure 8.2
Pre-challenge spirometry as (a) FEF25.75 and (b) FEVi for the active treatments
compared to pooled placebo. The values are arithmetic means (± SE)
219
20 -i




(a) Adenosine monophosphate bronchial challenge for active treatments compared to
pooled placebo, (b) Exhaled nitric oxide for active treatments compared to pooled







The rank order for patient preference between the three treatments. The results are
shown according to the marking system: first choice '3' marks, second choice '2' marks
and third ' 1' mark.
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8.4 DISCUSSION
The main findings from this study were: (a) Patients preferred combined treatment with
formoterol and budesonide to budesonide alone, which was mirrored by effects on
domiciliary peak expiratory flow and rescue medication, (b) Despite patient preference
and improved peak flow with combined therapy, this was not associated with improved
anti-inflammatory control (on exhaled nitric oxide, serum eosinophilic cationic protein
and adenosine monophosphate challenge) as compared to budesonide monotherapy, (c)
Formoterol monotherapy had no significant anti-inflammatory effects on exhaled nitric
oxide and exhibited antagonism against adenosine monophosphate challenge to a lesser
degree than budesonide monotherapy, (d) Budesonide exhibited a dose-related effect on
adenosine monophosphate challenge when given as monotherapy or combined therapy
in keeping with its anti-inflammatory activity, (e) All 3 treatments exhibited equivalent
improvements in FEV] and FEF25-75 .
In the study of Pauwels et al(62) adding formoterol to budesonide produced
improvements in peak expiratory flow and reductions in exacerbation rates. The data
from the study in this thesis showed that formoterol conferred additive effects on peak
expiratory flow, but exhibited no significant anti-inflammatory activity on its own.
Similarly the addition of salmeterol to beclomethasone has been shown to have no
significant effects on bronchoalveolar lavage cell profile(376). However, recent data have
suggested that monotherapy with formoterol may reduce the number of mast cells and
eosinophils in bronchial biopsies from patients with mild atopic asthma(270>.
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Pauwels et al(62) also showed a proportionally greater reduction in exacerbation rates by
increasing the dose of budesonide as monotherapy(from 200 to 800pg per day) as
compared to the additive effects of formoterol. This is in keeping with the data reported
here as doubling the dose of budesonide exhibited further protection against adenosine
monophosphate challenge irrespective of the addition of formoterol. These results,
showing greater suppression of exhaled nitric oxide and bronchial hyperreactivity with
budesonide alone compared to formoterol alone, are similar to observations of Verberne
et al(377) and Simons et al(378). These authors showed beclomethasone dipropionate to be
superior to salmeterol for effects on bronchial hyperreactivity (as methacholine
challenge) and exacerbation rates. This emphasizes the importance of optimizing anti¬
inflammatory control with inhaled corticosteroids before considering adding in regular
long-acting (32-agonist treatment.
The reason for the synergistic effects of inhaled corticosteroids and long acting p2
agonists on airways inflammation may be explained by their differential effects on
inflammatory cells. Glucocorticoids have been shown to have no effects on mast cell
mediator release although they are effective at inhibiting basophil mediator release.
Whereas the opposite is found for (32-agonists, which only attenuate the release of mast
cell mediators(379"381). Thus the combination will block both types of inflammatory cells.
Furthermore, Knightingale et al(382) suggested that long-acting p2 agonists may have a
mast cell stabalising effect as formoterol had a greater bronchoprotective effect than
salbutamol in terms of adenosine monophosphate bronchial challenge, but both drugs
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were equivalent in terms of histamine challenge. However in contrast to this, Taylor et
al(383) found albuterol to have a greater effect on adenosine monophosphate than
histamine challenge but there was no significant difference between these tests with
salmeterol.
The results of this study show a patient preference for the combination treatment
compared to corticosteroid alone, which was associated with increased peak expiratory
flow rates and lower rescue requirements. This preference may reflect the patients'
perception of a rapid onset of bronchodilator response with formoterol as compared to
the more gradual onset of action with corticosteroid. Combining long-acting p2-agonists
and inhaled corticosteroids in the same inhaler formulation (e.g. Flixotide plus Serovent
as Seretide, Glaxo-Wellcome, Uxbridge, UK) might conceivably result in improved
compliance, at least when initiating therapy.
Another finding of the study was that none of the corticosteroid containing regimens
caused a significant fall in urinary free Cortisol. Thus, increasing the dose of inhaled
budesonide up to 800pg per day was not associated with significant systemic bioactivity.
This finding is in keeping with data from a study which demonstrated no significant
effects of 400pg or 800pg of budesonide in terms of urine and serum Cortisol excretion
when given once daily(334).
There are several limitations of this study for example a small patient sample was
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investigated who had mild to moderate asthma. Mild to moderate patients were chosen
as the intention was to evaluate the comparative effects of budesonide and formoterol,
and consequently with the washout there was a potential 6 week period when the
patients might conceivably not be taking any inhaled corticosteroids. In order to make
sure that the patients did not develop acute worsening of their disease control, it was
decided to evaluate those who were using less than lOOOpg per day of inhaled
corticosteroids. Budesonide was used via a Turbohaler as it is licensed in the UK for use
as once daily therapy in a dose up to 800pg per day. Formoterol was used at night once
daily as it is often taken in this way for control ofnocturnal dips.
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CHAPTER 9
A COMPARISON OF SALMETEROL AND
MONTELUKAST AS SECOND-LINE





As stated in the Chapter 1, inhaled corticosteroid therapy is considered to be first-line
anti-inflammatory treatment for patients with persistent asthma(352). However, many
patients do not have adequate symptom control on low dose inhaled corticosteroids and
additional second-line therapy is necessary. As all inhaled corticosteroids have been
shown to be associated with dose-related adverse side effects, as illustrated in Chapters 3
to 5, there is increasing concern over the long-term risks ofhigh dose therapy.
The results from Chapter 7 revealed the beneficial effects of a leukotriene receptor
antagonist on disease control in patients with asthma and seasonal allergic rhinitis.
Chapter 8 reported on the effects of a long-acting P2 agonist when compared to inhaled
corticosteroids in managing patient with asthma. It required to be seen, therefore, how
these two forms of second-line therapy compare, in a head-to-head study, in patients not
adequately controlled on inhaled corticosteroids. In other words, this study was designed
to evaluate the best treatment option at stage 3 of the British Thoracic Society
Guidelines0 34). This area is a contentious issue as the current asthma management
guidelines were written prior to the introduction of leukotriene receptor antagonists and
therefore there is no consensus of opinion.
The primary end-point was to assess effects on adenosine monophosphate bronchial
challenge, however, other markers of inflammation (exhaled nitric oxide and blood
eosinophil count) were assessed as well as symptom control, rescue therapy
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requirements and lung function. As discussed in Chapter 1 (see section 1.5.1) long-
acting P2 agonist have been shown to exhibit desensitisation or tolerance. In order to
investigate potential tolerance to the bronchoprotective effects on adenosine
monophosphate challenge testing and lung function, these investigations were performed
at the end of the first dosing interval (i.e. 24 hours after dosing with montelukast or 12
hours after dosing with salmeterol), and after two weeks of treatment. It is important to
have a washout placebo phase, when patients use inhaled anticholinergic medication
rather than P2-agonist medication for rescue therapy, prior to this investigation in order
to ensure receptor regeneration1"275^.
Montelukast and salmeterol were chosen, as they are the most commonly prescribed
forms of medication in their class of therapy. Furthermore, the previous studies in this
thesis have evaluated montelukast and it is licensed for once daily dosing which will aid
compliance. Unfortunately, the previous study evaluated formoterol, in order to mirror
the FACET study{62), and therefore no direct comparison can be made between this, and
the previous study, in this thesis. However, the effects of formoterol and salmeterol are





Twenty patients with moderate asthma (9 female), mean (SE) age 32.5 (2.2) years, FEV)
79.1 (3.9) FEF25-75 51.5 (4.5) % predicted were recruited into the study. All patients were
required to be sub-optimally controlled despite taking more than 400pg per day of
inhaled corticosteroids as monotherapy (median dose 800pg per day, inter-quartile range
400-1000p,g per day) budesonide n=5 (800-1600pg per day); beclomethasone
dipropionate n=14 (400-1000pg per day), fluticasone propionate n=l (2000pg per day).
Patients were eligible for inclusion if they required at least 2 puffs per day of reliever
therapy with their usual short acting p2 agonist at had at least 10% diumal variability
between their morning and evening peak expiratory flow rates. All patients were
required to be responsive to adenosine monophosphate challenge testing with a
provocation concentration producing 20% fall in FEV) (PC20) of less than 200pg/dl
(geometric mean 32.9 ± 9.5 mg/ml) prior to run-in period.
Design
The study was of a randomised placebo controlled, single-blind, double dummy, cross¬
over design. Patients continued on their usual maintenance dose of inhaled corticosteroid
throughout the study. In addition, patients were randomised to receive the following: A)
50pg of inhaled salmeterol twice daily (as Serevent Accuhaler 50pg per actuation, Allen
& Hanburys Ltd., Uxbridge, UK) plus placebo tablet once daily, or B) lOmg oral
montelukast (as Singulair, Merck Sharp & Dohme Ltd., Herts UK) once daily plus
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placebo Accuhaler twice daily. Prior to each treatment, and at cross over, patients had a
one week treatment period with placebo Accuhaler (1 inhalation twice daily) and
placebo tablets once daily while continuing with their inhaled corticosteroid. All tablets
were taken at 0800hrs and inhaled medication was taken at 0800hrs and 2000hrs.
Inhaled ipratropium bromide 2 puffs (Atrovent Forte, 40pg per puff, Boehringer
Ingelheim, Bracknell UK) was used as required for symptomatic relief purposes as first-
line rescue, with inhaled salbutamol (Ventolin, Allen & Hanburys Ltd., Uxbridge, UK)
as second-line rescue.
Measurements
All laboratory measurements were performed at 0800hrs after the end of the one week
run-in and crossover washout placebo periods, and after each two weeks active treatment
periods. Patients also attended after the first dose of active therapy i.e. 12 hours after the
first dose of inhaled salmeterol and 24 hours after the first dose of oral montelukast:
Adenosine Monophosphate Challenge Testing
Exhaled Nitric Oxide
Spirometry and Total Body Plesthysmography
Diary Card Data
Peripheral Blood Eosinophil Count
Statistical Analysis
The study was designed with at least 80% power to detect a 1.0 doubling dose difference
(2.0 fold) in adenosine monophosphate PC20 (the primary end-point) with the alpha error
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set at 0.05 (two-tailed). For all domiciliary diary data, mean values for the 7 day run-in
and washout placebo periods and for the 2 weeks of each active treatment were
analysed. Overall comparisons between active treatments and placebos were made by
multifactorial analysis of variance (MANOVA) using subject, treatment, period and
duration of treatment (first dose/last dose) as factors. This was followed by Bonferroni
multiple range testing (set at 95% CI) in order to obviate multiple pair-wise
comparisons. Consequently, comparisons are only denoted as being significant (p <
0.05) or not significant in order to not confound the alpha error.
231
9.3 RESULTS
There were no significant carryover effects between the first and second placebo values
in sequence with any of the measurements [Table 9.1]. Consequently a pooled placebo
value was used for the purposes of analysis.
AMP Challenge, Blood Eosinophil Count and Exhaled NO
For AMP PC20 (mg/ml) compared to placebo (47.5 ± 13.0), there were significant
(p<0.05) differences with first (114.1 ± 36.9) and last (94.2 ± 30.4) doses ofmontelukast
as well as the first (160.1 ± 64.5) but not the last (70.1 ± 23.7) dose of salmeterol [Figure
9.1]. Salmeterol, but not montelukast, was shown to exhibit significant (p<0.05)
tolerance between the first and last dose protection against adenosine monophosphate
bronchial challenge. This amounted to 1.19 doubling doses (95% CI 0.60 to 1.78) for
salmeterol and 0.28 doubling doses (95% CI -0.31 to 0.85) for montelukast [Figure 9.2],
For blood eosinophil count after 2 weeks, there was a significant (p<0.05) difference
between montelukast vs placebo; and montelukast vs salmeterol. (Placebo: 0.40 (0.06)
xl09/l, montelukast: 0.31 (0.04) xl09/l, salmeterol: 0.44 (0.07) xl09/l). There was no
significant difference between either of the treatments and placebo in terms of exhaled
nitric oxide after 2 weeks of treatment. (Placebo 10.5 (1.3) ppb; montelukast: 10.2 (1.5)
ppb; salmeterol: 9.3 (1.6) ppb).
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Lung Function
For forced expiratory volume in one second (FEVi), forced mid expiratory flow (FEF25-
75), and specific airways conductance (sGaw), there was a significant (p<0.05) difference
between placebo and the first, but not the last, dose of salmeterol. For montelukast there
was no significant improvement except with the first dose in terms of FEF25-75 [Figure
9.3],
Domiciliary Diary Card Data [Table 9.2, Figure 9.4]
Salmeterol showed significant (p<0.05) improvements in terms of daytime and nighttime
asthma symptom scoring and rescue bronchodilator requirement as well as morning peak
expiratory flow rate. Montelukast showed significant (p<0.05) improvement in terms of




Means (SE) for first (run-in) and second (crossover) placebo washout periods in
sequence for adenosine monophosphate bronchial challenge PC20 (AMP PC20), exhaled
nitric oxide (NO), peripheral blood eosinophil count (EOS), specific airways resistance
(sGaw), forced expiratory volume in 1 second (FEVi), forced mid expiratory flow
(FEF25-75)), morning peak expiratory flow (PEFam), evening peak expiratory flow
(PEFpm), daytime rescue bronchodilator requirement (RESam), night-time rescue
bronchodilator requirement (RESpm), daytime symptom score (SYMam) and night-time
symptom score (SYMpm). There were no significant differences for and points.
First Second First Second
Placebo Placebo Placebo Placebo
AMP PC20 44.6 50.7 PEFam 423.1 419.4
mg/ml (12.4) (15.8) 1/min (17.5) (15.5)
NO 10.3 10.8 PEFpm 470.9 457.5
Ppb (1.9) (1.6) 1/min (18.3) (17.4)
EOS 0.42 0.39 RESam 2.5 2.4
xlO9 (0.06) (0.06) puffs/12 hr (0.4) (0.4)
SGaw 50.8 53.7 RESpm 1.2 1.1
% pred (6.9) (7.6) puffs/2 hrs (0.3) (0.3)
FEV, 75.0 74.5 SYMam 0.7 0.9
%pred (3.4) (3.4) units/12 hrs (0.1) (0.2)
FEF25-75 45.4 45.5 SYMpm 0.6 0.6
%pred (3.6) (3.6) units/12hrs (0.1) (0.1)
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Table 9.2
Means (SE) for domiciliary diary card data after 1 week of placebo (pooled), and after 2
weeks treatment of montelukast and salmeterol. Data are given for morning peak
expiratory flow (PEFam), evening peak expiratory flow (PEFpm), daytime rescue
bronchodilator requirement (RESam), night-time rescue bronchodilator requirement
(RESpm), daytime symptom score (SYMam) and night-time symptom score (SYMpm).
Asterisk denotes a significant difference between placebo and active treatments.
Placebo Montelukast Salmeterol
PEFam 426.3 433.5 * 450.0 *
Emin (17.2) (16.6) (20.3)
PEFpm 469.5 466.3 480.4
1/min (18.5) (17.8) (19.9)
RESam 2.41 1.54 * 1.42 *
Puffs/12 hr (0.37) (0.31) (0.40)
RESpm 1.14 0.76 * 0.64 *
Puffs/12 hr (0.30) (0.21) (0.20)
SYMam 0.81 0.61 0.47 *
Units/12 hr (0.12) (0.13) (0.11)
SYMpm 0.58 0.46 0.41 *
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1 day 2 wks
Figure 9.1
Means and SE for doubling dose difference from placebo (pooled) for adenosine
monophosphate bronchial challenge provocation dose causing 20% fall in FEVi (PC20)
after the first dose (day 1) and last dose after 2 weeks therapy (2 wks) for montelukast
and salmeterol. Asterisk denotes significant (p<0.05) difference from placebo. Cross
denotes significant (p<0.05) difference between first and last doses of each drug.
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Figure 9.2
Scatter plot (open circles) for individual values and mean (SE) (closed circles) for loss
of bronchoprotection against adenosine monophosphate between first dose and last dose
as doubling dose difference for montelukast and salmeterol. There was significant
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Figure 9.3
Means and SE for a) Forced expiratory volume in 1 second (FEVi) b) Forced mid
expiratory flow (FEF25-75) c) Specific airways conductance as percent predicted for
placebo (PL) and first dose (day 1) and last dose after 2 weeks therapy (2 wks) for
montelukast and salmeterol. Asterisk denotes significant (p<0.05) difference between
active treatment and placebo (pooled).
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Figure 9.4
Three point moving average for daytime (closed symbols) and nighttime (open symbols)
rescue bronchodilator requirement (puffs per 12 hours) for the 1 week placebo (pooled)
(square), and the first and second week of active treatment with salmeterol (circles) and
montelukast (triangles). There was a significant (p<0.05) difference for both drugs
compared to placebo for both daytime and night-time requirements.
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9.4 DISCUSSION
This is the first study to compare the effects of second-line therapy with a long-acting (32
agonist or a leukotriene receptor antagonist, in patients not adequately controlled with
inhaled corticosteroids, in terms of adenosine monophosphate bronchial challenge. It
revealed a significant bronchoprotective effect after two weeks with the addition of once
daily montelukast but not with twice daily salmeterol. This is in keeping with the study
from Edellman et al(301), who found that, after 4 weeks of regular therapy, montelukast
exhibited 57% protection against exercise induced bronchoconstriction compared to
placebo whereas salmeterol exhibited 17% protection. Villaran et al(308) also compared
montelukast and salmeterol in asthmatic patients, one quarter of which were taking
inhaled corticosteroids, and showed greater beneficial effects of montelukast than
salmeterol on exercise induced challenge.
In another study, salmeterol and zafirlukast have been compared in a 4 week parallel
group study in which more than 80% of the patients were receiving concomitant inhaled
corticosteroid therapy'300'. Both active treatments were associated with improvements
from baseline in pulmonary function, asthma symptoms and short acting (32-agonist use.
However, in contrast to the results in this chapter, salmeterol treatment resulted in
significantly greater improvements from baseline compared with zafirlukast for morning
peak expiratory flow (29.6 1/min vs 13.0 1/min), percentage of symptom free days
(22.4% vs 8.8%) and percentage of days and nights with no requirement for
supplemental short acting p2-agonist use (30.5% vs 11.3%).
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Previous studies have shown the benefit of adding a long acting p2 agonist to inhaled
corticosteroids in terms of symptom control and exacerbation rates(62). Leukotriene also
exhibit additive benefit when given in combination to inhaled corticosteroids(299'384). The
extra effect of leukotriene receptor antagonist on top of inhaled corticosteroids can be
partly explained by the poor suppression of leukotriene synthesis by inhaled
corticosteroids. This was shown in study where fluticasone propionate reduced the
response to allergen challenge but not the excretion ofurinary leukotriene(385).
In this study, salmeterol was demonstrated to be a better bronchodilator than
montelukast in terms of improvements in lung function in terms of spirometry after the
first dose compared with placebo. However, there was no significant difference for
either drug after two weeks of therapy compared to placebo. There was a significant
difference between the first and last doses of salmeterol but not montelukast after
adenosine monophosphate bronchial challenge, suggesting that tolerance to its effects
had occurred. This is also in keeping with a study by Villaran et al(308) who showed
tolerance to the effects of salmeterol after 4 weeks on exercise challenge.
There was no loss in the beneficial effects in terms of diurnal asthma control over the
two week period (Figure 9.4) in contrast to marked loss in bronchoprotection against
bronchial challenge (Figure 9.1). The apparent discrepancy between the comparative
effects on bronchial challenge or lung function and diurnal asthma control may be
explained by their relative degrees of tolerance. Tolerance with long-acting p2-agonists
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is recognised to be more pronounced with their bronchoprotective than bronchodilator
effects(275). Grove et al(386), showed in a study comparing the effects of salmeterol 50pg
bid or placebo in patients taking inhaled corticosteroids, that although there were
improvements in peak expiratory flow and reductions in rescue bronchodilator therapy,
there was only a 0.7 doubling dose residual protection against histamine challenge after
4 weeks. In a study with regular formoterol 24 pg bid on top of inhaled corticosteroid
therapy, there was 0.5 doubling dose protection against methacholine after 2 weeks with
sustained improvement in peak flows(387). Similarly with adenosine monophosphate
bronchial challenge there was a 0.8 fold protection after 1 week of regular formoterol
24 pg bid(388).
There was a significant reduction in blood eosinophil numbers with montelukast but not
with salmeterol, which is in keeping with previous studies(389'390). However, it may not
be valid to compare the effects of a topical drug, such as salmeterol, and a systemic
drug, such as montelukast, on a systemic marker of disease activity. In contrast to the
study in this chapter, recent data has shown that treatment with regular formoterol as
mono-therapy to induce significant reductions in eosinophil numbers in bronchial
biopsies(270).
Exhaled nitric oxide may be considered to be a sensitive marker of airway inflammation.
However, there was no difference with either treatment when compared to placebo. This
can be explained by data showing that the dose-response curve for exhaled nitric oxide
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becomes flat after 400pg per day of inhaled budesonide(355). As all of the patients
studied here were receiving inhaled corticosteroids at a dose greater than 400pg per day
prior to run-in, exhaled nitric oxide levels would not be expected to significantly change
with the addition of second-line treatment.
It would have been more satisfactory if this study was performed in a double-blind
fashion. However, the manufacturers of montelukast were not able to provide a
matching placebo tablet. Although the tablets were masked, as far as possible, and put
into separate bottles labeled only with code numbers, the tablets were not identical and






This thesis reports a series of pilot studies which explore aspects of anti-inflammatory
medication used in the management of allergic airways disease. The dose-response
characteristics for markers of the therapeutic and adverse effects of inhaled
corticosteroids were examined. Other disease modifying therapies were also assessed,
namely leukotriene receptor antagonists and long-acting P2-agonists, in terms of their
anti-inflammatory properties, and comparisons were made between these drugs and
inhaled corticosteroids.
10.2 Dose-response for systemic activity of inhaled corticosteroids
The studies in the first chapters investigated the systemic effects of inhaled and intra¬
nasal corticosteroids. By comparing the effects of two inhaled corticosteroids with
different pharmacological properties, it was shown that the combination of greater
topical potency, and blood and tissue accumulation potentates more severe systemic
effects (Chapter 3 - Study 1). However, when assessing the systemic activity of two
inhaled corticosteroids of similar potency there was no difference between the drugs
(Chapter 3 - Study 2). Therefore increasing the potency of a drug will not only increase
the clinical efficacy but also the adverse effects(391).
When the first studies were performed, the most widely used inhaled corticosteroids in
the United States of America were triamcinolone acetonide and flunisolide. Fluticasone
propionate had just received a license for use in USA. The first two studies therefore had
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important clinical implications for an American audience, as there were no dose-
response studies comparing triamcinolone acetonide with fluticasone propionate or
flunisolide using sensitive measures of adrenal function. The reason for performing
dose-response studies has been discussed previously (see sections 1.4.1 and 3.1), namely
the ability to determine whether comparisons are made on the flat or steep part of the
dose-response curve.
Evidence from these studies (Chapters 3, 4 and 5), i.e. inhaled corticosteroids cause
adverse systemic activity at high doses, is in keeping with other data(124'177'392). However
this is in contrast studies which had reported that fluticasone propionate causes no
adrenal suppression(179'180). The reason for this discrepancy may lie in the sensitivity of
the measures of adrenal function, as measurement of morning serum Cortisol is less
sensitive than measurement of overnight urinary Cortisol (see section 1.3.4).
Some consideration, therefore, needs to be taken regarding sensitivity of the measures of
systemic activity. In the first two studies in Chapter 3 there were no significant
difference between triamcinolone acetonide and placebo at 1600pg per day in terms of
8am serum Cortisol, but a significant difference in terms of overnight urinary
cortisol/creatinine ratio. It is therefore clearly possible to incorrectly report that a
particular inhaled corticosteroid has no detectable systemic bioactivity if an insensitive
test is used. In this respect some studies have concluded no significant systemic
bioactivity of intra-nasal corticosteroids by using the 6 hour 250pg ACTH stimulation
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test(238), although there may have been detectable suppression if a more sensitive test had
been used.
The low dose (0.5pg) ACTH stimulation test is thought to be more sensitive that the
standard (250pg) ACTH test(188), and comparable to the unpleasant insulin tolerance
test(187). However, there was a lack of response with inhaled (Chapter 3) or intra-nasal
(Chapter 5) corticosteroids using the low dose ACTH test, despite changes in urinary
Cortisol. This may be explained by the relatively short duration of treatment. The effects
on dynamic testing are thought to take longer to occur than basal measures of adrenal
function, as the former reflects adrenal atrophy. Indeed, in a study by O'Driscoll et al,
oral corticosteroids were stopped abruptly after a short period of treatment without any
evidence of rebound worsening of asthma and or adrenal crisis<393). However, Clark et
al(323) found that high dose inhaled corticosteroids attenuated the Cortisol response to
corticotropin stimulation after 3 days. Recently there has been concern regarding the low
dose ACTH stimulation test as a lack of response may be due to absorption of the drug
onto the surface of a plastic syringe or tubing used in administration(394).
The second study in Chapter 3 and the last study in Chapter 5 both highlight the
sensitivities of fractionated samples of urinary cortisol/creatinine. In Chapter 3, morning
and overnight urinary Cortisol measurements were more sensitive than morning serum
Cortisol and in Chapter 5, these measurements were shown to be as sensitive as
integrated 24 hour serum and urine Cortisol measures. Maclntyre et al(185) showed that
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timed morning and overnight samples of urine cortisol/creatinine were as sensitive as a
full 24 hour urinary free Cortisol collection at detecting changes in adrenal suppression
in patients receiving 2mg per day of beclomethasone dipropionate. The reason for the
greater sensitivity of an early morning urinary cortisol/creatinine sample is probably
because the collection reflects the time in the circadian cycle when Cortisol secretion is
at its highest (see Figures 5.6 and 5.9), and therefore giving the opportunity of high
signal to noise ratio. An early morning urine collection taken immediately on wakening
would also avoid the need for accurate timing, and it would not be difficult for patients
to collect and bring such a sample to an outpatient clinic for analysis. With further work
assessing patient variability and reliability, a sample of urine cortisol/creatinine collected
during the first hour ofwakening may be a prove to be a useful screening test.
The findings with triamcinolone acetonide in the first study in Chapter 3 are in contrast
to those of the last study in Chapter 5. In Chapter 3 there was no significant suppression
of overnight urinary or serum Cortisol compared to placebo at 1600pg per day, whereas
significant suppression was detected in Chapter 5. Both studies employed asthmatic
patients ofmild to moderate severity and the duration of treatment was similar (5 days
vs 3 days at the high dose). The discrepancy may be due to the fact that the third study in
Chapter 5 had supervised dosing and patients were admitted for 12 hours prior to the
8am serum Cortisol sample. By admitting the patients to hospital, it was possible to
ensure that the overnight urine collection was complete and that conditions were
standardised prior to morning serum Cortisol sampling. However, when analysing the
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data in terms of the number of patients with sub-normal values, the results of the two
studies were identical. There were 3/24 patients with an abnormal overnight urinary
Cortisol suppression in Chapter 3 and 3/24 and 4/24 patients with a subnormal 8am
serum Cortisol and 24 hour urinary Cortisol in Chapter 5 (see Figure 3.2 and Figure
5.10). Furthermore, the results from the third study in Chapter 5 are in keeping with the
main conclusions from the first study in Chapter 3 as there was a two-fold difference
between fluticasone propionate and triamcinolone acetonide with overnight urinary and
8am serum Cortisol.
On first inspection it would seem that there is a discrepancy between Chapter 6 and
Chapter 8 in terms of Cortisol suppression with budesonide. In the study comparing
budesonide with formoterol (Chapter 8) there was no suppression with either 400pg or
800pg per day of inhaled budesonide. However in Chapter 6 a dose-repose effect was
found for systemic activity of budesonide over a dose range of 400-1600p,g per day. In
both studies patients with mild to moderate asthma were investigated and budesonide
was dispensed using a Turbuhaler. However, in Chapter 8 budesonide was given once
daily whereas in Chapter 6 it was given twice daily. It is has been suggested that the
suppressive effects of corticosteroids on diurnal endogenous Cortisol production are less
when given as a once daily morning (or alternate day) dose compared to twice daily or
nocturnal dosing for a given level of clinical efficacy(235).
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10.3 Effect of inhaler device and drug delivery
It is important to consider, not only the particular inhaled corticosteroid and dose
prescribed to the patient, but also the drug delivery device. This is becoming
increasingly clinically relevant due to the expanding number of different inhaler devices
available. It is evident from the results shown in Chapter 3, that the inhaler device plays
an important role in the determination of adverse effects. Changing the delivery of
fluticasone propionate from an Accuhaler to a pressurised metered dose inhaler plus
spacer resulted in a 7.68-fold difference in overnight urinary cortisol/creatinine
suppression. This is much greater than was seen when comparing fluticasone propionate
and triamcinolone acetonide both via metered dose inhalers (1.9 fold difference).
Previous work has shown a spacer device decreases the systemic effects of
beclomethasone dipropionate(395) although this was probably due to a decrease in the
swallowed fraction of the inhaled drug. The influence of the swallowed fraction on
systemic bioactivity is much less with modern inhaled corticosteroids as a result of the
high first-pass hepatic metabolism.
The last study in Chapter 3, however, only investigated the influence of drug delivery on
the adverse profile in terms of systemic effects. However, it would be interesting to
investigate whether the delivery device would influence the beneficial effects and
therapeutic ratio of inhaled corticosteroids. In this respect the increased delivery with a
spacer has been shown improve the therapeutic ratio with budesonide(171). If an inhaler
delivers a drug with a low respirable fraction, the drug will be mainly deposited in the
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proximal airways(396'397). This is unlikely to have a beneficial effect on the small airways
which are effected in asthma, but is also may also exhibit less systemic absorption.
Further research requires to be performed to investigate the effects of the site of drug
delivery on systemic bioactivity, clinical efficacy and therapeutic ratio.
10.4 Comparison of inhaled and oral corticosteroids
Although there is little doubt that inhaled corticosteroids exhibit a greater therapeutic
ratio than oral corticosteroids, there is still useful clinical information to be gained from
comparing these two forms of therapy. Both practitioners and patients can identify with
the effects of oral corticosteroids. Some patients are aware that ingesting a tablet may
result in systemic effects but are unaware that inhaling a gas may do likewise. There
were no significant differences between the effect of prednisolone and fluticasone
propionate when compared on an 11:1 dose ratio. This is in keeping with a meta-analysis
of dose-response studies(398) which showed, when assessing the effects on 8 or 9am
serum/plasma Cortisol, fluticasone propionate was shown to have equivalent suppression
to prednisolone on a 10:1 milligram equivalent ratio.
When analysing the results of the study in Chapter 4, comparable adrenal suppression
was seen with oral prednisolone and fluticasone propionate but there was no significant
dose related suppression with nebulised budesonide up to a dose of 4mg per day. The
reason for the finding with nebulised budesonide is probably due to the inefficient
delivery characteristics of nebulisers as discussed above (see section 4.4). It is
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interesting to note the reproducibility of 8am serum Cortisol as a marker of systemic
effects of corticosteroids when the variability of lung delivery is removed by prescribing
this drug in tablet form. There was 67% and 69% suppression of plasma Cortisol with
20mg of oral prednisolone in the first and second studies respectively. Furthermore,
when analysing the numbers of Cortisol samples below the normal reference range
(150nmol/l) there were 42% and 36% in the two studies. The consistent systemic
bioavailability (as well as dose) may account for the relatively uniform improvement
with steroid responsive patients taking oral corticosteroids.
The results in Chapter 4 suggest that there are different effects of inhaled corticosteroids
on different tissues. There was a significant difference between placebo and all doses
with both inhaled fluticasone propionate and oral prednisolone in terms of 8am Cortisol
whereas for osteocalcin there was only suppression at the highest dose with fluticasone
propionate and the medium and high doses for osteocalcin. Although it may simply
represent the relative sensitivities of the tissue markers, studies have shown differential
effects on adrenal and bone function when comparing inhaled budesonide and oral
prednisolone(208'209). It could therefore have a clinically important implication if, for a
given change on adrenal function, bone metabolism (and therefore potential for
osteoporosis) is less effected. Regardless, it clearly indicates that screening for changes
in bone mass with bone densitometry is important and cannot be replaced by simple
screening for changes in adrenal function because the effects are not the same on
different tissues.
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10.5 Comparisons of intra-nasal corticosteroids
Similar findings for inhaled corticosteroids hold true when comparing therapeutic doses
of different intra-nasal corticosteroids (Chapter 5). There was no systemic bioactivity
with weakly potent corticosteroids, beclomethasone dipropionate and triamcinolone
acetonide, but treatment with fluticasone propionate resulted in significant suppression
in terms of overnight urinary Cortisol. Increased potency is clearly not the only reason
for detectable side effects with intra-nasal corticosteroids, as mometasone furoate, which
has equivalent potency to fluticasone propionate, did not exhibit any significant
suppression. The second study in Chapter 5 had greater statistical power than the second
study in that chapter, and utilised more sensitive measures of basal adrenal function
namely 24 integrated serum and urinary Cortisol1175). The reason for the lack of systemic
effects seen in the second study in Chapter 5 could be that patients with allergic rhinitis
were investigated (the first study evaluated healthy volunteers) and this is likely to have
altered the delivery to the nose.
Allergic rhinitis and asthma may be considered to be two clinical manifestations of the
same condi tion(37). As a result, patients may receive both inhaled and intra-nasal
corticosteroids simultaneously. Furthermore, patients with allergic asthma often need to
increase their dose of inhaled corticosteroid during the summer at the same time as
introducing intra-nasal corticosteroid due to increased pollen counts. Although the
effects on systemic activity of intra-nasal flunisolide in patients receiving inhaled
corticosteroids has been investigated in one study(399), the addition of combined inhaled
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and intra-nasal therapy is often ignored. The last study in Chapter 5 addresses this issue,
and the results are in keeping with the first studies in Chapters 3 and 5, as the addition of
intra-nasal to inhaled fluticasone propionate resulted in more patients having a
subnormal (<150nmol/l) 8am serum Cortisol value. Further studies are needed to
investigate the effects of the total steroid load when treating patients with seasonal
allergic rhinitis and asthma.
In all of the above studies the results have been expressed as both mean values and
number of values below a clinically relevant range. By assessing the number of
abnormal values, it is possible to address the clinical issue of whether a given patient is
likely to have clinically significant systemic adverse effects with a particular inhaled
corticosteroid. Furthermore, the data from Chapters 3, 5 and 6 show that patients with
low basal Cortisol values are more likely to have a subnormal response to FlPA-axis
stimulation, which is in keeping with Broide et al(l88). It can be seen by examining the
scatter plots from the studies in this thesis (Figures 3.2, 3.4, 3.6, 4.2, 4.4, 5.5, 5.10), that
there is a great deal of patient variation in response to inhaled corticosteroids. Further
studies are required to investigate any genetic susceptibility to exaggerated adverse
effects with corticosteroid therapy.
10.6 Limitations of the systemic effect studies in this thesis
There are limitations to all of the efficacy studies performed in Chapters 3, 4 and 5. All
of the studies were of short duration. Indeed most of the dosing intervals were only for 3
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or 4 days. However, the effect of exogenous corticosteroids on endogenous HPA-axis
activity is related to plasma drug levels. Therefore once drug levels have reached steady
state, prolonging the duration of the study is unlikely to significantly alter the results. As
fluticasone propionate has the longest elimination half-life it will take the longest time to
reach steady state. However, even with fluticasone propionate, constant serum levels
will be achieved within 3 days.
There is, however, evidence of tolerance to inhaled corticosteroids measured in terms of
glucocorticoid receptor down regulation. As shown by Knutsson et al(237), there was a
significant down regulation in peripheral lymphocyte glucocorticoid receptor (GCR)
messenger ribonucleic acid (mRNA) after 2 weeks of intra-nasal fluticasone propionate.
More recently, Andersson et al(400) showed 30% suppression of endobronchial biopsy
GCR mRNA and 70% suppression of lymphocyte CGR mRNA after 500pg fluticasone
propionate for 4 weeks. However, in a study by Altman et al(236), the effects of
triamcinolone acetonide on 24 hour urinary Cortisol were similar after 2 weeks and 6
months, therefore glucocorticoid receptor down regulation does not seem to be clinically
relevant when assessing the effects of inhaled corticosteroids.
For the same reasons it may be considered that the placebo washout periods may also be
too short. Indeed Rnutsson et al(237) also showed that the effects of fluticasone
propionate on GCR mRNA persisted for more than 1 week. However, in another study it
was shown that the effects of fluticasone propionate on basal and dynamic measures of
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HPA-axis activity returned to baseline after 3 days of placebo washout'401', which was
the minimum washout period in all of the studies in this thesis.
Another concern may be that the patients studied often had mild disease, and would not
be receiving the highest doses of inhaled corticosteroids investigated in the dose ranging
studies. In this respect airway calibre has been shown to be related to the systemic
bioavailability and therefore the adverse effects of drugs'402'. In other words, patients
with more severe asthma will have smaller airway calibre and therefore less systemic
absorption resulting from poorer lung delivery. Indeed Weiner et al'403' showed a
significant correlation between FEVj and fall in nocturnal Cortisol concentration in
patients receiving 500pg fluticasone propionate. For this reason in all of the adverse
effect studies (Chapters 3 and 4), spirometry was measured in order to ensure that
changes in systemic effects were not due to alterations in lung delivery.
Two studies, published as abstracts, show that the systemic activity of fluticasone
propionate is less in asthmatic patients than healthy volunteers'404'405'. However, the
relative effects of comparing two different inhaled corticosteroids, in healthy volunteers
as opposed to patients, are not established. Lofdahl & Thorsson'406' showed no
difference between these two subject groups when comparing fluticasone propionate and
budesonide in terms of plasma drug concentrations. However, Harrison et al'407', showed
greater systemic activity between fluticasone propionate and budesonide in healthy
volunteers but not in patients with asthma, in terms of Cortisol suppression. Although
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there may be differences in mucous production, mucociliary clearance and absorption of
drugs, it is likely that the difference in airway calibre is the major confounding factor.
In all of the studies, except for the comparisons with prednisolone in Chapter 4 where
potency ratios were calculated from previous data, the drugs were compared on
microgram equivalent dosing rather than on therapeutically equivalent doses. However,
there were no in vivo dose-response studies comparing the relative potency of inhaled
triamcinolone acetonide with fluticasone propionate or flunisolide which could be used
to give potency ratios. In one study, Condemi et al(408) compared triamcinolone
acetonide 200pg four times per day with fluticasone propionate 250pg twice daily and
showed that the lower daily dose of fluticasone propionate resulted in greater symptom
control. However, it is known that four times per day dosing results in poorer
compliance than twice daily dosing and this may have influenced the results, as
compliance was not measured during the study. As discussed previously (see section
1.3.2), it is not possible to accurately calculated dosing ratios by using potency data from
in vitro assays or from the McKenzie vasoconstrictor assay. It seemed logical therefore
to compare drugs on a microgram equivalent basis until further information is available.
This is particularly the case as practitioners often change patients from one inhaled
corticosteroid to another on microgram equivalent basis. However, in light of the results
from the first study further dose-response studies should be performed with higher doses
of triamcinolone acetonide in order to produce parallel dose-response curves and
determine a potency ratio.
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In all of the studies, apart from the third in the first paragraph and the nasal studies, the
treatments were given sequentially in increasing doses with no washout period in
between. This means that the duration of treatment as well as dose may have affected the
response. However, each treatment period was given to allow steady state levels, and
doses were given in sequentially doubling increments. Therefore it is likely that the
dose, rather than duration of treatment, had the major effect on outcome measures.
Ideally the doses should have been given in a random order with a washout period in
between. Alternatively a parallel study design could have been employed which would
have required the same number of patient groups as the product of the drugs and doses
to be compared. In other words when comparing fluticasone propionate and
triamcinolone acetonide in the first study in Chapter 3, there were two drugs, each given
at three different doses, requiring 6 patient groups in a parallel study. The first method
would have increased the duration of the study and the second would have considerably
increased the number of participants required to complete the study. Both of these
designs would have made the study more difficult to complete and more expensive to
perform. In this respect, it is important to consider the implication of resources and cost,
when designing a study.
10.7 Clinical relevance of systemic effect studies
What is the clinical relevance of these studies? Brown et al(184) showed that 20% of
patients receiving high dose inhaled corticosteroids had abnormalities of HPA-axis
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activity, which was mostly related to the duration of dose and previous oral
corticosteroids. The incidence of adrenal crisis as a result of inhaled corticosteroid usage
is extremely rare. However, there are case reports of clinically relevant adrenal
suppression with fluticasone propionate. A 50 year old woman presented with
Cushingoid features, depressive psychosis, adrenal suppression, osteopenia, and
hypertension after receiving 2mg per day of inhaled fluticasone propionate. Her
appearance, mental state and adrenal function returned to normal after her asthma
therapy was changed to inhaled budesonide 0.8mg per day, without deterioration in her
lung function(409>. Todd et al(410) have also reported on a 6 year girl with acute adrenal
insufficiency after changing from inhaled fluticasone propionate lmg per day to
budesonide 0.8mg per day. Other authors have reported cases of adrenal suppression
with fluticasone propionate(411). Addisonian crises have been seen on withdrawal of
budesonide, previously given at a high dose of 4.8 mg per day, in a 38 year old man(192),
and beclomethasone dipropionate, previously given at a dose of 400pg per day, in a 7
year old girl(193).
As previously discussed (see section 1.4.3.2) changes in serum markers of bone
metabolism may not be able to predict long term effects on bone mineral density and
osteoporosis. However, reduction in bone density is an important clinically adverse
effect of inhaled corticosteroids, which has been shown to be related to dose(203). Indeed
Wong et al(412) showed a 0.16 standard deviation reduction in bone density per doubling
dose of inhaled corticosteroids. McEvoy et al(413) reported an odds ratio of vertebral
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fraction in male asthmatics of taking inhaled corticosteroids of 1.35 compared to patients
not treated with inhaled corticosteroids. Patients, particularly post menopausal women,
receiving high dose inhaled corticosteroids should therefore take measures to reduce the
chances of osteoporosis, for example smoking cessation, physical activity, calcium
supplementation and hormone replacement therapy(201'414).
10.8 Dose-response for clinical efficacy
Just as there are differences in the sensitivities of markers of adverse effects of inhaled
corticosteroids, there are differences in the shape of the dose-response curve for
measures of efficacy. Although it is realised that the dose which relieves patients'
symptoms may not normalise their spirometry, the study in Chapter 7 examines the
dose-response effects on efficacy markers in more detail. An important clinical message
from this study is that the dose required to achieve spirometric control did not
necessarily produce adequate suppression of surrogate markers of airways inflammation.
As discussed in Chapter 7, this is in keeping with the finding of inflammation in pre-
symptomatic patients not receiving treatment. Monitoring steroid dose by spirometry
may miss underlying airways inflammation and potentially lead to long-term fixed
airways obstruction.
The clinical implication of the findings of the study in Chapter 6 is illustrated in a 2 year
prospective study(415). All 75 patients had measurement of methacholine bronchial
challenge testing, as well as spirometry and asthma symptoms. Patients were randomised
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to have their steroid dose adjusted according to a standardised computerised algorithm
using either symptoms and spirometry, or with the addition of airway
hyperresponsiveness data. After 2 years it was shown that by using bronchial
hyperresponsiveness data, not only did the patients have better spirometry values, but
they had fewer exacerbations. Mild exacerbations occurred at a rate of 0.52 per patient
per year in those who did not increase their inhaled corticosteroids dose, but met the
bronchial hyperreactivity criteria for doing so. Indeed patients who had severe asthma
and were treated according to hyperresponsiveness protocol had the same outcome as
patients with mild asthma, whereas severe patients monitored according to symptoms
had a significantly poorer outcome. More importantly, patients monitored according to
methacholine challenge had a greater improvement in bronchial airway thickness at the
end of 2 years, when bronchial biopsies were compared with enrolment samples.
These findings are probably a result of treating asymptomatic airway inflammation
which can be detected by methacholine bronchial challenge as shown in Chapter 6. The
more aggressive treatment of inflammation, however, resulted in a higher prescribed
dose of inhaled corticosteroids. The average dose was 400p.g per day in the standard
group and 800pg per day in the group monitored according to hyperresponsiveness. As
no measure was made of systemic effects, the benefit in terms of therapeutic ratio cannot
be determined. It also shows the importance of prescribing anti-inflammatory second-
line therapy and the need for the studies in Chapters 7-9.
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10.9 Measurements of clinical efficacy
Measurement of nasal and exhaled nitric oxide has been regarded as sensitive, non¬
invasive indicators of upper and lower airways inflammation respectively. Nitric oxide
levels have been shown to change in relation to corticosteroid therapy(369) and correlate
closely with other markers of inflammation such as induced sputum1'05' and blood
eosinophilia(416). The results from Chapter 7 illustrate the sensitivity of this marker.
Significant suppression of both exhaled and nasal nitric oxide in patients with asthma
and rhinitis was achieved by 400pg of inhaled budesonide and 200pg of intra-nasal
budesonide. Interestingly, in that study (Chapter 7), detectable suppression in exhaled
nitric oxide was seen after treatment with montelukast, which is in keeping with its anti¬
inflammatory properties. The results from the dose-response study in Chapter 6 are in
keeping with those of Jatakanon et al(355), who also found that, in mild to moderate
patients, the values for exhaled nitric oxide normalised at low dose (400pg per day) with
no further suppression at higher doses.
The results from Chapters 8 and 9 also support this finding. In Chapter 8, there was
significant suppression of nitric oxide with 400pg per day budesonide compared to
placebo, which amounted to a 1.9 fold difference. However, doubling the dose of
budesonide to 800pg per day resulted in no further suppression and indeed a similar
difference from placebo (2.1 fold difference). The results of the study comparing the
anti-inflammatory effects of montelukast and salmeterol (Chapter 9) were initially
surprising as there was no suppression of exhaled nitric oxide after treatment with the
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leukotriene receptor antagonist. This seemed to be in contrast to the study in Chapter 7.
However, it can be explained by the fact that all the patients were receiving inhaled
corticosteroids at a dose greater than 400pg per day and would have already suppressed
their exhaled nitric oxide to a low level. Thus exhaled nitric oxide may be useful in
monitoring the disease activity in mild patients but is of less value when comparing the
anti-inflammatory properties of second-line agents.
The different stimuli for a bronchial challenge testing have different advantages and
disadvantages. In keeping with other authors'360' adenosine monophosphate was found to
be more sensitive than direct bronchial challenge with methacholine in the dose-
response study in Chapter 6. Other authors have also shown adenosine monophosphate
challenge to be more specific in terms of diagnosing asthma from other chronic airway
diseases in children'417). This is probably because it does not exert its
bronchoconstrictive effects by acting on smooth muscle (as does methacholine and
histamine) but acts as an indirect stimulus like allergen, cold air or exercise. It is,
therefore, considered to be more representative of real-life asthmatic responses'79'. In
this respect, adenosine monophosphate bronchial challenge has been shown to cause
more discomfort in terms of "chest tightness" than methacholine'418'. This is probably
due to the action ofmediators on airways sensory nerves. It can also be seen from Figure
6.2 that the adenosine monophosphate dose-response curve is steep for mild to moderate
asthmatics between a dose of 400pg and 1600pg per day whereas methacholine is flatter
until 800pg per day.
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Adenosine monophosphate bronchial challenge was also shown to be reproducible in the
studies in this thesis. When comparing the effects of inhaled budesonide, as a doubling
dose difference from placebo, from all the relevant studies, a similar response was
found. There was a 2.67 doubling dose difference with 400pg inhaled budesonide in the
dose-response study (Chapter 6), a 2.67 doubling dose difference in the study comparing
budesonide (400pg per day) and montelukast (Chapter 7) and a 2.46 doubling dose
difference with low dose budesonide (400pg per day) in the study comparing
budesonide and formoterol (Chapter 8). This may have been because the patients were
all of mild to moderate severity and had a similar baseline adenosine monophosphate
PC20 after placebo in each study. Also of interest is the similar clinical efficacy achieved
by taking budesonide 400pg per day, as a once daily dose (Chapters 7 and 8) compared
to two divided doses (Chapter 6). Indeed, budesonide is licensed for once daily usage at
this dose.
However, there are problems when interpreting the results of bronchial challenge testing
in studies comparing different classes of anti-inflammatory therapy for asthma. As stated
above (see section 1.2.2), adenosine monophosphate acts by binding to adenosine
receptors on mast cells causing them to degranulate and release inflammatory mediators
inducing bronchoconstriction. Of these mediators, the most important are histamine,
prostaglandins and leukotrienes(419). Therefore it may be possible to block the effects of
adenosine monophosphate, without controlling airway inflammation, with a leukotriene
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receptor antagonist (as in Chapter 7) or an anti-histamine(420) or their combination(283).
However, montelukast also suppressed exhaled nitric oxide suggesting an anti¬
inflammatory property. This highlights the importance of performing more than one
measurement of disease control and taking a global picture from the results.
There were significant improvements in bronchoprotection with inhaled short-acting
(Figure 6.2) and long-acting P2-agonists (Chapter 9 and 10). The effects of p2-agonists
on bronchial challenge are probably due to functional antagonism as lesser effects are
seen with other markers of inflammation. Although the adenosine monophosphate
bronchial challenge has been used to study the effects of cromones(421), data evaluating
the effects of other anti-inflammatory medication on this challenge are sparse.
Evaluations of simple breathing tests and patients' symptoms are often used to monitor
disease activity in asthmatic patients. In Chapter 6, patients' symptoms and lung
function achieved their maximum response at a moderately low dose (400pg per day) of
inhaled budesonide, probably as their disease was of mild to moderate severity.
Measurements of spirometry performed at a clinic are relatively insensitive and therefore
large numbers of patients are required to make statistical conclusions. Not surprisingly,
therefore, there were no differences between any of the active treatments by using these
measures and only in one study was active treatment statistically different from placebo
(Chapter 8). Daily peak flow measurements are more sensitive as, even with the small
sample sizes in this thesis, it was possible to detect a difference between the combination
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of budesonide plus formoterol and either treatment as monotherapy (Chapter 8), and an
improvement with montelukast or salmeterol when compared to placebo in Chapter 9.
This shows the importance of providing asthmatic patients with a peak flow meter as
this cheap and simple method of monitoring asthma is not only sensitive but allows
patients to be in control ofmonitoring their own disease.
10.10 Second-line anti-inflammatory therapy in allergic airways disease
Increasing the dose of an inhaled corticosteroid has greater control of airway
inflammation (Chapter 6), although it also results in more systemic adverse effects
(Chapters 3,4,5). In this respect in Chapter 6, the therapeutic index was shown to be
poorer at the highest dose. Although there were more patients with a clinically
significant decrease in bronchial hyperresponsiveness there were also more patients with
sub-normal urinary Cortisol levels. The lowest possible maintenance should therefore be
prescribed in keeping with current asthma management guidelines0 34).
Further control of inflammation requires second-line treatment including long-acting p2
adrenoceptor agonists and leukotriene receptor antagonists. As discussed previously (see
section 1.5.1), there is currently a debate as to whether long-acting p2 agonists have anti¬
inflammatory properties or not. The results from the study designed to investigate this
further (Chapter 8) suggest that the beneficial effects of formoterol are not due to
controlling airway inflammation as there were no significant effects on exhaled nitric
oxide, adenosine monophosphate, bronchial challenge, or eosinophilic cationic protein.
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Furthermore, in terms of effects with salmeterol (Chapter 9), there were also no
improvements in eosinophilic cationic protein or bronchial challenge testing after
repeated dosing.
There is no doubt that long-acting p2-agonists improve lung function as can be seen in
both of these studies. Also patients seemed to prefer this form of treatment rather than
budesonide as monotherapy (Chapter 8). Given their reported benefits on exacerbation
rates and quality of life(62), long-acting p2-agonists have an important role in the
treatment of asthma. They are especially useful in achieving rapid control of brittle
asthmatics while other anti-inflammatory therapies take effect. Now that they are
becoming available in combination with inhaled corticosteroids in the one inhaler device
they may even increase the compliance with inhaled corticosteroids.
Leukotriene receptor antagonists are a new form of anti-inflammatory therapy available
for allergic patients. The results from the studies in this thesis suggest that they may
have an important role in both asthma, as first-line (Chapter 7) or second-line (Chapter
9), as well allergic rhinitis (Chapter 7). Montelukast offered symptomatic control of
allergic rhinitis, although there were significantly greater effects on nasal nitric oxide
and nasal peak inspiratory flow rate with intra-nasal budesonide. Similarly inhaled
budesonide improved bronchial hyperreactivity to a significantly greater effect than
montelukast, reflecting the high degree of anti-inflammatory activity of inhaled
corticosteroids0 34). In a head-to-head comparison with a long-acting p2 agonist
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(salmeterol), montelukast achieved equivalent control of symptoms and lung function
and seemed to have a greater effect on the inflammatory markers of eosinophilic cationic
protein and adenosine monophosphate bronchial challenge (Chapter 9).
It is also clear from Chapter 9, that the effects of leukotriene receptor antagonists occur
as quickly as long-acting p2 agonists (Figure 9.4). A significant improvement in lung
function and bronchial challenge testing occurred within 24 hour for both treatments.
This is obviously more rapid than the effects of inhaled corticosteroids which showed no
significant improvements in lung function after 1 week of treatment in the studies
assessing systemic effects (Chapters 3). It may be due to the bronchodilatory properties
of leukotriene receptor antagonists as they inhibit the very potent bronchoconstrictor
leukotriene D4(422). However, it does mean that there is potential for gaining patients'
confidence quickly. As discussed previously (see section 1.5.1) long-acting p2-agonists
exhibit tolerance to their therapeutic effects although the clinical importance of this is
uncertain. However, there was no evidence of tachyphylaxis with montelukast in terms
of spirometry or adenosine monophosphate bronchial challenge (Chapter 9).
10.11 Limitations of efficacy studies in this thesis
A weakness of the efficacy studies is the short duration of treatment. Although Kraan et
al(251) showed that there was no significant increase in bronchoprotection against
histamine challenge test with 800qg per day of budesonide after 8 weeks compared to 2
weeks, other authors report different findings. Vathenen et al(252) showed that histamine
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PD2o increased from 1.3 doubling doses to 2.4 doubling doses after 3 and 6 weeks
respectively with 1600pg per day of budesonide. Furthermore, Juniper et al(423) showed
that there was a strong treatment - time interaction with 400pg per day of budesonide in
terms of methacholine bronchial challenge testing measured monthly for 1 year. The
authors commented that the largest improvements occurred in the first 3 months but
some patients have increasing bronchoprotection throughout the year. The tendency to
reach a plateau was not related to asthma severity, age of onset or duration of therapy, or
the use of steroids. However the patients studied all had mild asthma with an average
FEVi of 90% predicted and only 3 out of 16 patients had ever received corticosteroid
therapy.
Bernstein et al(424) showed improvements in symptoms scores and peak flow rate
throughout a 6 week study of triamcinolone acetonide, however, there seemed to be a
plateau after the 4th week. Furthermore, the effects of adenosine monophosphate
challenge have been shown to occur much quicker. For example, Ketchell et al(425)
showed that fluticasone propionate at a dose of lOOOpg twice daily exhibited a 3.4
doubling dose shift in adenosine monophosphate bronchial challenge after 3 doses and a
3.75 doubling dose shift after 7 doses. Szefler et al(426) also showed statistical
improvements with fluticasone propionate after 1 week and a maximum effect within 2
weeks for symptoms and rescue inhaler usage, and a maximum in FEVi within 3 weeks.
However, had the treatments been given for longer durations in the studies in this thesis,
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greater effects may have been found for the efficacy measures, especially when
investigating inhaled corticosteroids.
All of the studies have been of crossover design rather than in parallel groups. This has
been done in order to increase the statistical power, as each person acts as his or her own
control. However, this design requires a washout period, which must be long enough for
all endpoints to return to baseline. In the studies investigating the effects of
corticosteroids on bronchial challenge testing (Chapter 8 and 9), a washout period of 1
week was used. Kraan et al(251) has shown that the effects of budesonide on
methacholine return to baseline in 1 week. In all studies there was no significant
difference between measurements after run-in and washout placebo periods. It is
accepted statistical practice to use the mean of the two baselines or placebo periods in
analysis with active treatment, as has been the case in this thesis.
10.12 Future studies arising from this thesis
There are still many unanswered questions which have been highlighted as a result of
the work in this thesis. Although it was found that fluticasone propionate had greater
effects on adrenal suppression than triamcinolone acetonide, the potency ratios for
systemic activity of triamcinolone acetonide and fluticasone propionate still need to be
calculated. This will require another dose-response study with higher doses of
triamcinolone acetonide than evaluated in this thesis. As discussed previously, the use of
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a spot morning urinary Cortisol sample as a screening tool for adrenal suppression and
the value of the low dose (0.5pg) ACTH stimulation test require further validation.
Many of the inhaled drugs investigated in this thesis were delivered by inhaler devices
which used carboflurocarbons as the propellant. However as the production of chloro-
fluro-carbons is now banned, new inhalers have been designed which contain
hydrofluroalkanes as the propellant. These have been shown to alter the delivery
characteristics of the aerosol(427) and therefore further studies require to be performed
using these new inhalers.
New inhaled corticosteroids are also being developed such as mometasone furoate(428) or
ciclesonide(359), and these drugs need to be investigated. There is also interest regarding
the "non-genomic" properties of corticosteroids, such as the effect on nuclear factor-
kappa B (see section 1.3.1), as these are thought to occur within minutes and be free
from the genomic type systemic adverse effects. It is realised that corticosteroids have
different proportions of genomic and non-genomic activity(429) and modifying their
properties may be a way of increasing the therapeutic ratio of intra-nasal and inhaled
corticosteroids.
The dose-response curves for systemic and efficacy effects for inhaled corticosteroids is
dependant on dose (as seen in Chapter 6), lung delivery(17l) and asthma severity(249).
Therefore each patient will have a unique dose with an optimal anti-inflammatory to
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adverse effect ratio. Further studies are required to investigate methods of titrating the
dose of inhaled corticosteroids on an individual patient basis in order to determine the
optimal dose.
The optimal therapy for patients not controlled with low dose inhaled corticosteroids is
yet to be determined. The last study in this thesis (Chapter 9) attempted to address this
issue however it was a small pilot study and it should be repeated on a much larger
basis, to further clarify this question. In the future, it may be possible to use genotype
analysis in order to guide physicians as to the most appropriate medication. In this
respect there is currently research looking at P2 receptor1-430' and the 5-lipoxygenase
enzyme(431) polymorphisms.
This thesis has investigated the role of blocking the effects of leukotrienes when
attempting to control airway inflammation. However, further studies are required to
investigate the effects of leukotrienes in addition to other mediator blockers, such as
anti-histamines. In the future there may be other inflammatory cytokine inhibitors which
are licensed for allergic airways disease.
The studies in this thesis have evaluated anti-inflammatory medication used in allergic
airway diseases, with the assumption that controlling inflammation will improve long
term quality of life by controlling airway remodeling'260'2621. For example bronchial
hyperresponsiveness induced by chronic inhaled allergen exposure in rats was shown to
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be accompanied by smooth muscle hypertrophy, airway narrowing and goblet cell
hyperplasia'432'. However, it is uncertain as to whether long-term unchecked
inflammation leads to airways remodeling with airways obstruction*344'. Indeed further
research is required to determine whether controlling inflammation is the key to
controlling allergic airways disease in the long-term.
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